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ABSTRACT 
The susceptibility of humankind to the deadly parasite Mycobacterium 
tuberculosis has been a grave source of concern throughout
 :history. M. tuberculosis, 
the scourge of humanity, is one of the most successful and scientifically challenging 
pathogens of all time. The success of this pathogen manifests as tuberculosis (TB), and 
the extent of its devastation is measured in claiming between 2 and 3 million lives 
yearly. Tuberculosis is the second leading cause of death worldwide from a single 
infectious agent. Declared a global health emergency more than a decade ago, 
tuberculosis resurgence is assuming threatening proportions. Among the important 
reasons for the causative killer parasite spiralling out of control at an alarming rate is 
attributed to the emergence of multidrug-resistant strains and the AIDS epidemic. 
The initial interaction of mononuclear phagocytes with M. tuberculosis gives 
rise to a cytokine profile dominated by TNF-a. It is well established that both 
phagocytic and non-phagocytic interaction of M. tuberculosis bacilli with 
mononuclear phagocytes as well as mycobacterial protein and non-protein components 
can induce this pro-inflammatory cytokine. In the early stages of infection, TNF-a 
secreted by macrophages is one of the pivotal pro-inflammatory cytokines responsible 
for disease localization and granuloma formation. Paradoxically, in the more advanced 
and chronic stage of mycobacterial diseases, TNF-a has been shown to be responsible 
for disease severity and pathogenesis. Antigen 85B is one of the many M. tuberculosis 
products that induce production of TNF-a. Along with the other two proteins in the M. 
tuberculosis 85 complex (85A and 85C), 85B is abundantly secreted by M. 
tuberculosis. 
The resurgence of tuberculosis as a major disease with an estimated 10.2 
million new cases in 2005 is fuelling an urgent need for developing novel therapeutic 
strategies against the causative organism, M. tuberculosis. Focus has now shifted to 
development of compounds from natural sources that have antimycobacterial activity. 
By boosting host immunologic responsiveness, these compounds may be particularly 
useful in the treatment of drug-resistant tuberculosis. We studied the incorporation of 
such compounds, like allicin from garlic, as the herbal component for tuberculosis 
management. 
ABSTRACT 
The initial part of the present study undertook a detailed characterization of 
sera and monocytes of patients with active tuberculosis to evaluate the expression of 
TNF-a and M. tuberculosis 85B. Direct binding ELISA on microtitre plates coated 
with protein antigens of H37Rv bacilli sonicate showed remarkable reactivity against 
antibodies found in sera of tuberculosis patients, as evidenced by an antibody titre 
>1:12800. Similarly, an appreciable reactivity was observed with tuberculosis sera 
against secreted culture filtrate protein antigens with an antibody titre > 1:6400, 
whereas no reactivity was observed with normal human sera in either case. 
M. tuberculosis infection gives rise to a cytokine profile that is dominated by 
TNF-a. In our study also, estimation by ELISA showed an appreciable magnitude of 
soluble TNF-a in sera of tuberculosis patients. Furthermore, M. tuberculosis 85B is a 
predominant protein produced during human M. tuberculosis infection; however its 
role in tuberculosis pathogenesis is not clear and warrants further investigation. The 
presence of circulating M. tuberculosis 85B antigen in sera of tuberculosis patients, 
either in the free form or complexed with fibronectin has been well established. We 
also found an appreciably elevated level of antigen 85B in sera of tuberculosis 
patients. 
After characterizing sera, an attempt was made to characterize monocytes from 
tuberculosis patients with respect to TNF-a and 85B. Monocytes from tuberculosis 
patients were subjected to TNF-a and 85B mRNA evaluation by real-time RT-PCR 
and revealed appreciably high basal levels of both mRNA expression. TNF-a and 85B 
proteins were also found to be significantly elevated in supernatants of monocyte 
cultures of tuberculosis patients. 
Despite encountering a robust immune response, M. tuberculosis successfully 
survives and persists in its human host. Of the various M. tuberculosis genes shown to 
be up regulated after M. tuberculosis infection of human mononuclear cells, the 85B 
gene was expressed most frequently. Antigen 85B is a mycolyl transferase involved in 
cell wall biosynthesis shown to catalyse the formation of trehalose dimycolate which 
enhances the host inflammatory response. Thus, in the present study, we investigated 
the early regulation of M. tuberculosis 85B gene by allicin in M. tuberculosis cultures. 
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Real-time RT-PCR data showed that allicin downregulated the expression of 
85B mRNA in M. tuberculosis (H37Rv) cultures in a dose-dependent manner, without 
any significant effect on the expression of the housekeeping gene of M. tuberculosis, 
i.e., 16S rRNA. An appreciable suppression of 85B mRNA by ~2 and 2.5 logs was 
recorded with 250 and 500 ng/ml of allicin, respectively. It is to be pointed out here 
that previous reports have shown M. tuberculosis growth to be affected by allicin at 
relatively much higher concentrations. From our data it is evident that although low 
concentrations of allicin that have been employed in this study do not affect M. 
tuberculosis growth, it appreciably downregulates the M. tuberculosis 85B gene 
expression. 
The effect of allicin on expression of M. tuberculosis antigen 85 complex 
(30/31 kDa) in M. tuberculosis sonic extract as revealed by gradient SDS-PAGE was 
also found to be dose-dependent. 250 and 500 ng/ml of allicin proved to be a potent 
inhibitor of antigen 85 complex protein expression. In supernatants obtained from 14 
days M. tuberculosis cultures receiving various doses of allicin, the secretion of 
antigen 85 complex was found to be dose-dependent. Allicin decreased the specificity 
of TB-IgG for M. tuberculosis protein antigens as revealed by immunoassays for sonic 
extract and culture filtrate protein antigens of M. tuberculosis co-cultured with allicin 
against TB-IgG. 
Interestingly, antigen 85B is immunodominant and potently induces TNF-a 
when complexed to fibronectin in mononuclear phagocytes. Therefore, the role of M. 
tuberculosis 85B in intracellular infection may be the maintenance of an inflammatory 
response. Through sustaining TNF-a activity, the abundant release of M. tuberculosis 
85B in situ may contribute to the pathogenesis of M. tuberculosis infection. The 
expression of 85B in M. tuberculosis-infected monocytes correlates positively with 
both the amount of secreted TNF-a and subsequent intracellular mycobacterial 
growth. 
It was observed in our study that M. tuberculosis infection had no effect on 
host housekeeping genes such as the R18 gene (18S rRNA) or p-actin gene as revealed 
by quantitative real-time RT-PCR and RT-PCR data. Also, the kinetics (0-120 hours) of 
expression of TNF-a and M. tuberculosis 85B mRNA in M. tuberculosis-infected 
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monocytes by real-time RT-PCR, RT-PCR and ELISA was investigated. The data 
revealed that the expression of TNF-a mRNA in infected monocytes as well as 
secreted TNF-a in culture supernatants was time-dependent, maximal at 24 hours of 
infection, followed by a substantial decrease at the remaining time intervals of 
infection. 
Furthermore, 16S rRNA expression in M. tuberculosis-infected monocytes was 
observed to linearly increase with time. The expression of M tuberculosis 85B mRNA 
was found to continue to increase up to 120 hours of infection. The ratio of 85B:16S 
was also increased with increasing time periods of infection and correlated with 85B 
mRNA levels at various time periods. Also, in the supernatants of infected monocyte 
cultures the expression of secreted antigen 85 complex increased with time. 
Furthermore, the M. tuberculosis-infected monocytes exhibited a linear time-
dependent decrease in GPx activity in comparison to control monocytes. 
The above data suggested a role for endogenous TNF-a in auto-induction and 
in the induction of M. tuberculosis 85B gene expression. To further assess the role of 
TNF-a, in other experiments, exogenous rhTNF-a and soluble TNF-a receptors were 
added to M. tuberculosis-infected monocytes, and then TNF-a and 85B mRNA were 
assessed. The cell activation by exogenous rhTNF-a induces both TNF-a and M. 
tuberculosis 85B genes in M. tuberculosis-infected monocytes, whereas inhibition of 
endogenous TNF-a by TNFR-I and TNFR-II was associated with down-modulation of 
both TNF-a and M. tuberculosis 85B gene expression. The results indicate sTNFR-I 
to be a stronger inhibitor of TNF-a and M. tuberculosis 85B gene expression in M. 
tuberculosis-infected monocytes than sTNFR-II. 
Cellular activation, and thereby induction of TNF-a, is mediated via NF-KB. It 
has been well documented that TNF-a induced nuclear translocation of NF-KB was 
inhibited in SN50 peptide-treated human monocytic cell lines as demonstrated in 
EMS A. Thus, we employed SN50, an inhibitor of NF-KB, to assess the role of NF-KB 
in activation of gene expression in M. tuberculosis-infected monocytes. Our results 
clearly show that the increased expression of TNF-a and 85B mRNA in M. 
tuberculosis-infected monocytes is mediated mainly via NF-KB. Interestingly, 
inhibition of reactive oxygen intermediates (ROIs) and reactive nitrogen intermediates 
ABSTRACT 
(RNIs), reduced expression of TNF-a and M. tuberculosis 85B genes in M. 
tuberculosis-infected monocytes. 
Allicin (diallyl thiosulfinate) is the major biologically active component and 
thiosulfinate compound of freshly crushed garlic. It has been reported to enhance the 
actions of antibiotics such as chloramphenicol and streptomycin against M. 
tuberculosis, besides affecting different biological activities such as antimicrobial, 
antiparasitic and antifungal activities. Allicin has radical scavenging properties in 
activated granulocytes and may also inhibit inducible nitric oxide synthase expression 
in activated macrophages. 
Here we investigated the effect of allicin on expression of TNF-a and M. 
tuberculosis 85B in M. tuberculosis-infected monocytes after 24 hours of infection. 
Since higher doses of allicin have previously proven to be toxic by various 
investigators, the present study employed lower concentrations (0-500 ng/ml), which 
failed to show any toxic effect on monocytes as revealed by MTT assay. Also, no 
effect was observed on housekeeping genes: R18 (18S rRNA) by quantitative real-
time RT-PCR, or (3-actin gene as revealed by RT-PCR, thereby indicating that allicin 
did not non-specifically affect human TNF-a transcription in M. tuberculosis-infected 
monocytes. Also, the effect of various doses of allicin employed in the present study 
failed to show any toxic or inhibitory effect on the mycobacterial housekeeping gene 
M. tuberculosis 16S rRNA by quantitative real-time RT-PCR as well as by RT-PCR in 
monocytes infected with M. tuberculosis. 
The present study revealed allicin to downregulate the expression of TNF-a 
gene in M. tuberculosis-infected monocytes as well as the secretion of soluble TNF-a 
in culture supernatants in a dose-dependent manner. The results indicate an 
appreciable suppression in endogenous TNF-a mRNA expression by -7.1 logs and 8.1 
logs with 250 and 500 ng/ml of allicin, respectively in M. tuberculosis-infected 
monocytes. Furthermore, allicin was also found to suppress the expression of 85B 
gene and secreted antigen 85 complex in a dose-dependent manner where 250 and 500 
ng/ml of allicin were found to be potent inhibitory concentrations in M. tuberculosis-
infected monocyte cultures after 24 hours of infection. Interestingly, in comparison to 
the inhibitory effects of allicin with those of NAC, SN50 and anti-TNF-a antibody, 
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allicin was found to be the most potent inhibitor of TNF-a and M. tuberculosis 85B 
expression in M. tuberculosis-infected monocytes. 
Our results indicate that the increased expression of TNF-a and 85B mRNA in 
M. tuberculosis-infected monocytes is mediated via activation of NF-KB, as evidenced 
by the suppression of TNF-a mRNA in the presence of SN50, an inhibitor of NF-KB. 
SN50/M, an inactive analogue of SN50 failed to show any such effect. In view of it, 
our data demonstrated that this effect involved inhibition of the NF-KB pathway 
induced by allicin probably by inhibiting the degradation of IicBa. Since a number of 
genes involved in inflammatory responses are regulated by NF-KB pathway, thus a 
high magnitude downregulation of the NF-KB pathway by allicin would predictably 
reduce the elaboration of NF-KB-mediated TNF-a mRNA expression and, in turn, 85B 
gene expression. 
Glutathione directly reacts with ROS, and glutathione peroxidase (GPx) 
catalyzes the removal of hydrogen peroxide. Decrease in GPx activity indicates 
impairment of hydrogen peroxide-neutralizing mechanisms. Here, we observed a 
decline in GPx activity in M. tuberculosis-infected monocytes. Enhancement of GPx 
activity in M. tuberculosis-infected monocyte cultures after addition of NAC, a 
precursor of the in vivo antioxidant glutathione, indicates reversal of impaired 
neutralizing mechanisms. Surprisingly, here a slightly greater augmentation in GPx 
activity was observed when allicin was co-cultured instead of NAC, indicating allicin 
to be an effective natural antioxidant combating ROS, generated as a consequence of 
cellular activation in M. tuberculosis-infected monocytes. 
In conclusion, the presence of elevated levels of TNF-a and M. tuberculosis 
85B in tuberculosis patients is the indication of severity of the disease. The expression 
of M. tuberculosis 85B was downregulated by allicin in a dose-dependent manner in 
H37Rv cultures. Furthermore, M. tuberculosis infection of monocytes leads to a 
concomitant activation of TNF-a and expression of M. tuberculosis 85B gene. M 
tuberculosis infection of human monocytes initiates a cascade of events whereby 
cellular activation by TNF-a, RNI, and ROI enhances the expression of M. 
tuberculosis 85B in monocytes. The augmented expression of TNF-a and M. 
tuberculosis 85B gene in M. tuberculosis-infected monocytes by cellular activation 
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and ROS was suppressed by allicin in a dose-dependent manner. The effect of allicin 
was mediated by suppression of NF-KB. Also, allicin enhanced the GPx activity, 
which correlated inversely with the downregulation of TNF-a and M. tuberculosis 85B 
in M. tuberculosis-infected monocytes. Allicin may prove to be valuable in the 
containment of M tuberculosis and, therefore, be useful as an adjunct in treatment of 
tuberculosis. These observations strengthen the idea that allicin should be tested in in 
vivo models to evaluate its therapeutic potential in the pathogenesis of tuberculosis. 
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ABSTRACT 
The susceptibility of humankind to the deadly parasite Mycobacterium 
tuberculosis has been a grave source of concern throughout history. M. tuberculosis, 
the scourge of humanity, is one of the most successful and scientifically challenging 
pathogens of all time. The success of this pathogen manifests as tuberculosis (TB), and 
the extent of its devastation is measured in claiming between 2 and 3 million lives 
yearly. Tuberculosis is the second leading cause of death worldwide from a single 
infectious agent. Declared a global health emergency more than a decade ago, 
tuberculosis resurgence is assuming threatening proportions. Among the important 
reasons for the causative killer parasite spiralling out of control at an alarming rate is 
attributed to the emergence of multidrug-resistant strains and the AIDS epidemic. 
The initial interaction of mononuclear phagocytes with M. tuberculosis gives 
rise to a cytokine profile dominated by TNF-a. It is well established that both 
phagocytic and non-phagocytic interaction of M. tuberculosis bacilli with 
mononuclear phagocytes as well as mycobacterial protein and non-protein components 
can induce this pro-inflammatory cytokine. In the early stages of infection, TNF-a 
secreted by macrophages is one of the pivotal pro-inflammatory cytokines responsible 
for disease localization and granuloma formation. Paradoxically, in the more advanced 
and chronic stage of mycobacterial diseases, TNF-a has been shown to be responsible 
for disease severity and pathogenesis. Antigen 85B is one of the many M. tuberculosis 
products that induce production of TNF-a. Along with the other two proteins in the M. 
tuberculosis 85 complex (85A and 85C), 85B is abundantly secreted by M. 
tuberculosis. 
The resurgence of tuberculosis as a major disease with an estimated 10.2 
million new cases in 2005 is fuelling an urgent need for developing novel therapeutic 
strategies against the causative organism, M. tuberculosis. Focus has now shifted to 
development of compounds from natural sources that have antimycobacterial activity. 
By boosting host immunologic responsiveness, these compounds may be particularly 
useful in the treatment of drug-resistant tuberculosis. We studied the incorporation of 
such compounds, like allicin from garlic, as the herbal component for tuberculosis 
management. 
i 
ABSTRACT 
The initial part of the present study undertook a detailed characterization of 
sera and monocytes of patients with active tuberculosis to evaluate the expression of 
TNF-a and M. tuberculosis 85B. Direct binding ELISA on microtitre plates coated 
with protein antigens of H37Rv bacilli sonicate showed remarkable reactivity against 
antibodies found in sera of tuberculosis patients, as evidenced by an antibody titre 
>1:12800. Similarly, an appreciable reactivity was observed with tuberculosis sera 
against secreted culture filtrate protein antigens with an antibody titre > 1:6400, 
whereas no reactivity was observed with normal human sera in either case. 
M. tuberculosis infection gives rise to a cytokine profile that is dominated by 
TNF-a. In our study also, estimation by ELISA showed an appreciable magnitude of 
soluble TNF-a in sera of tuberculosis patients. Furthermore, M. tuberculosis 85B is a 
predominant protein produced during human M. tuberculosis infection; however its 
role in tuberculosis pathogenesis is not clear and warrants further investigation. The 
presence of circulating M. tuberculosis 85B antigen in sera of tuberculosis patients, 
either in the free form or complexed with fibronectin has been well established. We 
also found an appreciably elevated level of antigen 85B in sera of tuberculosis 
patients. 
After characterizing sera, an attempt was made to characterize monocytes from 
tuberculosis patients with respect to TNF-a and 85B. Monocytes from tuberculosis 
patients were subjected to TNF-a and 85B mRNA evaluation by real-time RT-PCR 
and revealed appreciably high basal levels of both mRNA expression. TNF-a and 85B 
proteins were also found to be significantly elevated in supernatants of monocyte 
cultures of tuberculosis patients. 
Despite encountering a robust immune response, M. tuberculosis successfully 
survives and persists in its human host. Of the various M. tuberculosis genes shown to 
be up regulated after M. tuberculosis infection of human mononuclear cells, the 85B 
gene was expressed most frequently. Antigen 85B is a mycolyl transferase involved in 
cell wall biosynthesis shown to catalyse the formation of trehalose dimycolate which 
enhances the host inflammatory response. Thus, in the present study, we investigated 
the early regulation of M. tuberculosis 85B gene by allicin in M. tuberculosis cultures. 
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Real-time RT-PCR data showed that allicin downregulated the expression of 
85B mRNA in M. tuberculosis (H37Rv) cultures in a dose-dependent manner, without 
any significant effect on the expression of the housekeeping gene of M. tuberculosis, 
i.e., 16S rRNA. An appreciable suppression of 85B mRNA by ~2 and 2.5 logs was 
recorded with 250 and 500 ng/ml of allicin, respectively. It is to be pointed out here 
that previous reports have shown M. tuberculosis growth to be affected by allicin at 
relatively much higher concentrations. From our data it is evident that although low 
concentrations of allicin that have been employed in this study do not affect M. 
tuberculosis growth, it appreciably downregulates the M. tuberculosis 85B gene 
expression. 
The effect of allicin on expression of M. tuberculosis antigen 85 complex 
(30/31 kDa) in M. tuberculosis sonic extract as revealed by gradient SDS-PAGE was 
also found to be dose-dependent. 250 and 500 ng/ml of allicin proved to be a potent 
inhibitor of antigen 85 complex protein expression. In supernatants obtained from 14 
days M. tuberculosis cultures receiving various doses of allicin, the secretion of 
antigen 85 complex was found to be dose-dependent. Allicin decreased the specificity 
of TB-IgG for M. tuberculosis protein antigens as revealed by immunoassays for sonic 
extract and culture filtrate protein antigens of M. tuberculosis co-cultured with allicin 
against TB-IgG. 
Interestingly, antigen 85B is immunodominant and potently induces TNF-a 
when complexed to fibronectin in mononuclear phagocytes. Therefore, the role of M 
tuberculosis 85B in intracellular infection may be the maintenance of an inflammatory 
response. Through sustaining TNF-a activity, the abundant release of M. tuberculosis 
85B in situ may contribute to the pathogenesis of M. tuberculosis infection. The 
expression of 85B in M. tuberculosis-infected monocytes correlates positively with 
both the amount of secreted TNF-a and subsequent intracellular mycobacterial 
growth. 
It was observed in our study that M. tuberculosis infection had no effect on 
host housekeeping genes such as the R18 gene (18S rRNA) or 0-actin gene as revealed 
by quantitative real-time RT-PCR and RT-PCR data. Also, the kinetics (0-120 hours) of 
expression of TNF-a and M. tuberculosis 85B mRNA in M. tuberculosis-infected 
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monocytes by real-time RT-PCR, RT-PCR and ELISA was investigated. The data 
revealed that the expression of TNF-a mRNA in infected monocytes as well as 
secreted TNF-a in culture supernatants was time-dependent, maximal at 24 hours of 
infection, followed by a substantial decrease at the remaining time intervals of 
infection. 
Furthermore, 16S rRNA expression in M. tuberculosis-infected monocytes was 
observed to linearly increase with time. The expression of M. tuberculosis 85B mRNA 
was found to continue to increase up to 120 hours of infection. The ratio of 85B:16S 
was also increased with increasing time periods of infection and correlated with 85B 
mRNA levels at various time periods. Also, in the supernatants of infected monocyte 
cultures the expression of secreted antigen 85 complex increased with time. 
Furthermore, the M. tuberculosis-infected monocytes exhibited a linear time-
dependent decrease in GPx activity in comparison to control monocytes. 
The above data suggested a role for endogenous TNF-a in auto-induction and 
in the induction of M. tuberculosis 85B gene expression. To further assess the role of 
TNF-a, in other experiments, exogenous rhTNF-a and soluble TNF-a receptors were 
added to M. tuberculosis-infected monocytes, and then TNF-a and 85B mRNA were 
assessed. The cell activation by exogenous rhTNF-a induces both TNF-a and M. 
tuberculosis 85B genes in M. tuberculosis-infected monocytes, whereas inhibition of 
endogenous TNF-a by TNFR-I and TNFR-II was associated with down-modulation of 
both TNF-a and M. tuberculosis 85B gene expression. The results indicate sTNFR-I 
to be a stronger inhibitor of TNF-a and M. tuberculosis 85B gene expression in M 
tuberculosis-infected monocytes than sTNFR-II. 
Cellular activation, and thereby induction of TNF-a, is mediated via NF-KB. It 
has been well documented that TNF-a induced nuclear translocation of NF-KB was 
inhibited in SN50 peptide-treated human monocytic cell lines as demonstrated in 
EMSA. Thus, we employed SN50, an inhibitor of NF-KB, to assess the role of NF-KB 
in activation of gene expression in M. tuberculosis-infected monocytes. Our results 
clearly show that the increased expression of TNF-a and 85B mRNA in M. 
tuberculosis-infected monocytes is mediated mainly via NF-KB. Interestingly, 
inhibition of reactive oxygen intermediates (ROIs) and reactive nitrogen intermediates 
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(RNIs), reduced expression of TNF-a and M. tuberculosis 85B genes in M. 
tuberculosis-infected monocytes. 
Allicin (diallyl thiosulfinate) is the major biologically active component and 
thiosulfinate compound of freshly crushed garlic. It has been reported to enhance the 
actions of antibiotics such as chloramphenicol and streptomycin against M. 
tuberculosis, besides affecting different biological activities such as antimicrobial, 
antiparasitic and antifungal activities. Allicin has radical scavenging properties in 
activated granulocytes and may also inhibit inducible nitric oxide synthase expression 
in activated macrophages. 
Here we investigated the effect of allicin on expression of TNF-a and M. 
tuberculosis 85B in M. tuberculosis-infected monocytes after 24 hours of infection. 
Since higher doses of allicin have previously proven to be toxic by various 
investigators, the present study employed lower concentrations (0-500 ng/ml), which 
failed to show any toxic effect on monocytes as revealed by MTT assay. Also, no 
effect was observed on housekeeping genes: R18 (18S rRNA) by quantitative real-
time RT-PCR, or p-actin gene as revealed by RT-PCR, thereby indicating that allicin 
did not non-specifically affect human TNF-a transcription in M. tuberculosis-infected 
monocytes. Also, the effect of various doses of allicin employed in the present study 
failed to show any toxic or inhibitory effect on the mycobacterial housekeeping gene 
M. tuberculosis 16S rRNA by quantitative real-time RT-PCR as well as by RT-PCR in 
monocytes infected with M. tuberculosis. 
The present study revealed allicin to downregulate the expression of TNF-a 
gene in M. tuberculosis-infected monocytes as well as the secretion of soluble TNF-a 
in culture supernatants in a dose-dependent manner. The results indicate an 
appreciable suppression in endogenous TNF-a mRNA expression by -7.1 logs and 8.1 
logs with 250 and 500 ng/ml of allicin, respectively in M. tuberculosis-infected 
monocytes. Furthermore, allicin was also found to suppress the expression of 85B 
gene and secreted antigen 85 complex in a dose-dependent manner where 250 and 500 
ng/ml of allicin were found to be potent inhibitory concentrations in M. tuberculosis-
infected monocyte cultures after 24 hours of infection. Interestingly, in comparison to 
the inhibitory effects of allicin with those of NAC, SN50 and anti-TNF-a antibody, 
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allicin was found to be the most potent inhibitor of TNF-a and M. tuberculosis 85B 
expression in M. tuberculosis-infected monocytes. 
Our results indicate that the increased expression of TNF-a and 85B mRNA in 
M. tuberculosis-infected monocytes is mediated via activation of NF-KB, as evidenced 
by the suppression of TNF-a mRNA in the presence of SN50, an inhibitor of NF-KB. 
SN50/M, an inactive analogue of SN50 failed to show any such effect. In view of it, 
our data demonstrated that this effect involved inhibition of the NF-KB pathway 
induced by allicin probably by inhibiting the degradation of IicBa. Since a number of 
genes involved in inflammatory responses are regulated by NF-KB pathway, thus a 
high magnitude downregulation of the NF-KB pathway by allicin would predictably 
reduce the elaboration of NF-KB-mediated TNF-a mRNA expression and, in turn, 85B 
gene expression. 
Glutathione directly reacts with ROS, and glutathione peroxidase (GPx) 
catalyzes the removal of hydrogen peroxide. Decrease in GPx activity indicates 
impairment of hydrogen peroxide-neutralizing mechanisms. Here, we observed a 
decline in GPx activity in M. tuberculosis-infected monocytes. Enhancement of GPx 
activity in M. tuberculosis-infected monocyte cultures after addition of NAC, a 
precursor of the in vivo antioxidant glutathione, indicates reversal of impaired 
neutralizing mechanisms. Surprisingly, here a slightly greater augmentation in GPx 
activity was observed when allicin was co-cultured instead of NAC, indicating allicin 
to be an effective natural antioxidant combating ROS, generated as a consequence of 
cellular activation in M. tuberculosis-infected monocytes. 
In conclusion, the presence of elevated levels of TNF-a and M. tuberculosis 
85B in tuberculosis patients is the indication of severity of the disease. The expression 
of M. tuberculosis 85B was downregulated by allicin in a dose-dependent manner in 
H37Rv cultures. Furthermore, M. tuberculosis infection of monocytes leads to a 
concomitant activation of TNF-a and expression of M. tuberculosis 85B gene. M. 
tuberculosis infection of human monocytes initiates a cascade of events whereby 
cellular activation by TNF-a, RNI, and ROI enhances the expression of M. 
tuberculosis 85B in monocytes. The augmented expression of TNF-a and M. 
tuberculosis 85B gene in M. tuberculosis-infected monocytes by cellular activation 
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and ROS was suppressed by allicin in a dose-dependent manner. The effect of allicin 
was mediated by suppression of NF-KB. Also, allicin enhanced the GPx activity, 
which correlated inversely with the downregulation of TNF-a and M. tuberculosis 85B 
in M. tuberculosis-infected monocytes. Allicin may prove to be valuable in the 
containment of M tuberculosis and, therefore, be useful as an adjunct in treatment of 
tuberculosis. These observations strengthen the idea that allicin should be tested in in 
vivo models to evaluate its therapeutic potential in the pathogenesis of tuberculosis. 
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INTRODUCTION 
Tuberculosis, also called TB, phthisis, consumption, and nicknamed the white 
plague, is a potentially fatal contagious disease that can affect almost any part of the 
body, but is mainly an infection of the lungs. It is caused by a bacterial 
microorganism, the tubercle bacillus or Mycobacterium tuberculosis. 
Epidemiology: 
Tuberculosis is a devastating communicable disease and a global killer as the 
second leading cause of death worldwide from a single infectious agent (Frieden et al., 
2003). Tuberculosis has confounded attempts at control ever since the discovery of M. 
tuberculosis by Robert Koch 120 years ago, for which he was honoured with the 
Nobel Prize. The staggering extent of infection by this exclusively human pathogen, 
M. tuberculosis, encompasses a total of two billion persons, approximately eight 
million people develop active disease and nearly two million are killed each year 
(Barnes and Cave, 2003; Kusner, 2005). Moreover, it was declared a global health 
emergency by WHO in 1993 (WHO, 2002). Targets were established to measure 
progress in the implementation of the DOTS (directly observed treatment strategy) to 
combat tuberculosis by 2005. The targets include 100% population coverage with 
DOTS, 70% case detection and 85% treatment success rate. In spite of this, the 
number of new cases of tuberculosis is projected to reach 11.9 million by the end of 
2006, if current control efforts are not strengthened (Dolin et al., 1994). Although a 
cure was available for the second half of the 20th century, various demographic and 
socioeconomic factors make both prevention and treatment difficult (Tufariello et al., 
2003). Most cases are in populous and less developed countries of Asia, with India, 
China, Indonesia, Bangladesh and Pakistan together accounting for more than half the 
global burden. The global tuberculosis caseload appears to be growing slowly with 
increased incidence in the former Soviet Union and Africa (Frieden et al, 2003; 
WHO, 2003b). The recent resurgence in tuberculosis is attributed partly to the AIDS 
epidemic with the emergence of multidrug-resistant strains especially in areas where 
the WHO-recommended DOTS has not yet been implemented (Pablos-Mendez et al., 
1998; De Cock and Chaisso, 1999). Co-infection with the human immunodeficiency 
virus (HIV) and tuberculosis form a lethal combination, each speeding the other's 
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progress. Sub-Saharan Africa bears the brunt of the HIV-fuelled tuberculosis epidemic 
(Corbettetal.,2002). 
Clinical manifestations: 
The most common clinical manifestation of tuberculosis is pulmonary disease. 
Extrapulmonary tuberculosis accounts for about 20% of disease in HIV-seronegative 
people, but is more common in HIV-seropositive individuals (Shafer and Edlin, 1996). 
Among people not infected with HIV, extrapulmonary disease, particularly lymphatic 
tuberculosis, is particularly common in women and young children (Rieder, 1999). 
Pleural tuberculosis occurs as a result of either primary progressive M. tuberculosis 
infection or reactivation of latent infection. Unlike other clinical manifestations of 
tuberculosis, pleural disease probably represents an increased, rather than diminished, 
immune response (Frieden et al., 2003). 
The most serious clinical manifestation of tuberculosis is involvement of the 
central nervous system. Such involvement can include inflammation of the meninges, 
as well as space-occupying lesions (tuberculomas) of the brain. The clinical 
manifestations are due to the presence of M. tuberculosis as well as the inflammatory 
host immune response. Children under 5 years of age and HIV-infected individuals are 
at increased risk of tuberculous meningitis (Berenguer et al., 1992; Thwaites et al., 
2000), which can clinically manifest as chronic meningitis, with headache, fever, and 
changed mental status. Neurological manifestations can include cranial nerve palsies 
and motor, sensory, and cerebellar defects, according to the location of the 
tuberculomas; seizures can also occur. Meningitis is fatal in almost all cases without 
chemotherapy, and prompt identification and treatment is essential to prevent serious 
neurological sequelae (Frieden et al, 2003). 
Tuberculosis can affect any bone or joint, but the spine (i.e., Pott's disease) is 
the most common bony structure involved. In the spine, the most common location is 
the thoracic section. Vertebral-body involvement can be followed by disease of an 
adjacent intervertebral disc (Iseman, 2000). Genitourinary tuberculosis (including 
involvement of the renal and male and female genital tracts) is uncommon and is 
difficult to distinguish from other infections of the genitourinary tract (Frieden et al., 
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2003). In men, manifestations include those of prostatitis or prostate enlargement, 
epididymitis, and orchitis, but disease can also present as a painless scrotal mass. 
Urine analysis may show red or white blood cells, or both, with a negative urine 
culture for bacteria (sterile pyuria). In women, genitourinary tuberculosis is an 
important cause of infertility in areas with high tuberculosis incidence (Goldfarb and 
Saimn, 1996). 
Disseminated tuberculosis is defined as involvement of many organs 
simultaneously and can occur as a result of primary progressive disease or reactivation 
of latent infection. The clinical manifestation of pulmonary involvement is a miliary 
(millet seed) pattern rather than an infiltrate in most cases, but not all patients with 
disseminated disease have pulmonary involvement (Frieden et al., 2003). Mortality is 
high despite chemotherapy and may be related to delays in diagnosis and other 
commonly present underlying medical conditions (Rieder et al., 1990). 
Pathophysiology: 
The pathogenesis of tuberculosis is complex and its manifestations diverse, 
reflecting a lifetime of dynamic interactions between mycobacterial virulence factors 
and the human immune system (Ellner, 1997; Hingley-Wilson et al., 2003). M. 
tuberculosis is an extraordinarily effective human pathogen. Surveys with PPD 
(purified protein derivative) or positive tuberculin skin tests suggest that one third of 
the world's population is infected with the bacillus (Dye et al, 1999). Primary 
infection leads to active disease in only about 10% of infected individuals, mostly 
within two years (Styblo, 1980). In the remaining 90% majority of cases the immune 
system contains the infection and the individual is non-infectious and symptom-free. 
This clinical latency can persist throughout the person's lifetime. Reactivation of 
latent infection can result when host immune responses are perturbed through 
advanced immunosuppression (eg., AIDS/HIV infection, use of steroids, malnutrition, 
etc.) or advanced age (Flynn and Chan, 2001; Tufariello et al., 2003). Reactivation of 
latent infection contributes substantially to the incidence of adult tuberculosis, 
especially in more developed countries where disease prevalence is fairly low (Stead, 
1967). 
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Tuberculosis is spread by airborne aerosolized droplet nuclei, which are 
particles of 1-5 urn in diameter that contain M. tuberculosis. Because of their small 
size, the particles can remain airborne for minutes to hours after expectoration by 
diseased patients (Wells, 1934; Louden and Roberts, 1966). The infectious droplet 
nuclei are inhaled and lodge in the alveoli in the distal airways (Frieden et al., 2003). 
M. tuberculosis exhibits specific cellular tropism for mononuclear phagocytes, i.e., 
alveolar macrophages, monocytes and dendritic cells (Kusner, 2005). M. tuberculosis 
has the remarkable capacity to circumvent destruction within one of the most hostile 
cell types of a vertebrate host: the macrophage, where they establish a niche to survive 
and even replicate (Houben et al., 2006). M. tuberculosis infection initiates a cascade 
of events resulting in either successful containment of the infection or progression to 
active disease (Frieden et al., 2003). 
In brief, after being ingested by alveolar macrophages, M. tuberculosis 
replicates and spreads via the lymphatic system to the hilar lymph nodes. The 
bacterium thus utilizes the host cell as a mechanism of transport into the blood stream 
and deeper tissues. Cell-mediated immunity usually develops 2-8 weeks after 
infection. Activated lymphocytes and macrophages form granulomas that limit further 
replication and spread of the organism (Schluger and Rom, 1998). Although the host 
response is essential to control of infection, the tubercle bacillus participates in the 
establishment of latency by using various strategies to evade elimination by the host. 
The evasion and interaction of pathogenic mycobacteria with the host immune system 
is discussed in greater detail in the following pages. 
An orchestrated series of innate immune pathways, and T-helper 1 (Thl)-
dominant adaptive immune pathways are activated following phagocytosis of the 
bacteria, to culminate in a granuloma at the initial focus of infection (Salgame, 2005). 
The innate host response is necessary for induction of adaptive immunity to M. 
tuberculosis (Crevel et al., 2002). 
(A) Non-specific innate host defense and immune-evasion strategies of 
M. tuberculosis: 
The first step in the innate host defense is cellular uptake of M. tuberculosis, 
which involves different cellular receptors and humoral factors. Toll-like receptors 
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seem to play a crucial role in immune recognition of M tuberculosis, which is the next 
step. The subsequent inflammatory response is regulated by production of pro- and 
anti-inflammatory cytokines and chemokines. Effector mechanisms also contribute to 
innate immunity. Most of the mediators at this point are derived from macrophages 
and dendritic cells. The initial response determines the local outgrowth, sometimes 
dissemination of M. tuberculosis or containment of infection (Crevel et al., 2002). 
Phagocytic cells also play a key role in antigen presentation and the initiation of T cell 
immunity which follows. 
(1) Phagocytosis of M. tuberculosis'. 
M. tuberculosis primarily infects macrophages and later dendritic cells and 
monocyte-derived macrophages by using multiple phagocytic cell surface receptors to 
gain entry (Aderem and Underhill, 1999). These receptors include the mannose 
receptors, complement receptors and Fc receptors. Endocytosis involves receptor-
binding to non-opsonized M. tuberculosis or recognition of opsonins on the surface of 
M. tuberculosis (Crevel et al., 2002). The best characterized receptor for non-opsonin 
mediated phagocytosis of M. tuberculosis is the macrophage mannose receptor, which 
recognizes terminal mannose residues on mycobacteria (Schlesinger et al, 1996). 
Phagocytosis through mannose receptors does not trigger C»2~ production (Astarie-
Dequeker, 1999) and M. tuberculosis exerts an anti-inflammatory signal through this 
receptor (Nigou et al., 2001). M. tuberculosis opsonized with complement factor C3 
bind and are taken up through complement receptor 1 (CR1), CR3 and CR4. 
Fc receptors, which facilitate phagocytosis of particles coated with IgG 
antibodies, seem to play little role in tuberculosis (Armstrong and Hart, 1975). 
However, Fc receptor-mediated phagocytosis is directly linked to an inflammatory 
response (binding to CR is not) (Aderem and Underhill, 1999). Distinct routes of entry 
of M. tuberculosis may lead to differences in signal transduction, immune activation 
and intracellular survival of M. tuberculosis (Crevel et al., 2002). 
(2) Recognition of M. tuberculosis - Role of toll-like receptors: 
The initial interaction of M. tuberculosis with phagocytes through toll-like 
receptors (TLRs) can affect induction of the adaptive response by inflammatory 
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cytokine production as well as begin the process of bacterial containment by induction 
of antimycobacterial functions (Flynn and Ernst, 2000). It is partly through this 
interaction with TLRs that macrophages produce inflammatory cytokines and 
chemokines that serve as signals of infection (Tufariello et al., 2003). TLRs mediate 
the activation of cells of the innate immune system, resulting in destruction of 
invading microbes through the activation of several signalling cascades. TLRs are 
phylogenetically conserved mediators of innate immunity, which are essential for 
microbial recognition on macrophages and dendritic cells (Belvin and Anderson, 
1996; Medzhitov et al., 1997). Activation of TLRs is an important link between innate 
cellular responses and the subsequent activation of adaptive immune defenses against 
microbial pathogens (Salgame, 2005). 
TLR-signalling leads to the nuclear translocation of NF-KB (nuclear factor-
KB). NF-KB is a transcription factor involved in the expression of many immune 
response genes such as those encoding the cytokines TNF-a and interleukins (Houben 
et al, 2006). TLR-signalling also triggers differentiation of monocytes into 
macrophages and dendritic cells, thereby generating the cellular populations necessary 
for a potent innate and adaptive immune response (Krutzik et al., 2005). 
Members of the TLR family are transmembrane proteins containing repeated 
leucine-rich motifs in their extracellular domains, similar to other pattern-recognizing 
proteins of the innate immune system (Crevel et al., 2002). The cytoplasmic domain of 
TLR is homologous to the signalling domain of IL-1R (IL-1 receptor) and links to 
IRAK (IL-1R associated kinase), a serine kinase that activates transcription factors 
like NF-KB to signal the production of cytokines (Oddo et al., 1998). 
Through TLRs M. tuberculosis lysate or soluble mycobacterial cell wall-
associated lipoproteins induce production of IL-12, a strong pro-inflammatory 
cytokine (Brightbill et al., 1999). Myeloid differentiation protein 88 (MyD88), a 
common signalling component that links all TLRs to IRAK (Oddo et al., 1998), was 
found to be essential for M. tuberculosis-induced macrophage activation (Underhill et 
al, 1999). From several lines of evidence it has become clear that phagocytosis does 
not lead to immune activation in the absence of functional TLRs (Crevel et al, 2002). 
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Besides generating cytokine activity, TLR stimulation in macrophages 
upregulates phagocytosis of bacteria (Doyle et al., 2004) and apoptotic cells 
(Shiratsuchi et al., 2004). TLRs also appear to regulate fusion events between 
phagosomes and lysosomes (Doyle et al., 2004). Whether or not pathogenic 
mycobacteria interfere with TLR signalling to block their delivery to phagosomes, eg., 
through modulation of MAPK signalling pathways remains to be established in vivo 
(Houben et al, 2006). 
(3) Effector mechanisms for killing of M. tuberculosis: 
(a) Avoidance of macrophage-mediated killing: 
Although macrophages provide an effective initial barrier against infection by 
bacterial pathogens, M. tuberculosis has evolved numerous strategies that allow it to 
survive and set up initial residence within these cells (Zahrt, 2003) after gaining entry 
via multiple cell surface receptors (eg., mannose receptors, complement receptors and 
Fc receptors). Pathogenic mycobacteria coat themselves with a serum protein that is 
recognized by complement, thereby avoiding host inflammatory response (Caron and 
Hall, 1998). M. tuberculosis crosses the first line of defense, i.e., the alveolar barrier 
by invading the alveolar epithelial cell and secondarily, the endothelial layer, or it does 
so within infected macrophages (Bermudez and Sangarib, 2001). M. tuberculosis 
evades the innate antimicrobial defenses of macrophages by inhibiting the maturation 
of its phagosome to a bactericidal phagolysosome (Kusner, 2005). Mycobacterium-
induced inhibition of phagosome-lysosome fusion has been considered the central 
feature of tuberculous pathogenesis, providing the organism with a means to avoid 
both the direct antimicrobial activity of the innate immune system as well as effective 
antigen presentation by inhibiting MHC class II dependent antigen presentation 
pathway and elicitation of adaptive immunity (Vergne et al, 2003; Kusner, 2004). 
Thus, the survival mechanisms or pathogenic strategies involved include inhibition of 
phagosome maturation and acidification, modification of the normal phagosomal 
trafficking pathway, and alteration of recruitment or association of various proteins to 
the phagosomal membrane. These are discussed below: 
Inhibition of phagosome maturation and the consequent intracellular survival 
of M. tuberculosis occurs via inhibition of macrophage Ca +-mediated signal 
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transduction through inhibition of macrophage sphingosine kinase (Kusner, 2005). 
Many lipid components of the mycobacterial cell wall have essential roles in the 
innate ability of mycobacteria to block the fusion of the bacterial phagosome to 
lysosomes (Houben et al., 2006). Altered phagosomal maturation is associated with 
alteration in the protein content of the vacuole including altered Rab GTPase 
composition (Clemens et al, 2000), exclusion of the vacuolar protein ATPase with 
consequent lack of acidification (Sturgill-Koszycki et al., 1994), and retention of a 
protein designated TACO (tryptophan aspartate rich coat protein) (Ferrari et al., 1999). 
Whereas some mycobacterial cell wall lipids, such as trehalose mycolates, influence 
the inflammatory response (Geisel et al, 2005; Rao et al., 2005), other components 
modulate trafficking inside the macrophage. For example, the M. tuberculosis Ptdlns-
3P analog, glycosylated phosphatidyl inisitol lipoarabinomannan (ManLAM), blocks 
phagosome maturation (Fratti et al., 2003) and inhibits the rise in Ca2+ concentration 
in the macrophage cytosol upon phagocytosis of mycobacteria. 
(b) Role of nitric oxide (NO): 
Putative and effective host defense mechanisms by innate immune cells to M. 
tuberculosis within the phagolysosomes of activated macrophages include the 
production of reactive oxygen (ROI) and reactive nitrogen intermediates (RNI). 
Catalytic action of the respiratory burst by the NADPH-oxidase complex produces 
ROI such as hydrogen peroxide (H2O2), superoxide anion (O2") and hydroxyl radical 
(OH ) (Chan et al., 2001). NO is a non-specific, chemically reactive molecule that is 
important in host defense against a wide variety of microbial pathogens. Although 
controversial, there is a growing body of evidence that NO produced by M. 
tuberculosis-infected human macrophages and epithelial cells is also 
antimycobacterial against M. tuberculosis (Rockett et al, 1998; Jagannath et al., 
1998). Human macrophages produce NO from increased iNOS activity (Chan et al, 
2001) as in human lung epithelial cells (Robbins et al., 1994). TNF-a and IL-lp\ along 
with IFN-y produced by T lymphocytes, can induce NO in macrophages via inducible 
form of the enzyme nitric oxide synthase (iNOS) (Kwon, 1997). Mycobacterial cell 
wall components such as LAM and 19 kDa lipoprotein, along with T cell-derived IFN-
j may also induce NO expression (Adams et al, 1993; Brightbill et al., 1999). 
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(c) Apoptosis: 
Apoptosis of infected phagocytic cells may prevent dissemination of infection 
by reducing viability of intracellular M. tuberculosis and limiting its outgrowth (Keane 
et al., 1997; Placido et al., 1997). NO may induce such apoptosis (Chan et al., 2001). 
TNF-a is also required for induction of apoptosis in response to M. tuberculosis 
infection (Keane et al., 1997). Another potential mechanism for apoptosis-induced 
mycobacterial killing is that, as with host nuclear fragmentation, mycobacterial DNA 
may also be destroyed during apoptosis (Molloy and Kaplan, 1996). The selective 
induction of IL-10 by M. tuberculosis may lead to decreased TNF-a activity and 
reduced apoptosis of infected cells (Astarie-Dequeker et al., 1999). In addition, 
increased expression of Fas ligand in infected macrophages may also contribute to 
decreased macrophage apoptosis (Mustafa et al., 1999). 
(4) Cytokine production driven by M. tuberculosis: 
Cytokines are a group of hormone-like polypeptides that play a variety of 
regulatory roles in host defense against infection (Poveda et al., 1999). Once infection 
is established, a focal nonspecific inflammatory response follows. This response is 
regulated by a network of pro- and anti-inflammatory cytokines and chemokines 
(Crevel et al., 2002), which serve as signals of infection (Means et al, 1999). There 
are two kinds of cytokines, pro-inflammatory and anti-inflammatory. The pro-
inflammatory cytokine network plays a crucial role in the inflammatory response and 
the outcome of mycobacterial function. This response is antagonized by anti-
inflammatory mechanisms. In addition some cytokines may inhibit the production or 
the effects of pro-inflammatory cytokines in tuberculosis (Crevel et al., 2002). 
(a) Pro-inflammatory cytokines: 
(i) TNF-a: 
Stimulation of monocytes, macrophages and dendritic cells with mycobacteria 
or mycobacterial products induces TNF-a production (Henderson et al., 1997; Valone 
et al., 1988). This prototype pro-inflammatory cytokine plays a key role in granuloma 
formation (Senaldi et al, 1996), induces macrophage activation and has 
immunoregulatory properties (Tsenova et al, 1999). However, systemic spillover of 
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TNF-a may account for unwanted inflammatory effects like fever and wasting (Crevel 
et al., 2002). Thus, TNF-a has both adverse and beneficial effects in the human 
immune response (Tufariello et al., 2003). To limit the deleterious effects of TNF-a 
(Hernandez and Rook, 1994; Bekker et al., 2000), systemic production of TNF-a is 
downregulated (Friedland et al., 1995; Takashima et al., 1990). In spite of this, anti-
TNF-a therapy in the treatment of tuberculosis is associated with an increased risk of 
developing tuberculosis (Keane and Gershon, 2002), mainly due to reactivation of a 
chronic infection (Keane et al., 2001). In addition, TNF-a has an important role in the 
maintenance of the granulomatous response in latent tuberculosis, and in maintaining 
the organization of the granuloma, the integrity of which contributes to the 
containment of M. tuberculosis (Tufariello et al., 2003). 
(ii) IL-lp: 
This pro-inflammatory cytokine is produced mainly by monocytes, 
macrophages and dendritic cells (Dahl et al., 1996; Gerosa et al., 1999). It is expressed 
in excess (Schauf et al., 1993) and at the site of disease in tuberculosis patients 
(Bergeron et al, 1997). IL-1R antagonist (IL-IRa) is the naturally occurring 
antagonist of IL-1. It has been suggested that an increased IL-ip/IL-IRa ratio protects 
against a more severe presentation of tuberculosis, especially tuberculosis pleuritis 
(Wilkinson etal., 1999). 
(iii) IL-6: 
This is an early cytokine, which has both pro- and anti-inflammatory properties 
(VanHeyningen et al., 1997) and is produced at the site of infection (Hoheisel et al., 
1998). IL-6 may be harmful in mycobacterial infections, as it inhibits the production 
of TNF-a and IL-ip (Schindler et al., 1990). However, other reports indicate a 
protective role for IL-6, which seems related to optimal IFN-y production early in M. 
tuberculosis infection (Ladel et al., 1997a). 
(iv) IL-12: 
IL-12 is produced mainly by phagocytic cells after phagocytosis of M. 
tuberculosis (Ladel et al., 1997b). It is an important early pro-inflammatory cytokine 
that drives the production of IFN-y from natural killer (NK) cells (Trinchieri, 2003). 
Thus, IL-12 is the inducer cytokine and IFN-y is the effector cytokine that mediates 
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protection (Ismail et al., 2002) as discussed further. IL-12 is a regulatory cytokine that 
connects the innate and adaptive host response to mycobacteria (Trinchieri, 1995) and 
which exerts its protective effects mainly through the induction of IFN-y (Cooper et 
al., 1997). In tuberculosis, IL-12 has been detected in lung infiltrates (Taha et al., 
1997), and in granulomas (Bergeron et al, 1997). The expression of IL-12 receptors is 
also increased at the site of disease (Zhang et al., 1999). Three additional cytokines 
with IL-12-like activities have been identified, notably IL-18, IL-23 and IL-27 (Vosse 
et al., 2004). IL-18, a novel pro-inflammatory cytokine shares many features with IL-1 
(Dinarello et al, 1998) and acts as an IFN-y inducing factor, synergistic with IL-12 
(O'Neill and Greene, 1998). It also stimulates the production of other pro-
inflammatory cytokines, chemokines, and transcription factors (Netea et al, 2000). IL-
15 is similar to IL-2 in its biological activities and stimulates T cell and NK cell 
proliferation and activation (Kennedy and Park, 1996). However, unlike IL-2, the 
production of IL-15 is mainly by monocytes and macrophages (Crevel et al., 2002). 
(v) IFN-y: 
An important macrophage-activating molecule involved in the immune defense 
against pathogenic mycobacteria is interferon-y. Production of IFN-y is regulated by 
other cytokines, particularly IL-12. In the early phase of the immune response, IL-12 
drives the production of IFN-y from NK cells (Trinchieri, 2003). Several immune 
mechanisms, such as antigen presentation, leukocyte-endothelium cell interactions, 
cell growth and apoptosis, reactive nitrogen and oxygen intermediates as well as 
phagosome-lysosome fusion can be modulated through the activity of IFN-y (Houben 
et al, 2006). Activation of macrophages by IFN-y also induces autophagy, which is a 
normal degradative pathway implicated in innate immune mechanisms against M. 
tuberculosis (Ogawa et al., 2005). 
(b) Anti-inflammatory cytokines: 
The pro-inflammatory response is antagonized by anti-inflammatory 
mechanisms. Soluble cytokine receptors prevent binding of cytokines to cellular 
receptors, blocking further signalling (Crevel et al., 2002). Anti-inflammatory 
cytokines are also important in immuno-regulation. 
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(i) IL-10: 
IL-10 is produced by macrophages after M. tuberculosis phagocytosis (Shaw et 
al., 2000) and after binding of LAM (Dahl et al., 1996), by dendritic cells and 
macrophages (Tufariello et al., 2003). IL-10 downregulates the production of the pro-
inflammatory cytokines IFN-y, TNF-oc and IL-12 (Fulton et al., 1998; Hirsch et al., 
1999). IL-10 can deactivate macrophages and dampen the immune response to prevent 
or limit pathology from an over-exuberant inflammatory response to a pathogen. This 
cytokine may have a role in the chronic phase of infection, since downregulation of a 
type I immune response is likely to be beneficial to the host, at least in terms of lung 
pathology (Tufariello et al., 2003). IL-10 expression in tuberculosis has been 
demonstrated in circulating mononuclear cells, at the site of disease in pleural fluid 
and in alveolar lavage fluid (Barnes et al., 1993; Gerosa et al, 1999). 
(ii) TGF-P: 
TGF-(3 is produced by monocytes and dendritic cells following induction by 
mycobacterial products (Toossi et al., 1995). TGF-P suppresses cell-mediated 
immunity; in T cells it inhibits proliferation and IFN-y production; in macrophages it 
antagonizes antigen presentation, pro-inflammatory cytokine production, and cellular 
activation. TGF-P may be involved in tissue damage and fibrosis during tuberculosis, 
as it promotes the production and deposition of macrophage collagenases (Toossi and 
Ellner, 1998). 
(iii) IL-4: 
IL-4 has deleterious effects in tuberculosis, which have been ascribed to this 
cytokine's suppression of IFN-y production (Powrie and Coffman, 1993) and 
macrophage activation (Appelberg et al., 1992). 
(5) N F - K B activation - Role in innate immunity: 
It is well established that the classical NF-KB pathway, based on IKKp-
dependent IKB degradation, is essential for innate immunity (Bonizzi and Karin, 
2004). The activation and nuclear translocation of classical NF-KB dimers is 
associated with increased transcription of genes encoding chemokines, cytokines, 
adhesion molecules [intracellular adhesion molecule-1 (ICAM-1), vascular cell 
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adhesion molecule-1 (VCAM-1) and endothelial-leukocyte adhesion molecule-1 
(ELAM-1)], enzymes that produce secondary inflammatory mediators and inhibitors 
of apoptosis (Ghosh et al., 1998). These molecules are important components of the 
innate immune response to invading microorganisms and are required for migration of 
inflammatory and phagocytic cells to tissues where NF-KB has been activated in 
response to infection or injury (Bonizzi and Karin, 2004). Indirect pathways that lead 
to NF-KB activation are illustrated by infection of pulmonary epithelial cells with M. 
tuberculosis, which results in the release of IL-1 and activation of the classical NF-KB 
pathway in adjacent cells (Wickremasinghe et al., 1999). 
(B) Specific acquired/adaptive immune response: 
(1) T-cell mediated immunity: 
In most infected individuals, cell-mediated immunity develops 2-8 weeks after 
infection. The development of cell-mediated immunity is associated with the 
development of a positive result in the tuberculin skin test (Frieden et al., 2003). 
Macrophages and dendritic cells, the primary cell types involved in the innate immune 
response to M. tuberculosis, play a crucial role in the initiation of adaptive immunity 
(Crevel et al, 2002). The initial interaction of M. tuberculosis with phagocytes 
through TLRs can affect induction of the adaptive response by inflammatory cytokine 
production, as well as begin the process of bacterial containment by induction of 
antimycobacterial functions. The initiation of the adaptive immune response to the 
organism is likely to be a major determinant of long-term control of the infection 
(Flynn and Ernst, 2000). Thus, TLRs are an important link between innate and 
adaptive immunity (Duin et al., 2005). The significance of TLRs in activating adaptive 
immunity is well established (Iwasaki and Medzhitov, 2004); TLR-mediated 
activation of dendritic cells is a crucial step in this process. Other mechanisms 
involved include induction of expression of cytokines and co-stimulatory proteins 
(Duin et al., 2005). Signalling through TLRs favours the development of a Thl-type 
response, in which IL-12 has an important role (Trinchieri, 2003). 
CD4+ T cells have a crucial role in protection against tuberculosis (Selwyn et 
al., 1989; Tufariello et al, 2003). In human beings, CD8+ T cells have been reported to 
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be involved in the control of both acute and chronic infection (Rolph et al., 2001; 
Turner et al., 2001). CD8+ T cells specific for M. tuberculosis can directly kill 
intracellular bacilli via a granule-associated protein, granulysin (Stenger et al., 1998). 
In brief, at the focal site of infection in the lungs, the dendritic cells that engulf 
bacteria mature (Hertz et al, 2001; Bodnar et al, 2001) and migrate to the required 
lymph node. Once there, CD4+ and CD8+ T cells are primed against mycobacterial 
antigens. Primed T cells expand and migrate back to the lungs and through the lung 
tissue to the focus of infection, presumably in response to signals such as chemokines 
produced by or in response to infected cells (Tufariello et al., 2003). M. tuberculosis-
infected macrophages release IL-12 and IL-18 which stimulate the CD4+ and CD8+ T 
cells to release IFN-y (Sodhi et al, 1997; Ellner, 1997). IFN-y is crucial for the control 
of M. tuberculosis infection (Flynn et al., 1993). It stimulates phagocytosis of M. 
tuberculosis and also the release of TNF-a from macrophages, which is important in 
granuloma formation and control of the extent of infection (Flynn et al., 1995; Bean et 
al , 1999). 
Three processes contribute to the infection of adaptive immunity: antigen 
presentation, costimulation, and cytokine production. These are discussed below: 
(a) Antigen presentation: 
The T lymphocyte response is antigen specific and is influenced by the major 
histocompatibility complex (MHC) (Flynn and Ernst, 2000). MHC class II molecules 
are expressed on professional antigen-presenting cells (APCs). They present 
mycobacterial proteins to antigen-specific CD4+ T cells. These antigens are processed 
in the phagolysosomes of APCs (Crevel et al, 2002). MHC class I molecules are 
expressed on all nucleated cells. They present mycobacterial proteins to antigen-
specific CD8+ T cells. This is important for the presentation of cytosolic antigens, 
which may be important as certain mycobacteral antigens may somehow escape the 
phagosome (Mazzaccaro et al., 1996). 
Pro-inflammatory cytokines, primarily IFN-y stimulate MHC expression, 
whereas anti-inflammatory cytokines inhibit its expression. Polymorphism of MHC 
may contribute to differences in disease susceptibility or outcome (Goldfeld et al., 
1998). The expression of particular class I and class II MHC alleles in an individual 
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determines mycobacterial antigens and epitopes (Crevel et al., 2002). Certain allelic 
human leukocyte antigen variants (HLA polymorphism) have been associated with 
tuberculosis and susceptibility to it (Goldfeld et al., 1998; Ravikumar et al., 1999). 
(b) Costimulation: 
Maturation of dendritic cells induced by TLR stimulation results in 
accumulation of antigen-MHC II complexes on the cell surface, thus facilitating 
antigen presentation (Cella et al., 1997; Hertz et al., 2001). Antigen presentation only 
leads to T cell stimulation in the presence of particular costimulatory signals. The co-
stimulatory proteins CD80 (Kindler et al., 1989), CD86 (Sarno et al., 1991) and CD70 
are upregulated on antigen-presenting cells after TLR activation (Iwasaki and 
Medzhitov, 2004). These molecules (CD80 and CD86) bind to CD28 and CTLA-4 on 
T cells (Crevel et al., 2002). In the absence of proper co-stimulatory signals, antigen 
presentation may lead to increased apoptosis of T cells (Hirsch et al., 2001). 
(c) Cytokine production: 
Cytokine production by activated macrophages and dendritic cells is important 
for T cell stimulation. These cytokines include IL-12, IL-18, and IL-23 as well as IL-1 
and TNF-cc (Dinarello, 1996; Tsenova et al., 1999; Oppmann et al., 2000). IL-12 is the 
inducer cytokine that mediates protection (Ismail et al, 2002). During the ensuing 
immune response, IL-12 plays a key part in driving the activation, differentiation from 
CD4+ T cells, and expansion of antigen-specific Thl cells. These cells are a major 
source of IFN-y during the adaptive immune response and are necessary for the 
control of the chronic phase of infection (Janeway and Medzhitov, 2002). The 
activation of infected macrophages by IFN-y in synergy with TNF-a is a major 
effector mechanism of cell-mediated immunity. M. tuberculosis induces TNF-a 
synthesis by a TLR2-dependent pathway (Underhill et al., 1999). IFN-y, together with 
TNF-a, which is released by T cells and phagocytes, activates microbicidal 
mechanisms in mononuclear phagocytes (Vosse et al, 2004). 
(2) Granuloma formation: 
The granuloma is a hallmark protective immunopathological response of the 
host following infection with M. tuberculosis. It is considered to be a protective 
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structure since it curtails the spread of the pathogen and at the same time localizes 
inflammation and damage to the lungs (Salgame, 2005). Primed T cells in the lymph 
nodes expand and migrate back to the lungs and then through the lung tissue to the 
focus of infection in response to chemokine signals especially TNF-a. This culminates 
in the formation of a granuloma, a characteristic feature of tuberculosis (Tufariello et 
al., 2003). Besides T cells and infected macrophages, additional immune host cells are 
recruited, including B cells, dendritic cells, endothelial cells, fibroblasts, and probably 
stromal cells (Gonzalez-Juarrero et al., 2001). The granuloma encompasses the bacilli, 
which reside within macrophages, and serves to wall off the bacteria from the rest of 
the lung, limiting spread. In addition, the granuloma functions as an immune 
microenvironment to facilitate interactions between T cells, macrophages and 
cytokines. However, the granuloma can also provide a home for M. tuberculosis for an 
extended period, because some bacteria can avoid elimination within the granuloma 
(Tufariello et al., 2003). The granuloma subsequently develops central areas of 
necrosis (called caseum, from the word 'cheese'), resulting in the death of the majority 
of the bacteria and destruction of the surrounding host tissue. The surviving bacilli 
exist in a latent state and can become reactivated to develop active disease (Grosset, 
2003). Proteosome-mediated inactivation of NO stress is important for the survival of 
mycobacteria within granuloma structures (Darwin et al., 2003; Pieters and Ploegh, 
2003). Although excessive replication of bacteria seems to result in loss of granuloma 
structure, extensive necrosis, and cavity formation, in most cases the granuloma 
contains the infection, but a limited number of bacilli survive, which is termed latent 
tuberculosis. A person who has a delayed type hypersensitivity response to 
mycobacterial antigens (PPD) without signs of active tuberculosis is deemed to have 
latent infection and not to be contagious. 
The Bacterium: 
The causative organism of tuberculosis, Mycobacterium tuberculosis is a 
Gram-positive aerobic bacterium that divides every 16-20 hours. It is a small rod-like 
bacillus which can withstand weak disinfectants and can survive in a dry state for 
weeks but can only grow within a host organism. 
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(A) M. tuberculosis cell envelope - Architecture and composition: 
M. tuberculosis is surrounded by a complex envelope of unusually low 
permeability, which contributes to the resistance of this bacterium to host defense 
mechanisms (Jarlier and Nikaido, 1994; Daffe and Draper, 1998). In general, the 
bacterial cell envelope is composed of a plasma membrane, a complex wall 
comprising a variety of covalently and non-covalently linked carbohydrates and lipids, 
and finally an outer layer (capsule) of polysaccharides, proteins and small amounts of 
lipids. The plasma membrane is a typical bilayer of proteins and phospholipids (Daffe 
and Draper, 1998). Similar to classical bacterial cell walls, the cell envelope of M. 
tuberculosis contains a cell membrane and a peptidoglycan layer (Glickman and 
Jacobs, 2001). The thick peptidoglycan layer is covalently linked to a 
heteropolysaccharide, namely arabinogalactan. However, in other aspects, the M. 
tuberculosis cell envelope differs substantially from the canonical cell wall structures 
of both Gram-negative and Gram-positive bacteria (Fig. 1). The cell envelope is 
typified by the presence of a large hydrophobic layer of unusual long-chain fatty acids: 
mycolic acids, esterified to the cell wall, named the mycolyl arabinogalactan (mAG) 
(Glickman and Jacobs, 2001). Mycolic acids are long chain (60-90 carbon atoms), 
branched, a-|3 hydroxyl fatty acids that exist either covalently attached to the cell wall 
or non-covalently attached in the form of trehalose dimycolate (TDM). The arabinan 
segments of arabinogalactan in the peptidoglycan layer are terminated by a hexa-
arabinosyl unit esterified by the various types of mycolic acid residues elaborated by 
the species (Daffe, 2000). These long-chain fatty acids are probably arranged into an 
asymmetric bilayer with other non-covalently linked lipids, which forms a virtually 
impermeable outer barrier obstructing access of hydrophilic substances. Mycolic acids 
are thought to play an important role in the structure of the cell wall and to contribute 
to the resistance of mycobacteria to many therapeutic agents (Jarlier and Nikaido, 
1994). Among the non-covalently linked lipids that can be found in the outer bilayer 
are TDM, trehalose monomycolates (TMM), glycerol monomycolates and 
phospholipids. A wide array of unique lipids and glycolipids are non-covalently 
associated with the cell envelope and confer extreme hydrophobicity to the outer 
surface of the organism (Daffe, 2000). 
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Figure 1. Schematic Diagram of the Cell Envelope of M. tuberculosis: The cell envelope of M. 
tuberculosis contains a cell membrane (CM) and a peptidoglycan layer (PG) similar to 
those of classical bacterial cell walls. In contrast to other bacteria, M. tuberculosis has a 
thick hydrophobic layer of mycotic acids esterified to the cell wall, named the mycolyl 
arabinogalactan (mAG). (Source: Glickman and Jacobs. Cell. 2001 104: 477-485.) 
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Many of these molecules are potent immunomodulators, suggesting a role in 
virulence. For example, lipoarabinomannan, a major cell wall-associated glycolipid, 
has been extensively examined in vitro and can inhibit IFN-y activation of 
macrophages (Sibley et al., 1988; 1990), induce TNF-a release from macrophages 
(Chatterjee et al., 1992), and scavenge oxygen free radicals (Chan et al., 1991). TDM, 
a mycolic acid-containing glycolipid, can produce granulomatous inflammation and 
thymic atrophy when injected into mice (Ozeki et al., 1997), in addition to affecting 
membrane fusion in model systems (Spargo et al., 1991). 
Like Gram-positive bacteria, the mycobacterial cell envelope contains 
proteins, including some with pore-forming ability (Daffe, 2000). The increasing 
number of enzymes recently identified as being involved in cell envelope biogenesis 
includes the three predominant secreted proteins of M. tuberculosis, antigens 8 5A, 
85B and 85C (Wiker and Harboe, 1992). 
(B) M. tuberculosis antigen 85 complex: 
The antigen 85 complex consists of three internally cross-reacting antigens 
encoded by three independent genes, fbpA, fbpB, fbpC, found in the genomes of M. 
tuberculosis, M. leprae and M. avium (Wiker et al., 1990; Content et al., 1991; Daffe, 
2000). In antigen 85 complex, the gene for antigen 85A encodes a 294 amino acid 
mature protein (Borremans et al., 1989), which shows 79% homology with the 
deduced 285 amino acid sequence of antigen 85B (Matsuo et al., 1988). The antigen 
85 complex is often referred to as the 30/31 kDa doublet and the molecular masses of 
the individual components of the antigen 85 complex are as follows: antigen 85B, 30 
kDa; antigen 85A, 31 kDa; antigen 85C, 31.5 kDa. Antigen 85C appears to be slightly 
heavier than antigen 85A, and in most SDS-PAGE runs these two components are not 
properly resolved (Wiker and Harboe, 1992). Thus, the pattern in Western 
immunoblotting usually reveals a doublet in the 30 kDa region, as exemplified by 
using the monoclonal antibody HYT27 (Schou et al., 1985) which reacts with all three 
components of the complex (Wiker et al, 1992). The components are clearly resolved 
in isoelectric focusing, providing three distinct bands (Vooren et al., 1991). In M. 
tuberculosis H37Rv culture fluid obtained from a batch with minimal cell lysis, the 
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quantitatively dominating components of the antigen 85 complex, antigens 85A and 
85B, constituted about 60% of total protein and there was slightly more antigen 85B 
than antigen 85A. Although antigen 85 complex is a major constituent of the 
mycobacterial culture fluid, it is also found in association with the bacterial surface. 
The monoclonal antibody HYT27 gave a positive signal in ELISA with whole M 
tuberculosis cells (Schou et al., 1985). The localization index for antigen 85A has 
consistently been found to be higher than for antigen 85B, indicating that antigen 85B 
may be less efficiently secreted and more closely associated with the bacterial surface 
(Wiker et al., 1991; Wiker and Harboe, 1992). Worsaae et al. (Worsaae et al., 1988) 
performed skin testing with the antigen 85 complex affinity purified with monoclonal 
antibody HYT27. The available results indicate that antigen 85B is a relatively good 
skin test reagent whereas antigen 85A is not. The information on antigen 85C remains 
to be established (Wiker and Harboe, 1992). 
Antigen 85B is a mycolyl transferase involved in cell wall biosynthesis. In an 
in vitro enzymatic assay, antigen 85B has been shown to catalyse the transfer of a 
mycolyl residue from one molecule of TMM to another, leading to the formation of 
TDM (or cord factor) (Belisle et al, 1997). It stimulates lymphocyte blastogenesis and 
IFN-y production in healthy individuals, but not in patients with pulmonary 
tuberculosis (Huygen et al., 1988; Havlir et al., 1991). In contrast, antibody to the 85B 
antigen is increased in patients with tuberculosis (Torres et al., 1994). Interestingly, 
antigen 85B is immunodominant (Abou-Zeid et al., 1988) and potently induces TNF-a 
when complexed to fibronectin in mononuclear phagocytes (Aung et al., 1996). 
Fibronectins are a family of high molecular weight glycoproteins found in plasma and 
tissues that are involved in cell motility and adhesion, regulation of cell morphology, 
phagocytic function, and wound healing (Proctor, 1987). The expression of 85B in M. 
tuberculosis-infected monocytes correlates positively with both the amount of secreted 
TNF-a and subsequent intracellular mycobacterial growth (Wilkinson et al , 2001). 
Antigen 85B mRNA in both broth cultures and sputum specimens correlates well with 
the yield of viable M. tuberculosis (Desjardin et al., 1999; Hellyer et al., 1999). 
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Modern laboratory diagnosis of tuberculosis: 
The emergence of multidrug-resistant M. tuberculosis strains, and increasing 
co-infection with HIV has fuelled the current pandemic and global resurgence in 
tuberculosis (De Cock and Chaisson, 1999; Drobniewski et al., 2003). Early diagnosis 
of tuberculosis and drug resistance improves survival and by identifying infectious 
cases, promotes contact tracing, implementation of institutional cross-infection 
procedures, and other public health actions (Drobniewski et al., 2003). 
(A) Active disease: 
Patients with persistent cough (eg., lasting longer than 2 weeks) should be 
assessed for tuberculosis (WHO, 2003a). Other common symptoms include fever, 
night sweats, weight loss, shortness of breath, haemoptysis and chest pain (American 
Thoracic Society, 2000). 
(1) Microscopy: 
Introduced by Robert Koch in 1882, microscopy remains a cornerstone of 
tuberculosis control because it identifies sputum-smear-positive (most infectious) 
cases (Drobniewski et al., 2003). It is rapid and inexpensive, although it has limited 
specificity: the smear is positive in only 50-80% of individuals with culture-confirmed 
primary tuberculosis (Grzybowski et al., 1975; Frieden et al., 2003). Fluorescent 
staining methods offer higher specimen throughput and possibly greater sensitivity 
(Drobniewski et al., 2003). 
(2) Culture: 
Culture is required for definite diagnosis and is essential for drug-susceptibility 
testing. Rapid automated continuous mycobacterial liquid culture systems should be 
used in addition to solid culture (eg., the egg-based Lowenstein-Jensen medium or the 
agar-based Middlebrook formulations, 7H10 or 7H11). Solid culture media allows 
examination of colony morphology and the identification of mixed cultures, whereas 
liquid culture enables more rapid diagnosis (Frieden et al., 2003). This is because 
growth generally occurs within 7-21 days in liquid media (Morgan et al, 1983). Solid 
media allows prolonged and inexpensive incubation of cultures, with growth occurring 
in 6 weeks or longer. Positive cultures from these systems are analyzed using DNA 
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hybridization or comparable systems for the presence/identification of M. tuberculosis 
(Drobniewski et al., 2003). 
(3) Radiographic findings: 
Findings indicative of tuberculosis include upper-lobe infiltrates, cavity 
infiltrates, and hilar or paratracheal adenopathy. However, radiographic findings may 
be subtle or difficult to interpret in HIV-infected patients (Perlman et al., 1997; 
Frieden et al., 2003). 
(B) Latent infection: 
The condition of clinical latency in the presence of infection with live M. 
tuberculosis is described as latent tuberculosis infection (Drobniewski et al, 2003). 
This is demonstrated by a positive reaction to a tuberculin skin test. 
(1) Tuberculin skin test (TST): 
The intradermal administration of tuberculin has been used as a diagnostic test 
for tuberculosis infection since the early nineteenth century (Von Pirquet, 1909); the 
more consistent form of tuberculin, standardized purified protein derivative (PPD-S), 
has been used to assess latent M. tuberculosis infection since 1939 (Seibert and Glen, 
1941; Lee and Holzman, 2002). The TST attempts to measure cell-mediated immunity 
in the form of a delayed-type hypersensitivity response to PPD, which is a crude 
mixture of antigens, many of which are shared among M. tuberculosis, M. bovis BCG 
and several non-tuberculous mycobacteria. Thus, its limitations include low sensitivity 
in immunocompromised patients (with depressed immunity eg., AIDS patients), cross-
reactivity with bacille Calmette-Guerin (BCG) vaccine and a requirement that patients 
must return 48-72 hours after the test is done to have the result read by measuring the 
induration (Huebner et al, 1993). 
(2) Interferon-y release assay (IGRA): 
This is a whole blood cellular immune-based test that quantifies IFN-y 
response. IGRA is based on the principle that T cells of individuals sensitized with 
tuberculosis antigens produce IFN-y when they re-encounter mycobacterial antigens 
(Andersen et al., 2000). A level of IFN-y production therefore, is presumed to be 
indicative of tuberculosis infection. An enzyme-linked immunospot (ELISPOT) assay, 
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which measures IFN-y production from whole blood or peripheral blood mononuclear 
cells (PBMC) stimulated with either PPD or more specific antigens has shown 
promise as a test for latency (Lalvani et al., 2001; Doherty et al., 2002). IGRAs have 
several advantages over the TST (Lalvani, 2003; Barnes, 2004). Because the test is 
done in vitro and does not involve measurements such as skin induration, the results 
are less subjective, and a single visit by the patient is adequate. Newer assays that use 
M. tuberculosis-specific region of difference 1 (RD1) antigens may have advantages 
over the PPD-based TST, in terms of higher specificity (Andersen et al, 2000; 
Lalvani, 2003), better correlation with exposure to M. tuberculosis, and less cross-
reactivity due to BCG vaccination and non-tuberculous mycobacterial infection. 
Treatment and control: 
The goals of treatment are to ensure cure without relapse, to prevent death, to 
stop transmission, and to prevent the emergence of drug resistance (Frieden et al., 
2003). To control tuberculosis, WHO and IUATLD recommend the DOTS (WHO, 
2002), which has five elements: political commitment, diagnosis primarily by sputum-
smear microscopy among patients attending health facilities, short-course treatment 
with effective case management (i.e., direct observation), regular drug supply, and 
systematic monitoring to assess outcome of every patient started on treatment. The 
international targets for tuberculosis control by 2005 are to detect 70% of new 
pulmonary smear-positive cases annually, and to treat 85% of detected cases 
successfully (WHO, 2000). 
Tumor necrosis factor-alpha (TNF-a): 
TNF-a was first discovered in 1975 as a macrophage-derived molecule that 
induced a haemorrhagic necrosis of tumors transplanted subcutaneously in mice 
(Carswell et al., 1975). It is a member of the TNF superfamily of cytokines, consisting 
mainly of homotrimeric proteins involved with immune regulation and inflammation 
that includes lymphotoxin-a (TNF-P), CD40 ligand and Fas ligand (Darnay and 
Aggarwal, 1999). TNF-a is a pleiotropic cytokine that plays a central role in 
inflammation and apoptosis (Sedgwick et al., 2000; MacEwan, 2002). It is synthesized 
as a 26 kDa, type II transmembrane protein that is 233 amino acids in length (Pennica 
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et al., 1984; MacEwan, 2002). It contains a 30 amino acids cytoplasmic domain, a 26 
amino acids transmembrane segment, and a 177 amino acids extracellular region 
(Wang et al., 1985; Ishisaka et al., 1999). TNF-a is assembled intracellularly to form a 
transmembrane, non-covalently-linked homotrimeric protein. The 157 amino acids 
residue soluble form of TNF-a (sTNF-a) is released from the C-terminus of the 
transmembrane protein through the activity of TNF-a-converting enzyme (TACE), a 
membrane-bound disintegrin metalloproteinase (Moss et al., 1997; Kriegler et al., 
1988). 
The granulomatous immune response is characterized by delayed hypersensitivity 
and is mediated by various cytokines released by the stimulated mononuclear 
phagocytes, including TNF-a (Morimoto et al., 1989; Ellner and Wallis, 1989). TNF-a 
is a pro-inflammatory cytokine and following appropriate stimulation, many cells 
produce TNF-a. The main cellular sources of TNF-a during an inflammatory response 
are monocytes (Frankenberger et al., 1996) and macrophages (Sakurai et al., 1985), 
but it can also be produced by other cells including NK cells, T and B lymphocytes 
(Ware et al., 1992), mast cells (Bissonnette et al., 1995), dendritic cells (Zhou et al, 
1995), astrocytes (Lee et al, 1993), osteoblasts (Modrowski et al., 1995) and neurons 
(Tchelingerian et al., 1996). Expression of the TNF-a gene in macrophages can be 
stimulated by both exogenous and endogenous factors: bacteria, viruses, parasitic 
organisms, irradiation, trauma, ischemia, cytokines [IL-ip, IL-2, IFN-y, granulocyte 
macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating 
factor (M-CSF)] and by TNF-a itself (Larche et al, 2005). Lipopolysaccharide (LPS) 
and bacterial products are strong stimuli of TNF-a synthesis (Bazzoni and Beutler, 
1996). TNF-a is recognized as a significant mediator of macrophage activation for 
intracellular killing of bacilli following ingestion by phagocytic cells (Wallis et al., 
1993). Evidence is accumulating that TNF-a is vital to host defense and antibacterial 
resistance against infections caused by facultative intracellular organisms, particularly 
by M. tuberculosis which is a potent inducer of cytokine production (Valone et al., 
1988; Takashima et al., 1990). 
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Although this cytokine is involved in multiple cell regulatory and 
differentiation processes leading to immunity in tuberculous infection, however, TNF-
a also mediates effects deleterious to the host contributing to the pathophysiology of 
tuberculosis. High levels of the cytokine at the site of infection induce an excessive 
damaging inflammatory response that overwhelms its beneficial effects (Bekker et al., 
2000). Therefore, an understanding of the mechanisms that regulate TNF-a expression 
is important in achieving a harmonious balance between the outcome of both its 
beneficial and pathologic effects. 
(A) Ligand structure and receptors: 
The crystal structure of TNF indicates that it is biologically active as a trimer, 
both as a soluble and as a transmembrane factor (McWhirter et al., 1999; Idriss and 
Naismith, 2000). The type II transmembrane protein TNF can be considered as the 
prototype of the TNF cytokine superfamily, a core group of structurally related ligands 
[encompassing lymphotoxin (LT)a, LT0, and LIGHT] (Locksley et al., 2001; Granger 
and Ware, 2001). The TNF cytokine family members interact with more than one 
receptor of the corresponding superfamily of cognate receptors (Fig. 2). These 
cytokines and receptors play important roles in the coordinated development of the 
immune system and the protection from pathogens (Pfeffer, 2003). 
Both the homotrimer TNF receptors, TNFR-I (TNFRp55: 55 kDa) and TNFR-
II (TNFRp75: 75 kDa) interact with, and are involved in binding and signal 
transduction to both soluble and transmembrane TNF (Ehlers, 2003). However, the 
membrane-associated form mostly binds to TNFR-II, whereas soluble TNF 
preferentially binds to TNFR-I, with greater functional consequences than the former 
(Papadakis and Targan, 2000). TNFR-I contains a characteristic structural cassette, 
termed death domain, in its intracytoplasmic sequence that is conserved within a 
distinct subset of other TNFR family members, such as CD95, DR3, DR4 and DR5 
(Tartaglia et al., 1993; Locksley et al, 2001). 
(B) TNF-a signal transduction machinery: 
TNFR-I has been shown to be essential for surviving infections with 
intracellular bacteria, such as M. tuberculosis, Salmonella typhimurium, M. avium, 
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Figure 2. Schematic View of the Members of the Core TNF and TNFR Superfamilies: Arrows 
show the interaction of the individual cytokines with their cognate receptors. 
(Source: Klaus Pfeffer. Cytokine & Growth Factor Reviews. 2003 14:185-191) 
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Listeria monocytogenes (Pfeffer et al., 1993; Everest et al., 1998; Ehlers et al., 1999). 
The death domain is required for the signal transduction of the physiological functions 
of TNFR-I in vivo (Plitz et al., 1999). TNF-a exerts its functions by interaction with 
the death domain-containing TNFR-I and the non-death domain-containing TNFR-II. 
Important proteins that interact directly or indirectly with the cytoplasmic domains of 
TNFR-I and TNFR-II are receptor-interacting protein (RIP), a serine/threonine kinase, 
and TNF receptor-associated factor (TRAF)-l and -2 (Orlinick and Chao, 1998; 
Verrecchia and Mauviel, 2004). RIP is required for NF-KB activation in response to 
TNF-a but not IL-1 or LPS (Kelliher et al, 1998). TRAF-1 and -2 define a novel 
group of adaptor proteins involved in signal transduction by most members of the TNF 
receptor family, of IL-1 receptor and IL-17 receptor, as well as some members of the 
TLRs family (Verrecchia and Mauviel, 2004). TRAF-2 is currently the best 
characterized TRAF family member, having a key role in mediating TNFR1-induced 
signalling cascades leading to activation of NF-KB and JNK (c-Jun N-terminal kinase) 
(Wajant and Scheurich, 2001; Chen and Goeddel, 2002). 
(1) NF-KB activation pathway: 
NF-KB proteins are a family of cytoplasmic heterodimeric transcription factors 
that are inactive due to their association with an inhibitory protein IKB (Verrecchia and 
Mauviel, 2004). Potent activators, such as TNF-a, IL-1, or LPS, activate IKK complex 
(Bonizzi and Karin, 2004) (Fig. 3). Once activated, IKK induces rapid degradation of 
the IKBS (especially iKBa) within minutes. For IicBa this degradation process consists 
of a series of well-characterized steps, which seem to be relevant to the other IKBS 
(Baldwin, 1996; Ghosh et al., 1998). Inducible IKB phosphorylation, one of the 
earliest events in the common activation pathway, occurs at serines 32 and 36 in IKBO, 
and mutation of either serine (even to a threonine) greatly inhibits the degradation 
process (Traenckner et al., 1995; DiDonato et al., 1996). Phosphorylation leads to the 
immediate recognition of kBa by the recently identified F-box/WD40 E3RSkB/p-
TrCP (Yaron et al., 1998; Laney and Hochstrasser, 1999; Maniatis, 1999), which 
consequently results in the polyubiquitinylation of IicBa primarily at lysines 21 and 22 
by an SKpl-Cullin-F-box (SCF)-type E3 (Scherer et al , 1995; Baldi et al, 1996). 
This modification then targets IKBCL for rapid degradation by the 26S proteasome. 
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Figure 3. Schematic Model of the NF-KB Activation Pathway. 
(Source: Karin and Ben-Neriah. Annual Review of Immunology. 2000 18: 621-663) 
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The degradation of its inhibitor exposes the nuclear localization sequence (NLS) of 
NF-KB resulting in binding to karyopherins and translocation of NF-KB to the nucleus 
(Karin and Ben-Neriah, 2000). It is important that inhibitors of the 26S proteasome 
efficiently block NF-KB nuclear translocation, indicating that neither phosphorylation 
nor ubiquitinylation is sufficient to dissociate IKB from NF-KB (DiDonato et al., 1995; 
Alkalay et al., 1995). 
(2) MAP kinase pathway: 
JNK is typically activated by a variety of physical and chemical stresses, but 
also by cytokines like TNF-a. JNK can be triggered by two members of the MAPK 
kinase (MKK): MKK4 and MKK7, which are targets of a variety of MAP3Ks (such as 
apoptosis signal-regulating kinase: ASK-1) which interact with TRAF-2. Thus, the 
pathway from TNFR-I to JNK might include TRADD, TRAF-2 and a MAP3K, 
initiating the kinase cascade leading to JNK and cJun (Verrecchia and Mauviel, 2004). 
(C) Induction of TNF-a by Mycobacterium virulence factors: 
TNF-a exhibits both beneficial and pathologic effects, a feature that requires 
rigorous control of its expression (Yao et al., 1997). Regulation of human TNF-a 
expression in cells of monocytic lineage is quite complex, involving controls at both 
transcriptional and post-transcriptional levels (Han et al., 1990). Mycobacterial cell 
walls contain the polysaccharide LAM, which has a capacity for induction of TNF-a, 
through CD 14 and synthesis at the transcriptional level (Zhang et al, 1993), similar to 
that of LPS in Gram-negative bacilli (Moreno et al., 1989). There are structural 
similarities between LAM and LPS. The promoter region of the human TNF-a gene 
contains a complex array of potential regulatory elements, and studies indicate that 
maximal LPS induction of the TNF-a promotor is mediated by concerted participation 
of at least two separate cw-acting regulatory elements (Yao et al., 1997). LAM has 
been considered an important virulence factor of M. tuberculosis with ability to 
downregulate IFN-y-inducible genes in macrophages, inhibit protein-antigen 
processing by antigen-presenting cells, scavenge superoxide anion, and decrease 
protein kinase C activity (Sibley et al, 1990; Chan et al., 1991). Proteins with the 
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capacity to induce monocyte cytokine production, such as the 58 kDa protein may also 
be particularly immunogenic (Wallis et al., 1993). 
(D) Role of TNF-a in tuberculosis: 
TNF-a is a pleiotropic cytokine, and its role in harmful or beneficial 
inflammatory processes is complex (Keane, 2005). Regulatory processes, influenced 
by TNF-a, supporting a beneficial outcome for the host are the following: TNF-a has 
been shown to modify the endothelium and induce chemokine expression, thereby 
facilitating extravassation of monocytes and T cells from the blood and directing this 
migration of cells to the infected site (Ming et al., 1987; Wuyts et al., 1998). Thus, 
TNF-a with its ability to regulate the expression of chemokines, chemokine receptors, 
and adhesion molecules, is a potent modulator of cell migration, which is important 
for granuloma formation (Sedgwick et al., 2000; Mohan et al, 2001). TNF-a also acts 
as a macrophage-activating factor in mycobacterial infection, facilitating intracellular 
killing of bacilli following ingestion by phagocytic cells (Bermudez et al., 1990). In 
addition, TNF-a has a role in apoptosis of macrophages infected with M. tuberculosis 
(Keane et al., 2000), mediating macrophage apoptosis, which can kill the infecting 
bacillus (Keane et al., 2002). TNF-a production is a requirement for formation of 
granulomas, which sequester mycobacteria and prevent their dissemination. TNF-a is 
necessary for the accumulation and organization of monocytes, macrophages, and 
lymphocytes into well-differentiated granulomas (Kindler et al., 1989). 
However, in addition to these protective effects, TNF-a also has detrimental 
pathogenic effects to the host, such as damaging inflammation leading to tissue 
necrosis (Rothstein and Schrieber, 1988). Excessive production of TNF-a and 
increased tissue sensitivity to the cytokine have been implicated in the 
immunopathology of tuberculosis, such as caseous necrotising reactions, which 
promote the replication and dissemination of the bacteria (Gardam et al , 2003). TNF-
a may also mediate induction of HIV expression in latently infected cells in HIV co-
infected tuberculosis patients (Fauci, 1991). TNF-a is also an important mediator of 
systemic inflammation, clinically manifested by fever and wasting. Depending on the 
production, TNF-a thus promotes containment or dissemination of M. tuberculosis and 
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can contribute to both immune protection and pathology (Rook and Hernandez, 1996; 
Kaplan and Freedman, 1996). 
(E) TNF-a blockade: Anti-TNF-a agents: 
Attenuation of the biological activity of TNF has lately become an important 
therapeutic intervention in the management of a wide variety of chronic inflammatory 
diseases (Shanahan and St Clair, 2002). Currently two major protocols are being used 
for the treatment of various chronic inflammatory diseases: Infliximab, an anti-TNF-a 
neutralizing antibody, and Etanercept, a recombinant molecule made up of two 
identical chains of the human 75 kDa TNF receptor II fused to the Fc portion of 
human IgGl (Gardam et al., 2003). 
Infliximab is a human-murine (25% murine) chimeric monoclonal antibody 
with high binding affinity (Bekker et al., 2000) and specificity for TNF-a (Knight et 
al., 1993). It forms stable complexes with the monomeric and trimeric forms of 
soluble TNF-a and with the transmembrane forms of TNF-a (Scallon et al, 2002). It 
also has the ability to cross-link TNF-a molecules. Binding to transmembrane TNF-a 
results in macrophage and monocyte lysis by cytotoxicity that depends on antibodies 
and complement (Lugering et al., 2001). Infliximab does not bind to related cytokines, 
such as TNF-P, which is involved in the Thl response (Falcone et al., 1994). 
There are subtle differences in the mechanisms of action of these two agents; 
in particular, drug-mediated apoptosis and monocytopenia appear to be unique to 
infliximab (Gardam et al., 2003). Infliximab binds more avidly than etanercept does to 
transmembrane TNF-a and form a more stable complex. More infliximab than 
etanercept binds to transmembrane TNF-a. Infliximab is more effective at inhibiting 
transmembrane TNF-a-mediated activation of endothelial cells. Infliximab binds both 
the monomeric and trimeric form of soluble TNF-a, whereas etanercept effectively 
binds only to the trimeric form. Etanercept-TNF-a complexes are unstable, resulting in 
the release of soluble TNF-a. On the basis of these differences, infliximab might be 
predicted to have a more significant effect on the host's ability to suppress M. 
tuberculosis infection (Gardam et al, 2003). 
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Drawback of current treatment and control regimens: 
There is a growing body of clinical evidence that neutralization of TNF-a is 
associated with an increased risk of opportunistic infections, including mycobacterial 
diseases (Dinarello, 2003). A major side effect of anti-TNF-a therapy is the increased 
risk of developing tuberculosis (Gardam et al., 2003). TNF-blockade-associated 
tuberculosis shows granuloma disorganization, which may be deficient in restricting 
inflammation to a localized environment. This could lead to extension of the 
inflammatory response into otherwise unaffected lung tissues, resulting in the aberrant 
pathology observed in tuberculous patients treated with TNF blockade (Mohan et al., 
2001). Treatment with anti-TNF-a antibodies readily leads to tuberculosis reactivation 
in patients with rheumatoid arthritis (Maini et al., 1999). 
In addition, drug-induced hepatotoxicity, a leading cause of liver injury, is an 
important and commonly encountered adverse effect with anti-tuberculosis treatment 
with three potential hepatotoxic drugs: isoniazid, rifampicin and pyrazinamide 
(Sharma, 2004). Pyrazinamide was found to significantly contribute to the 
development of hepatotoxicity when given along with isoniazid and rifampicin (Yee et 
al, 2003). The use or misuse of these drugs over the years has led to an increasing 
prevalence of MDR strains, establishing an urgent need to develop new effective 
agents (Cox et al, 2003). MDR-tuberculosis is defined as the disease due to 
tuberculosis bacilli resistant to atleast isoniazid and rifampicin, the two most powerful 
anti-tuberculosis drugs (Girard et al., 2005). 
The current vaccine BCG is an attenuated strain of M. bovis, which primarily 
causes bovine disease and is a close relative of M. tuberculosis. This strain was 
generated in the early 1920s by the French researches Albert Calmette and Cannille 
Guerin by cultivation on solid medium containing bile (Kaufmann, 2005). Most 
studies have demonstrated that BCG vaccines afford a higher degree of protection 
against severe forms of tuberculosis, such as meningitis and disseminated tuberculosis, 
than against moderate forms of the disease (Girard et al, 2005). Even with high 
coverage, BCG has not had any substantial effect on transmission or incidence, 
because its main action is to prevent serious (but infectious) disease in children 
(Styblo, 1991). Adverse events from BCG vaccination can occur, including local 
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subcutaneous abscess and ulcers, suppurative lymphadenitis, and, more rarely, 
disseminated disease (Lotte et al., 1988). In addition, BCG vaccination may only 
provide protection against primary infection and be of little help in already infected 
individuals or in cases of reactivation tuberculosis (Smith and Starke, 2004). Despite 
continuing efforts to develop more effective tuberculosis vaccines, none have been 
identified to date. Even if one were to be developed, it might not prevent progression 
to active disease among the more than two billion people already infected with M. 
tuberculosis. Therefore, even if a new vaccine were to be implemented worldwide, 
more effective treatment systems would be required for decades (Frieden et al., 2003). 
Natural products in tuberculosis prevention - Garlic and allicin: 
Garlic {Allium sativum) is well known for its medicinal benefits and has been 
used in herbal medicine for thousands of years (Juszkiewicz et al., 2004). It has been 
cultivated since ancient times and used as a food, spice/condiment and folk remedy for 
many centuries (Rassoula et al., 2005). Garlic has a wide spectrum of pleiotropic 
actions, including antibacterial, antifungal and antioxidant activity. It is a strong 
antibacterial agent and acts as an inhibitor of both Gram-positive and Gram-negative 
bacteria (Ankri and Mirelman, 1999; Juszkiewicz et al, 2004). It also has beneficial 
effects on the cardiovascular and immune systems (Harris et al, 2001). During the 
past years, there has been a growing awareness of the potential medicinal uses of 
garlic. The antioxidant properties of garlic are well documented (Gedik et al., 2005; 
Sener et al., 2005). Garlic has been related to various vasoprotective and anti-
inflammatory effects (Borek, 2001; Sela et al, 2004). Garlic extracts can modulate the 
IL-la-mediated cell response (adhesion) of human endothelial cells (Rassoula et al., 
2005). Adhesion of mononuclear monocytes to endothelial cells and trans-endothelial 
migration of monocytes mediated by cell adhesion molecules (CAMs) are important 
steps in both inflammation and in the atherosclerotic process (Lkeda et al., 1998; 
Richter et al., 2003). Antioxidants act at the cellular level to downregulate cytokine-
stimulated CAM expression in endothelial cells with a subsequent decrease in 
leukocyte adhesion (Zapolska-Downar et al., 2001). Since several components of 
garlic are known to possess antioxidant properties (Borek, 2001), garlic extract may be 
useful in reducing oxidative stress. Garlic oils stimulate the activity of glutathione 
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peroxidase and inhibit the decreased ratio of reduced to oxidized glutathione produced 
by 12-0-tetradecanoylphorbol-13-acetate in epidermal cells (Perchellet et al., 1986). 
In addition, garlic extract was identified as a potent inhibitor of leukocyte migration 
(Hofbaueretal.,2001). 
Ninety-five percent of the sulphur in intact garlic cloves is found in two classes 
of compounds in similar abundance: the S-alkylcysteine sulfoxides and y-glutamyl-S-
alylcysteines (Lawson, 1998). Upon cutting or crushing garlic cloves, odourless 
cysteine sulfoxides are very rapidly converted to a new class of compounds, the 
thiosulfmates, which are responsible for the odour of freshly chopped garlic. The most 
abundant sulphur compound in garlic is alliin (S-allylcysteine sulfoxide) and the main 
thiosulfinate formed upon crushing garlic is allicin. The formation of thiosulfmates 
takes place when the cysteine sulfoxides, which are located only in the clove 
mesophyll storage cells, come in contact with the enzyme allinase or alliin lyase (E.C. 
4.4.1.4.), which is located only in the vascular bundle sheath cells (Juszkiewicz et al., 
2004; Chaverri et al., 2005): 
R-S(0)-CH2-CH(NH2)C02H + H20 allinase ^ R-SOH + CH3-C(0)-C02H + NH3 
alk(en)ylcysteine sulfoxide alk(en)yl sulfenic acid pyruvate ammonia 
2R-SOH • R-S(0)S-R + H20 
thiosulfinate 
At the initial period of this reaction, pyruvate, ammonia and alk(en)yl sulfenic acid 
RS(0)H are formed; the latter undergoes rapid condensation to form thiosulfmates R-
S(0)S-R, where R represents: methyl, l-propenyl or 2-propenyl group (Juszkiewicz et 
al., 2004). 
Allicin (diallyl thiosulfinate) is the major biologically active component and 
thiosulfinate compound of freshly crushed garlic (chemical structure shown in Fig. 4). 
Garlic-rich organosulphur compounds and their precursors (allicin, diallyl sulfide 
and diallyl trisulfide) are believed to play a key role in the biological effects of garlic 
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Figure 4. Structures of Allicin 
(Source: www.3dchem.com/molecules.asp?ID=l56) 
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(Ankri and Mirelman, 1999). Garlic extract and S-allyl cysteine reduce hydrogen 
peroxide or TNF-induced NF-KB activation (Ide and Lau, 2001). Allicin was reported 
to affect different biological activities such as antimicrobial, antiparasitic and 
antifungal activities (Ross et al., 2001). Allicin has radical scavenging properties in 
activated granulocytes (Siegers et al., 1999) and may also inhibit inducible nitric oxide 
synthase expression in activated macrophages (Dirsch et al., 1998). The antimicrobial 
activity of allicin is considered to depend on its inhibitory effects on certain thiol-
containing enzymes via strong SH-modifying properties, as reflected by the 
production of S-allylmercaptocysteine (Ankri and Mirelman, 1999; Rabinkov et al., 
2000). Allicin freely permeates into or across phospholipid bilayers and interacts with 
the thiol groups of intracellular molecules (Miron et al., 2000). L-Cysteine of the 
antioxidant glutathione may also be a target of allicin (Rabinkov et al., 2000). It has 
been found that allicin scavenges OH' and inhibits lipid peroxidation (Prasad et al., 
1995). Higher doses (>100 uM) of allicin have proven toxic to mammalian cells. At 
present a variety of biological effects of allicin are attributed both to its SH-modifying 
and its antioxidant activity (Ankri et al., 1997). Although allicin, the active component 
of freshly crushed garlic, has different biological activities, however its anti-
inflammatory properties warrant further investigation. Thus, we studied the 
incorporation of this herbal component as an anti-inflammatory agent for tuberculosis 
management. 
Objectives of the present study: 
The human immune response to M. tuberculosis is not well characterized. To 
better understand the cellular immune response to tuberculosis, in the present study, a 
human monocyte culture system infected with M. tuberculosis at an infective ratio of 
1:1 (bacteria: cell) was employed. Here we have examined the interaction of virulent 
M. tuberculosis (H37Rv) with human monocytes, focussing on the role of TNF-a and 
M. tuberculosis 85B. In this investigation, a systematic study was carried out to 
characterize the sera and monocytes of tuberculosis patients with respect to TNF-a and 
M. tuberculosis 85B by real-time RT-PCR, direct binding ELISA and competition 
ELISA. The modulatory effects of the natural antioxidant allicin on M. tuberculosis 
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85B expression in H37Rv cultures were evaluated by real-time RT-PCR, SDS-PAGE, 
gel retardation assay, direct binding ELISA and competition ELISA. The interaction 
of M. tuberculosis 85B and TNF-a after 24 hours of infection of human monocytes 
with M. tuberculosis was investigated by RT-PCR and real-time RT-PCR. To fully 
delineate the contribution of the innate immune response to the pathogenesis of M. 
tuberculosis infection, the roles played by ROIs and RNIs, induction of TNF-a, 
activation of NF-KB and monocyte activation, in the expression of M. tuberculosis 
85B were examined. 
Toxicity assessment of allicin on viability of human monocytes was assessed 
by cell viability assays like MTT and trypan blue exclusion assay as well as by 
assessing human housekeeping genes like (3-actin and 18S rRNA by RT-PCR and real-
time RT-PCR, respectively. The effects of allicin on expression of TNF-a and M. 
tuberculosis 85B in M. tuberculosis-infected monocytes after 24 hours of infection 
were probed by RT-PCR, real-time RT-PCR and ELISA. The repertoire of TNF-a, 
TNFR-I and TNFR-II in supernatants of M. tuberculosis-infected monocyte cultures 
that were treated and untreated with allicin was assessed by commercially available 
ELISA kits. Glutathione peroxidase activity was also evaluated in M. tuberculosis-
infected monocytes after 24 hours of infection in the presence or absence of allicin. 
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Materials: 
Recombinant human (rh) TNF-a, monoclonal anti-TNF-a antibody, soluble 
TNFR-I, soluble TNFR-II, N-acetyl-cysteine, H202, SN50 (an inhibitor of NF-KB) and 
its analogue SN50/M, oxidized ATP, NG-monomethyl-L-arginine-monoacetate, 
nonoate-9, sodium nitroprusside, agarose, bovine serum albumin, Coomassie Brilliant 
Blue G-250 and R-250, p-nitrophenyl phosphate, anti-human IgG alkaline phosphate 
conjugate, Tween-20, dithiothreiotol, phenylmethylsulphonyl fluoride, standard 
protein markers, protein A sepharose CL-4B, sodium azide, ethidium bromide, 
chloroform, isoamyl alcohol, reduced glutathione, glutathione reductase, cumene 
hydroperoxide and reduced [3-nicotinamide adenine dinucleotide phosphate were from 
Sigma Chemical Company, U.S.A. SN50 is a hybrid peptide containing nuclear 
localization sequence of p50 subunit of NF-KB heterodimer and has been shown to 
completely inhibit the translocation of NF-KB in human cell lines at 100 ug/ml (Lin et 
al, 1995). 
Allicin was obtained from LKT Laboratories, Inc. U.S.A. Ficoll-Paque was 
from Pharmacia, Piscataway, NJ, U.S.A. Middlebrook 7H9 broth, Middlebrook ADC 
enrichment fluid, RPMI-1640 medium were from HiMedia, India. MTT cell viability 
assay kit and immunoassay kits for TNF-a and its receptors were from R & D 
Systems, U.S.A. 12-wells tissue culture plates were obtained from Techno Plastic 
Products (TPP), Switzerland. Polystyrene microtitre flat bottom ELISA plates having 
96 wells (7 mm diameter) were from NUNC, Denmark. All other chemicals were of 
the highest analytical grade available. 
Study subjects: 
Venous blood was obtained from healthy nonsmoking adult volunteers with no 
history of tuberculosis or positive tuberculin skin test. Also, blood from patients with 
active pulmonary tuberculosis was obtained from the patients admitted to the J.N. 
Medical College Hospital of A.M.U. The diagnosis of tuberculosis was based on 
demonstration of acid-fast bacilli on sputum smear and later confirmed by positive 
culture of M. tuberculosis. Serum was separated and stored at -20°C until required. 
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Determination of protein concentration: 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford 
(1976). 
(A) Protein estimation by the Lowry (Folin-Ciocalteau) method: 
Protein estimation by this method involves complexing of the protein's peptide 
bonds with Cu2+ under alkaline conditions (Lowry et al., 1951). The resultant Cu+ 
appears to catalyze the oxidation of tyrosine and tryptophan residues by reducing 
phosphomolybdotungstate anions in the Folin reagent (a mixture of sodium tungstate, 
molybdate and phosphate), added subsequently. This reaction develops a blue colour 
due to the formation of heteropolymolybdenum blue, which can be quantified by its 
absorbance at 660 nm. 
Reagents: 
(i) Folin-Ciocalteau reagent 
The reagent was diluted 1:4 with distilled water before use. 
(ii) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(a) 2% sodium carbonate in 100 mM NaOH 
(b) 0.5% copper sulphate in 1% sodium potassium tartarate 
The working reagent was prepared fresh before use by mixing the two 
components in the ratio 50:1, respectively. 
Procedure: 
To 1.0 ml of protein sample was added 5.0 ml of freshly prepared alkaline 
copper reagent. After thorough mixing, the reaction mixture was allowed to stand at 
room temperature for 10 minutes, followed by the addition of 1.0 ml of 1:4 times 
diluted Folin-Ciocalteau reagent. The contents were mixed immediately. The reaction 
was allowed to proceed for 30 minutes at room temperature and each tube was 
subsequently monitored at 660 nm. The protein content of the unknown sample was 
determined by using bovine serum albumin to construct a standard calibration curve. 
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(B) Protein estimation by the Bradford method: 
This method is based on strong binding of the dye Coomassie Brilliant Blue 
G-250, in acidic medium, to protein hydrophobically and at positively charged groups 
(Bradford, 1976). In the environment of these positively charged groups, protonation 
is suppressed and a blue color develops (Xmax-595 nm). 
Preparation of dye: 
100 mg of Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% 
ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting 
solution was diluted to a final volume of 1.0 litre and filtered through Whatman No. 1 
filter paper to remove undissolved particles. 
Procedure: 
To 1.0 ml of solution containing 10-100 ug protein was added 5.0 ml of dye 
solution. The contents were mixed thoroughly by vortexing. The absorbance was read 
at 595 nm after 5 minutes against a reagent blank. 
Polyacrylamide gel electrophoresis of proteins: 
Polyacrylamide gel electrophoresis was performed under denaturing conditions 
as described by Laemmli (1970). 
Reagents: 
(i) Acrylamide-bisacrylamide (30:0.8) 
A stock solution of 30% acrylamide containing 0.8% bisacrylamide was 
prepared by dissolving 30 gm of acrylamide and 0.8 gm of bisacrylamide in a total 
volume of 100 ml. The solution was stored at 4°C in an amber coloured bottle. 
(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48 ml of 1 N 
HC1. The contents were mixed, pH adjusted to 8.8 and the final volume brought to 100 
ml with distilled water. 
(iii) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with 
1 N HC1 and the final volume adjusted to 100 ml with distilled water. 
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(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled 
water, pH adjusted to 8.3 and the final volume made up to 1.0 litre with distilled 
water. 
(v) Sample buffer 
(a) 6.0 gm of Tris was dissolved in 80 ml distilled water and pH adjusted to 
6.8 with phosphoric acid. The final volume was brought to 100 ml with 
distilled water. 
(b) 1.0 mg of bromophenol blue and 12.5 ml of glycerol were added to 12.5 
ml of the above solution. P-mercaptoethanol was added just before use. 
Recipe for 10-20% Gradient Gel 
Resolving Gel (total volume: 30 ml) 
Reagents 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
10% 
5.0 ml 
3.8 ml 
150 ul 
50 ul 
10 ul 
20% 
10 ml 
3.8 ml 
150 ul 
50 ul 
10 ul 
The final volume was raised to 15 ml each with distilled water. 
2.5% Stacking Gel (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Stacking gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
0.8 ml 
2.5 ml 
100 ul 
75 jU 
25 ul 
The final volume was raised to 10 ml with distilled water. 
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Recipe for 7.5% SDS-PAGE (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10%SDS 
10% Ammonium persulphate 
TEMED 
2.5 ml 
2.5 ml 
100 ul 
50 ul 
10 ul 
The final volume was raised to 10 ml with distilled water. 
Procedure: 
The glass plates (18 cm x 16 cm) were soaked in chromic acid and thoroughly 
washed with tap water followed by a final rinse with distilled water and ethanol. The 
plates were dried and sealed with 1% agarose and 1.5 mm thick spacers. The reagents 
were mixed and poured between the glass plates. The resolving gel was allowed to 
polymerize at room temperature, following which, the stacking gel was layered on top. 
A well-forming comb was inserted immediately and the gel was left to polymerize at 
room temperature. In case of gradient gels, a gradient of resolving gel was formed 
with the help of a gradient former (Bio-Rad, model 385). After ensuring complete 
polymerization, the protein samples (25-100 ug) in one-fourth volume of sample 
buffer were electrophoresed at 80 volts at room temperature. The gels were stained 
using 0.25% Coomassie Brilliant Blue R-250 or with silver stain reagent. 
Silver staining: 
Silver staining was done by the method of Merril et al. (1983). Briefly, the gel 
was incubated in 40% methanol and 12% acetic acid for 45 minutes followed by 
incubation in 50% ethanol for 30 minutes. Next the gel was treated with 0.02% hypo 
(sodium thiosulphate) for 1 minute. After washing with distilled water, the gel was 
placed in 0.2% silver nitrate (with 0.05% v/v formaldehyde), washed again with 
distilled water, and transferred to a 6% solution of sodium carbonate (with 0.05% v/v 
formaldehyde). After colour development, the gel was washed with distilled water and 
the reaction was arrested by treating the gel with 3% v/v acetic acid and 5% v/v 
methanol. All the reagents used in this procedure were freshly prepared. 
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Agarose gel electrophoresis: 
Agarose gel was prepared by bringing 2% agarose to molten state in 
electrophoresis buffer (0.04 M Tris acetate, pH 8.0 containing 0.002 M EDTA). 
Molten agarose was poured on the gel tray and allowed to solidify for 1 hour at room 
temperature. The nucleic acid samples in one-tenth volume of stop-mix (30% ficoll, 
0.025% xylene cyanole FF and 500 mM EDTA in 10X TAE buffer) were 
electropheresed for 2-A hours at 30 mA in the same buffer. The gel was stained with 
ethidiufn bromide (0.5 ug/ml). 
Isolation of IgG by affinity chromatography: 
Protein A sepharose CL-4B was employed as the affinity matrix. It was 
swelled in 10 mM PBS, pH 7.4 at room temperature for 12 hours. The swelled matrix 
was washed with PBS and packed in a column having a dimension of 0.9 cm x 5 cm. 
The packed column was washed with 0.1 M sodium citrate, pH 3.0 in order to elute 
any bound material. This was followed by equilibration of the packed matrix with 5 
volumes of PBS, pH 7.4. Serum diluted with equal volume of PBS, pH 7.4 was 
loaded onto the column and allowed to bind at a flow rate of 20 ml/hour. Unbound 
protein was eliminated with PBS and absorbance of the effluent monitored till a 
negative absorbance was obtained at 280 nm. The bound IgG was eluted with 0.58% 
acetic acid in 0.85% sodium chloride. To prevent the effect of acidic elution buffer on 
IgG, fractions were collected in 1 M Tris-HCl, pH 8.5. The fractions containing IgG 
were monitored at 280 nm. The IgG concentration was determined considering 1.4 
OD28o = 1.0 mg IgG/ml. The isolated IgG was dialyzed against 10 mM PBS, pH 7.4 
and stored at -20°C with 0.1% sodium azide. To check the purity of IgG, the samples 
were subjected to 7.5% SDS-PAGE. 
Gel retardation assay: 
The binding of TB-IgG with M. tuberculosis sonic extract proteins as well as 
with MTCF proteins was analyzed by altered electrophoretic mobility on SDS-PAGE 
under non-reducing conditions. M. tuberculosis proteins were allowed to interact with 
TB-IgG for 2 hours at 37°C and overnight at 4°C. This resulted in the formation of 
immune complex (IC). Thereafter, the complex was electrophoresed on 7% SDS-PAGE 
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under non-reducing conditions for 2 hours at 80 V. The electrophoresed gels were 
visualized by staining with 0.25% Coomassie Brilliant Blue R-250. 
Enzyme-linked immunosorbent assay (ELISA): 
Antibodies were detected and quantified by ELISA using polystyrene flat-
bottom microtitre plates as solid phase. The method described by Alam and Ali 
(1992), Islam and Ali (1998) was followed for the assay. 
Buffers and reagents: 
(i) Tris-buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
(ii) Tris-buffered saline Tween-20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KC1 and 1.0 ml/litre Tween-20, 
pH7.4 
(iii) Bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6 
(iv) Substrate buffer (for anti-human IgG alkaline phosphatase conjugate) 
15 mM sodium carbonate, 35 mM sodium bicarbonate and 2 mM 
magnesium chloride, pH 9.6 
Substrate: 0.5 mg/ml of p-nitrophenyl phosphate 
(A) Direct binding ELISA: 
Polystyrene microtitre plates were incubated with 100 ul of protein antigen (30 
ug/ml in carbonate/bicarbonate buffer, pH 9.6) for two hours at room temperature 
followed by overnight incubation at 4°C. The plates were washed thrice with TBS-T 
and unoccupied sites blocked by 150 ul of BSA (1.5% in TBS, pH 7.4) for 4-6 hours 
at room temperature. Serially diluted sera in TBS were added to antigen-coated as well 
as control (antigen uncoated) wells. The antigen-antibody interaction was allowed to 
proceed for two hours at room temperature followed by overnight incubation at 4°C 
and subsequently the plates were washed four times with TBS-T in order to remove 
the unbound antibodies. Bound antibodies were assayed by means of appropriate 
anti-immunoglobulin alkaline phosphatase conjugate using p-NPP as substrate. 
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The reaction was stopped with 3 N NaOH and the absorbance of each well was 
monitored at 405 nm on an ELISA microplate reader. Each sample was coated in 
duplicate and the results were expressed as a mean of Atest - ACOntroi-
(B) Inhibition ELISA: 
The antigen binding specificity of antibody was determined by inhibition 
experiments (Hasan et al., 1991). Varying concentration of inhibitors (0-20 (ig/ml) 
were mixed with a constant amount of antiserum or IgG. The mixture was incubated 
for two hours at 37°C followed by overnight incubation at 4°C. The resulting immune 
complex was employed in the immunoassay instead of serum. The rest of the steps 
were as in direct binding ELISA. The results were expressed as percent inhibition. 
•"^inhibited 
Percent inhibition = (1 ) x 100 
•"•uninhibited 
Preparation of mycobacteria: 
Virulent laboratory-adapted M. tuberculosis (H37Rv) were grown in 
Middlebrook 7H9 broth supplemented with Middlebrook ADC enrichment fluid at 
37°C in 5% CO2. Mycobacterial cultures were harvested at midlogarithmic (14 days) 
phase. Aliquots of the stock were kept at -70°C until use. The viability of the stock 
remained >99% at 1 year. Before use, aliquots were defrosted, then vortexed with 
glass beads for 15 minutes, followed by equilibration at 37°C for 45 minutes. This 
treatment results in single cell suspension of mycobacteria (Toossi et al., 1996). 
Isolation of mycobacterial antigens: 
Midlogarithmic mycobacterial cultures (14 days) were heat-killed at 100°C for 
one hour in a boiling water bath, followed by centrifugation at 10,000 rpm for 30 
minutes at 4°C. The culture filtrate containing secreted proteins was separated and 
stored at -20°C until further use. 
(A) Desalting of M. tuberculosis culture filtrate (MTCF) proteins: 
The supernatant was sterilized by filtration through a 0.22 micron pore size 
membrane (Millipore Corp., USA). MTCF was concentrated 50 fold by ammonium 
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sulphate and dialyzed against 10 mM PBS, pH 7.4 for desalting. The protein content 
was determined by the method of Lowry et al. (1951) against a BSA standard. The 
culture filtrate preparations were stored in small aliquots at -20°C. 
(B) M. tuberculosis sonic extract (MTSE) proteins: 
Heat-killed bacilli were washed with sterile TBS, pH 7.4 and suspended in 
sonicating buffer containing 1 mM DTT, 1 mM PMSF, 1.0 ul/ml |3-mercaptoethanol 
and proteinase inhibitors cocktail in TBS, pH 7.4. The cell suspension was disrupted 
by sonicating at 4°C for 15 minutes in a sonicator and the cell debris was removed by 
ultra centrifugation at 20,000 rpm for 15 minutes. The protein content was determined 
by the method of Lowry et al. (1951). The sonic extract preparations were stored at -
20°C in small aliquots until required. 
Preparation of RPMI-1640 medium: 
Dehydrated RPMI-1640 medium of one unit vial (16.3 gm) was suspended in 
950 ml of tissue culture-grade water at room temperature with constant, gentle stirring 
until the medium was completely dissolved. The container was rinsed with tissue 
culture grade water to remove all traces of powder and added to the above solution. 
3.7 gm sodium bicarbonate was added to the medium and stirred until dissolved. The 
final volume was brought to 1000 ml with tissue culture grade water. The medium was 
sterilized immediately by filtering through a sterile membrane filter with a porosity of 
0.22 micron using positive pressure rather than vacuum to minimize the loss of carbon 
dioxide, and stored at 4°C till use. 
Preparation of PBMC: 
Step 1: In order to isolate peripheral blood mononuclear cells (PBMCs), 60 ml of 
blood was drawn from a healthy volunteer into 60 cm syringes containing 3.8 
units heparin/ml. The heparinized blood, in 15 ml aliquots, was transferred to 
sterile 50 ml polypropylene centrifuge tubes and diluted 1:1 with sterile 10 
mM, PBS, pH 7.4 at room temperature, followed by gentle mixing by inverting 
the tube a few times. 
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Step 2: Diluted blood was underlayered with 15 ml of Ficoll-Paque at room temperature 
using an 18 gauge spinal needle. Care was taken to prevent mixing of the layers. 
The gradient was centrifuged at 1800 rpm for 30 minutes at room temperature 
with the centrifuge brake turned off. 
Step 3: Using a sterile pipette, the upper clear layer containing plasma was removed. 
The PBMCs appeared as a dense white band (buffy layer) above the red blood 
cells and granulocytes layer. This was removed with another sterile pipette. 
The banded cells were combined in 10 ml aliquots. 
Step 4: Ten milliliters of banded PBMCs were diluted with 25 ml of PBS in sterile 50 
ml polypropylene centrifuge tubes and centrifuged at 1100 rpm for 12 minutes 
at room temperature to remove platelets, which remain in the supernatant. The 
PBMC pellets were combined to four tubes, diluted in 30 ml PBS and 
centrifuged at 1100 rpm for 10 minutes at room temperature. This wash was 
repeated. 
Step 5: The pellets were then combined and resuspended in 30 ml complete medium 
(CM) (RPMI-1640 medium containing 2 M L-glutamine, 25 mM HEPES, and 
no antibiotics). An aliquot was diluted 20-fold and counted using a 
hemocytometer under a light microscope using lOx ocular and 40x objective. 
Preparation of autologous serum for monocyte culture: 
From the same donor, 30 ml of blood was drawn without anticoagulant and 
transferred to serum separator tubes. The blood was allowed to clot for at least 30 
minutes, then centrifuged at 3000 rpm for 15 minutes at room temperature and the 
serum filtered through a sterile 0.22 um filter unit. Autologous serum can be stored for 
a year or longer at -20°C. 
Cell culture: 
PBMCs (5x106 cells/well) were added in 12-wells tissue culture plates in 
complete RPMI-1640 medium, and were subsequently incubated at 37°C, 5% CO2 for 
1-2 hours for adherence. Thereafter, non-adherent cells were removed by washing the 
plates extensively 4 times with RPMI-1640 medium. The adherent monocytes were 
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cultured in RPMI-1640 supplemented with 2% autologous serum, followed by 
overnight resting at 37°C, 5% CO2. This population of adherent cells is up to 95% 
monocytes, as observed by cytostaining and is 99% viable (Toossi et al., 1996). Prior 
to infection, the plates were washed twice with RPMI-1640 medium. 
Infection and co-culture of monocytes with supplements: 
Monocytes were infected with M. tuberculosis (H37Rv) at 1:1 (bacteria/cell) in 
30% autologous unheated serum for 90 minutes at 37°C, 5% CO2. Subsequent to this, 
the infected monocytes were washed four times with complete medium. Cells 
harvested at this time point were considered as time zero after infection (t0). Other 
cultures received RPMI-1640 medium with 2% autologous serum. As per experimental 
design, some cultures, immediately after infection received 10 ng/ml rhTNF-a, 10 
ng/ml anti-TNF-a antibodies, varying doses of allicin (0-500 ng/ml) and a mixture of 
10 ng/ml rhTNF-a and 500 ng/ml allicin, respectively. Also, some cultures received 10 
nM H202, 10 mM NAC, 100 (ig/ml SN50 and SN50/M. Cultures were then harvested 
after 24 hours and cells were lysed in 0.5 ml of TRIZOL Reagent (Invitrogen Inc. 
Carlsbad, CA, USA). The cell-free culture supernatants were kept at -70°C. 
Treatment with allicin and monocytes viability assay: 
The effect of allicin (0-500 ng/ml) on the viability of monocytes was assessed 
by using MTT Cell Viability Assay Kit ( R & D Systems) according to the 
manufacture's instructions provided. 
Reagents supplied in the kit: 
Component 
MTT reagent 
Detergent reagent 
Quantity 
25 ml 
250 ml 
Storage conditions 
2-8°C 
18-24°C 
Assay procedure: 
Adherent monocytes infected with M. tuberculosis (H37Rv) at 1:1 
(bacteria/cell) were gently scraped with RPMI-1640 medium. After this, monocytes 
(3 x 104 cells/well in 100 (al) were added in 96-well tissue culture plates. Cells were 
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incubated in RPMI-1640 with 2% autologous serum containing allicin (50, 100, 250, 
and 500 ng/ml) for 24 hours at 37°C, 5% C02. After 24 hours, 10 ul of MTT reagent 
(3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was added to each 
well and incubation was continued for an additional two hours. When a purple 
precipitate was clearly visible under the microscope, 100 ul of detergent reagent was 
added to all wells, including control wells and incubated for two hours in the dark at 
20°C. After incubation, the precipitate was solubilized and the absorbance of the 
resulting solution was measured at 570 nm using a microplate reader. Control cells 
were treated exactly the same except that no allicin was added to the wells. The 
percentage of viable cells was calculated by the formula as described by Islam et al. 
(2000) and the results are expressed as "Viable cells (% of control cells)". 
Absorbance value of control cells 
Viable monocytes (% of control cells) = x 100 
Absorbance value of treated cells 
Trypan blue exclusion assay for monocytes viability: 
Adherent monocytes were gently scraped with RPMI-1640 medium. Trypan 
blue suspension (1.6 mg/ml in saline solution) was added to the monocytes at a final 
concentration of 0.8 mg/ml. The cells were kept at 37°C for 7 minutes in a CO2 
chamber (5%), mounted on a hemocytometer and then observed under light 
microscope. The cells taking up Trypan blue (dead cells), and cells excluding the dye 
(viable cells) were counted. Percentage of viable cells was calculated by the following 
formula: 
Total viable cells (unstained) 
% Cell viability = x 100 
Total cells (stained plus unstained) 
TNF-a Immunoassay: 
The concentration of TNF-a in various culture supernatants as well as in serum 
of tuberculosis patients was determined by use of a commercial ELISA Kit ( R & D 
Systems). This assay employed the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for TNF-a was available pre-coated onto a 
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microplate. Standards and samples were pipetted into the wells and any soluble TNF-a 
present was bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for TNF- a was added to 
the wells. Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution was added to the wells and colour developed in proportion to the 
amount of TNF-a bound in the initial step. The colour development was stopped and 
the intensity of the colour was measured. 
Reagents supplied in the kit: 
TNF-a microplate - 96 well polystyrene microplate (12 strips of 8 wells) coated with 
a mouse monoclonal antibody against TNF-a. 
TNF-a conjugate - 21 ml of polyclonal antibody against TNF-a conjugated to 
horseradish peroxidase, with preservatives. 
TNF-a standard - 10 ng of recombinant human TNF-a in a buffered protein base 
with preservatives, lyophilized. 
Assay diluent RD1F - 6 ml of a buffered protein base with preservatives. It contained 
a precipitate and was mixed well before and during use. 
Calibrator diluent RD6-35 - 21 ml of animal serum with preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution of buffered 
surfactant with preservatives. 
Colour reagent A - 12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B - 12.5 ml of stabilized chromogen (tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Working reagents: 
Wash buffer - 20 ml of wash buffer concentrate was diluted into deionized or distilled 
water to prepare 500 ml of wash buffer. 
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Diluted calibrator diluent RD6-35 - 20 ml of calibrator diluent RD6-35 was mixed 
with 80 ml of deionized or distilled water to yield 100 ml of diluted calibrator diluent 
RD6-35. 
Substrate solution - Colour reagents A and B were mixed together in equal volumes 
within 15 minutes of use to form substrate solution. It was protected from light. 
TNF-a standard - TNF-a standard was reconstituted with 1.0 ml of distilled water. 
This reconstitution produced a stock solution of 10,000 pg/ml. The standard was 
allowed to sit for a minimum of 15 minutes with gentle agitation prior to making 
dilutions. 
Assay procedure: 
50 ul of assay diluent RD1F was added to each well of 96 well polystyrene 
microplate coated with a mouse monoclonal antibody against TNF-a. Thereafter, 200 
ul of standards, samples, or control per well was added, covered with the adhesive 
strip provided and incubated for 2 hours at room temperature. The plate was washed 
four times by filling each well with wash buffer using a squirt bottle. After washing, 
200 ul of TNF-a conjugate was added to each well, covered with a new adhesive strip 
and incubated for 1 hour for cell culture supernatants and 2 hours for serum samples at 
room temperature. After four washings with wash buffer, 200 ul of substrate solution 
was added to each well and incubated for 20 minutes at room temperature in the dark, 
a blue colour appeared. Thereafter, 50 ul of stop solution was added to each well to 
stop the reaction. Then the absorbance of each well was determined within 30 minutes, 
using a microplate reader set to 450 nm. The cut off or lower limit of sensitivity was 
4.4 pg/ml. 
Soluble TNFR-I and TNFR-II Immunoassay: 
The concentrations of soluble TNFR-I and TNFR-II in various culture 
supernatants were determined by use of commercial ELISA Kits (R&D Systems). 
Reagents supplied with TNFR-I kit: 
sTNFR-I microplate - 96 well polystyrene microplate (12 strips of 8 wells) coated 
with a mouse monoclonal antibody against sTNFR-I. 
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sTNFR-I conjugate - 21 ml of polyclonal antibody against sTNFR-I conjugated to 
horseradish peroxidase, with preservatives. 
sTNFR-I standard - 2.5 ng of recombinant human sTNFR-I in a buffered protein 
base with preservatives, lyophilized. 
Assay diluent HD1-7 - 6 ml of a buffered protein base with preservatives. 
Calibrator diluent RD5-5 - 2 vials (21 ml/vial) of a buffered protein base with 
preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution of buffered 
surfactant with preservatives. 
Colour reagent A -12.5 ml of stabilized hydrogen peroxide. 
Colour reagent B -12.5 ml of stabilized chromogen (tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Reagents supplied with TNFR-II kit: 
sTNFR-II microplate - 96 well polystyrene microplate (12 strips of 8 wells) coated 
with a mouse monoclonal antibody against sTNFR-II. 
sTNFR-II conjugate - 21 ml of polyclonal antibody against sTNFR-II conjugated to 
horseradish peroxidase, with preservatives. 
sTNFR-II standard - 2.5 ng of recombinant human sTNFR-II in a buffered protein 
base with preservatives, lyophilized. 
Assay diluent RD1-6 -11 ml of a buffered protein base with preservatives. 
Calibrator diluent RD5-5 - 2 vials (21 ml/vial) of a buffered protein base with 
preservatives. 
Wash buffer concentrate - 21 ml of a 25-fold concentrated solution of buffered 
surfactant with preservatives. 
Colour reagent A -12.5 ml of stabilized hydrogen peroxide. 
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Colour reagent B - 12.5 ml of stabilized chromogen (tetramethylbenzidine). 
Stop solution - 6 ml of 2 N sulphuric acid. 
Plate covers - 4 adhesive strips. 
Working reagents: 
Wash buffer - 20 ml of wash buffer concentrate was diluted to 500 ml with distilled 
water to prepare wash buffer. 
Substrate solution - Colour reagents A and B were mixed together in equal volumes 
within 15 minutes of use. 
sTNFR-I and sTNFR-II standards - sTNFR-I or sTNFR-II were reconstituted with 5 
ml of calibrator diluent RD5-5 to make a stock solution of 500 pg/ml. 
Assay procedure: 
50 jil of assay diluents HD1-7 for sTNFR-I and RD1-6 for sTNFR-II were 
added to each well of microplate coated with mouse monoclonal antibody against 
sTNFR-I and sTNFR-II, respectively. Thereafter, 200 ul of standards and each sample 
(culture supernatants) were added to the wells and incubated for 2 hours at room 
temperature, followed by washing three times with wash buffer. 200 ul of sTNFR-I 
conjugate or sTNFR-II conjugate were added to each well, incubated for 2 hours for 
TNFR-I or 1 hour for TNFR-II at room temperature and washed thrice. Thereafter, 
200 ul of substrate solutions were added and incubated for 20 minutes at room 
temperature, followed by the addition of 50 ul of stop solution to each well to stop the 
reaction. Absorbance of each well was determined at 450 nm using a microplate 
reader. 
Measurement of M. tuberculosis 85 complex protein by ELISA: 
An ELISA for detection of the mycobacterial 85 complex (includes M. 
tuberculosis 85A, B, and C proteins) was used by the method of Islam et al. (2004). 
Immunoplates of 96-wells were coated with 100 ul of monoclonal antibody to 
mycobacterial 85 complex (CS-90; Colorado State University, Fort Collins) and 
incubated overnight at 4°C. The wells were then washed twice and then non-specific 
sites in the coated wells were blocked by the addition of 150 ul of 1.5% BSA and 
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incubated for 4-6 hours at room temperature. The blocking solution was then removed 
from the wells. 100 ul of the samples was added to the wells and incubated at 37°C for 
90 minutes. The wells were again washed two times. 100 ul of polyclonal rabbit anti-
Mycobacterium bovis antibody (Dako, Carpinteria, CA, USA) as detection reagent 
was added to the wells and incubated for 2 hours at room temperature. The wells were 
again washed four times. 100 ul of alkaline phosphatase-conjugated anti-rabbit IgG 
diluted 1:10,000 in TBS was added into the wells and incubated for 2 hours at room 
temperature. After another four washings, lOOul of p-NPP substrate solution was 
added into the wells and incubated at room temperature for about 30 minutes. The 
absorbance of each well was read at 405 nm on a microplate reader. Purified antigen 
85 complex (Colorado State University) was used as a standard. The results from the 
specimens were compared to those of a serially diluted standard at 1-1000 pg/ml. 
Glutathione peroxidase assay: 
The activity of glutathione peroxidase (GPx) was measured as described 
elsewhere (Mohandas et al., 1984; Mates et al., 1999). The oxidized glutathione 
(GSSG) produced during GPx reaction was immediately reduced by NADPH and 
glutathione reductase. Therefore, the rate of NADPH consumption was regarded as the 
rate of GSSG formation during the GPx reaction. M. tuberculosis-infected monocytes 
were co-cultured for 24 hours with or without 10 mM NAC, 100 ug/ml SN50, 100 
ug/ml SN50/M and 0-500 ng/ml allicin in the presence or absence of 10 nM H2O2. 
Thereafter, cells were gently scraped with lysis buffer containing protease inhibitors 
(50 mM Tris/HCl, pH 7.4; 1 mM EDTA; 500 mM PMSF). The cell suspension was 
homogenized with a sonicator on ice and centrifuged at 10,000 rpm for 10 minutes. 
Protein concentrations of supernatants were determined by the method of Bradford 
with BSA as the standard, and were subjected to GPx activity determination. The 
reaction mixture (1.0 ml) containing 50 mM potassium phosphate (pH 7.0), 1 mM 
sodium azide, 2 mM GSH, 0.2 mM NADPH, 1 unit/ml glutathione reductase, 1.5 mM 
cumene hydroperoxide, and 20-100 ul of samples were incubated at 25°C for 5 
minutes. The reaction was initiated by the addition of cumene hydroperoxide. The 
kinetic change was spectrophotometrically recorded at 340 nm (37°C) for 3 minutes. 
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GPx activity was calculated after subtraction of the blank value, as u.njoi*b§^^EWPH 
,s ^AzidmS 
oxidized/minute/mg protein (U/mg protein). / / * / - \ t'fo 
RNA extraction: f ( 4 ' x ^ V.VJ . 
After lysis of monocytes in 0.5 ml TRIZOL Reagenr&trjeViell lysates \yefe 
agitated with glass beads to complete cell wall disruption. After^ eQ i^rjfe^ott^ fcgjIffe 
tubes were again subjected to repeated disruption as above. The tubes were cooled and 
200 ul of chloroform was added to each sample, followed by vortexing for 2 minutes, 
and centrifugation at 3000 rpm for 5 minutes. Samples were then transferred to fresh 
eppendorf tubes and centrifuged at 14,000 rpm for 15 minutes at 4°C. The aqueous 
layer was harvested and transferred to a fresh tube. After addition of 100 ul 
Cleanascite (CPG Inc., Lincoln Park, NJ, USA), samples were gently rocked for 10 
minutes and then centrifuged at 14,000 rpm for one minute. The aqueous layer 
obtained was mixed with 500 ul of chloroform-isoamyl alcohol (24:1) and vortexed. 
RNA was precipitated using 50 ul of 1 M sodium acetate, and 475 ul of isopropanol at 
-20°C for 3 hours in the presence of glycogen. This was followed by centrifugation at 
14,000 rpm and the pellet obtained was washed two times with 75% ethanol, and 
resuspended in 87 ul DEPC-water. DNAase 1 digestion (10 ul of 10X DNAse 1 buffer 
in 0.5 M Tris pH 7.5, 0.1 M MgCl2, 1 mM DTT; and 50 ug/ml BSA, 2.0 ul RNAase 
inhibitor; 10U RNAase free DNAase 1) was employed to remove DNA. The reaction 
was stopped by the addition of 700 ul of 0.5 M NH4OAc and the RNA was re-
extracted using 500 ul of acid phenol-chloroform (1:1). The aqueous layer was 
harvested, extracted again with chloroform-isoamyl alcohol and precipitated. 
Reverse transcriptase polymerase chain reaction (RT-PCR): 
The DNAase-treated RNA was subjected to reverse transcription using 
oligo(dT) primers with Superscript II reverse transcriptase (Invitrogen, Life 
Technologies, USA) according to the manufacturer's instructions. RNA (2 ug) was 
transcribed into cDNA in a 20 ul reaction volume containing 50 mM Tris-HCl, pH 
8.3, 75 mM KC1, 3 mM MgCl2, 10 mM DTT, 0.5 mM of each deoxynucleotide 
triphosphate, 25 ug/ml oligo(dT)i2-i8 primers and 10 U/ul of Superscript II reverse 
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transcriptase, at 42°C for 50 minutes. The reaction was then stopped by heating at 
70°C for 15 minutes followed by rapid chilling on ice. 
PCR: The primers used in the PCR are listed in Table 1. cDNA for P-actin was 
amplified with various primer sets supplied by (Stratagene, La Jolla, CA, USA). For 
PCR, 2.0 ul of each cDNA sample was used as template in the PCR amplification. The 
reactions were carried out in a 50 ul reaction volume containing 20 mM Tris-HCl, pH 
8.4, 50 mM KC1, 1.5 mM MgCl2, 0.2 mM of each of the four dNTPs, 2U of Taq DNA 
polymerase (Invitrogen) and 0.2 uM of each forward and reverse primers. After initial 
denaturation for 2 minutes at 95°C, 35 cycles at 95°C for 15 seconds, 60°C for 45 
seconds were performed, followed by 72°C for 1 minute. The reaction products were 
visualized by electrophoresis in 2% agarose after staining with 0.5 (xg/ml ethidium 
bromide. 
Quantitative real-time RT-PCR: 
Real-time quantitative reverse transcriptase PCR (RT-PCR), which is the latest 
innovation in the field of PCR technology, provides a sensitive, reproducible, and 
accurate method for determining mRNA levels in tissues or cells. The method is based 
on the detection of a fluorescent signal produced and monitored during the 
amplification process, without the need for post-PCR processing (Heid et al., 1996). 
Two important findings led to the discovery of real-time PCR. First, the Taq 
polymerase has a 5-3 ' exonuclease activity (Holland et al , 1991), apart from its 
polymerase activity. Second, dual-labelled fluorogenic oligonucleotide probes have 
been created which emit a fluorescent signal only upon cleavage, based on the 
principle of fluorescence resonance energy transfer (Cardullo et al., 1988). In the 
TaqMan assay (Applied Biosystems, Foster City, CA, USA), these two principles are 
combined. In this system a probe, the so-called TaqMan probe, is designed to anneal 
to the target sequence between the classical forward and reverse primers. The probe is 
dually labelled, with a reporter fiuorochrome (eg., 5-carbofluorescein, or FAM) at one 
end and a quencher dye (eg., N,N,N',N'-tetramethyl-6-carborhodamine, or TAMRA) 
at the other end. In the intact probe, the fluorescence emission of the reporter dye will 
be absorbed by the quencher dye. The probe will be degraded during the extension 
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Table 1. Sequences of primers and probes for quantification of human TNF-a and M. 
tuberculosis 85B mRNA in infected monocytes. 
Target, strain, 
primer 
Human 
TNF-a 
RT 
Forward 
Reverse 
R18 
RT 
Forward 
Reverse 
M. tuberculosis 
85B 
RT 
Forward 
Reverse 
16S 
RT 
Forward 
Reverse 
PCR primer sequence, Taqman probe sequence, 
5 ' ^ 3 ' 5'->3' 
CCAGAGGGAAGAGTTCCCCAGGGAC 
GGTTTCTACAACA 
AGGCGGTGCTTGTTCCTCA 
GTTCGAGAAGATGATCTGACTGCC 
ACCGGCGCMGACGGACCAGA 
GACGGTATCTGATC 
CGCCGCTAGAGGTGAAATTC 
CATTCTTGGCAAATGCTTTC 
TCGAGTGACCCGGCATGGGAGCG 
TGTTGTTTGCGA 
TCAGGGGATGGGGCCTAGCC 
GCTTGGGGATCTGCTGCGTA 
AGCACCGGCCAACTACGTGCCAG 
CCCAGTAATTCC 
TTCTCTCGGATTGACGGTAGGT 
CGCTCGCACCCTACGTATTAC 
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phase by the 5-3' exonuclease activity of the Taq polymerase, separating the reporter 
and quencher, thus resulting in an increase in reporter fluorescence emission. The 
amount of fluorescence released is directly proportional to the amount of product 
generated in each PCR cycle and thus can be applied as a quantitative measure of PCR 
product formation. 
Procedure: 
Internal fluorescent hybridization probes were used in ABI Prism 7700 
Detection System (ABI/PerkinElmer (PE) Biosystems, Foster City, CA, USA), which 
allows the sensitive and specific quantification of individual host (Hartel et al., 1999), 
as well as M. tuberculosis RNA, transcripts (Wilkinson et al., 2001) by quantitative 
real-time RT-PCR. TaqMan™ PCR primers and probes as well as target-specific RT 
primer for each assay were designed as described elsewhere (Wilkinson et al., 2001; 
Islam et al, 2004). The primer and probe sequences used as depicted in Table 1 have 
been previously reported (Islam et al., 2004). The primer and probe combination for 
M. tuberculosis 85B is specific for 85B and does not detect the closely related 85A or 
85C sequences. All probes were dually labeled with FAM at the 5' end and TAMRA 
at the 3' end. The proximity of the dye (FAM) and the quencher (TAMRA) on the 
intact probe prevents detection of any fluorescence. However, degradation of the 
probe during the course of PCR allows the release and detection of FAM (Holland et 
al., 1991). The PCRs for all amplifications were similar: 5 ul of each cDNA, 20 ul of 
Taqman Universal PCR Master Mix (PE Biosystems), which contains optimal 
amounts of AmpliTaq Gold DNA polymerase (which protects against amplicon 
carryover) and of dNTPs, and optimal amounts of probe and primers calibrated to 
allow measurement of the targets. First, cDNA was synthesized in the presence of 0.5 
ul of murine leukemia virus enzyme (Invitrogen, USA)/reaction and 10 uM each RT 
primer, dNTPs, and other substrate. Conditions for PCR were similar for all products 
(1 cycle of 2 minutes at 50°C and 1 cycle of 10 minutes at 95°C and then 40 cycles of 
15 seconds at 95°C and 1 minute at 60°C). The cycle threshold for each sample was 
compared with the cycle threshold values of known amounts of a standard DNA 
constructed for each target and amplified simultaneously. To assure lack of DNA 
contamination in the RNA samples, in some experiments, a duplicate tube of sample 
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with no RT enzyme was included as control. DNA contamination remained negligible. 
In each sample, host 18S ribosomal RNA was used as the internal control. Expression of 
TNF-a mRNA was corrected to internal control (host 18S rRNA) in the same sample 
and was expressed as copies of TNF-a in 1010 copies of R18 (equivalent to 1 x 106 
monocytes). M. tuberculosis 85B mRNA was corrected to mycobacterial 16S rRNA in 
the same sample and expressed as 85B:16S. 
Statistical analysis: 
Results were analyzed by paired t-test and the data expressed as mean ± SEM 
of six experiments unless otherwise specified. P<0.05 was considered statistically 
significant. 
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RESULTS 
(A) Characterization of Sera and Monocytes from Tuberculosis Patients: 
Direct binding and inhibition ELISA: 
An attempt was made to probe the reactivity of sera from tuberculosis patients 
(n=15) used in this study, against M. tuberculosis antigens secreted in M. tuberculosis 
(H37Rv) culture filtrate (MTCF) as well as against intracellular protein antigens in 
bacilli sonic extract (MTSE). Direct binding ELISA on microtitre plates coated with 
total protein antigens of MTSE showed remarkable reactivity against antibodies found 
in sera of tuberculosis patients, as evident from Table 2, where most of the sera 
exhibited an antibody titre >1:12800. No binding was observed with normal human 
sera. Similarly, an appreciable reactivity was observed with tuberculosis sera against 
secreted MTCF protein antigens that were coated on microtitre plates. Here, most of 
the sera showed an antibody titre >1:6400 (Table 2). Thus, the results show that all the 
patients selected in this study had a high degree of active tuberculosis. 
After detecting the reactivity of selected tuberculosis sera against M 
tuberculosis antigens, we attempted to determine the specificity by employing 
inhibition ELISA. The data obtained from competition inhibition ELISA, depicted in 
Table 3, exhibited high magnitude inhibition of tuberculosis sera antibody activity 
with MTSE and MTCF protein antigens. A maximum of 76.4% inhibition in antibody 
activity was achieved at a maximum inhibitor concentration of 20 u.g/ml of MTSE 
protein antigens. 50% inhibition was recorded at an inhibitor concentration of 0.7 
(ig/ml. Similarly, with MTCF proteins as an inhibitor, a maximum of 70.2% inhibition 
in the antibody activity was observed at a maximum inhibitor concentration of 20 
ug/ml, where 50% inhibition was achieved at an inhibitor concentration of 0.9 ug/ml. 
Thus, inhibition data showed that the intracellular protein antigens, liberated from 
bacilli by sonication, as well as secretory MTCF protein antigens have high magnitude 
of specificity for tuberculosis antibody. Thereafter, tuberculosis IgG was isolated from 
serum by protein A sepharose CL-4B affinity chromatography. The purity of IgG was 
ascertained by SDS-PAGE under non-reducing conditions (Fig. 5), with the IgG 
appearing as a single band. This was employed in ELISA. The isolated IgG showed a 
very high degree of specificity towards MTSE as well as MTCF proteins, as only 
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Table 2. Direct binding ELISA of Mycobacterium tuberculosis sonic extract (MTSE) 
and culture filtrate (MTCF) protein antigens with tuberculosis antibodies. 
Number of 
tuberculosis sera 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
MTSE protein antigens 
Antibody titre 
> 1:12800 
> 1:6400 
> 1:12800 
> 1:12800 
> 1:12800 
> 1:12800 
> 1:12800 
> 1:12800 
> 1:12800 
> 1:6400 
> 1:6400 
> 1:12800 
> 1:12800 
> 1:12800 
> 1:12800 
MTCF protein antigens 
Antibody titre* 
> 1:6400 
> 1:3200 
> 1:3200 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:3200 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
> 1:6400 
The microtitre plates were coated with MTSE and MTCF proteins (30 (J,g/ml). 
* Antibody titres of tuberculosis sera were calculated with respect to normal human 
sera. 
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Table 3. Competition ELISA of Mycobacterium tuberculosis sonic extract (MTSE) 
and culture filtrate (MTCF) protein antigens with tuberculosis antibodies. 
Inhibitor •• 
Tuberculosis 
sera 
t 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Mean ± SD 
TBIgG 
MTSE protein antigens 
Concentration 
for 50% 
inhibition 
(ng/ml) 
0.6 
1.0 
0.8 
0.1 
1.1 
0.6 
0.5 
0.6 
1.5 
1.3 
1.1 
0.3 
0.1 
0.5 
0.4 
0.7 ± 0.4 
0.08 
Maximum 
inhibition 
(at 20 jig/ml) 
(%) 
72.8 
75.1 
76.4 
79.2 
71.6 
76.9 
77.8 
78.9 
70.5 
72.7 
75.5 
80.3 
82.2 
78.5 
77.6 
76.4 ± 3.3 
89.0 
MTCF protein antigens 
Concentration 
for 50% 
inhibition 
(jig/ml) 
0.9 
0.5 
1.3 
0.2 
1.2 
1.8 
0.9 
0.7 
1.6 
1.3 
0.8 
1.2 
0.3 
0.4 
0.3 
0.9 ± 0.5 
0.09 
Maximum 
inhibition 
(at 20 ug/ml) 
(%) 
70.4 
71.6 
69.5 
72.5 
68.6 
66.6 
69.7 
71.8 
68.5 
68.7 
70.6 
67.9 
73.6 
71.5 
72.5 
70.2 ± 2.0 
75.0 
The microtitre plates were coated with MTSE and MTCF proteins (30 ug/ml). 
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Figure 5. Elution profile of tuberculosis IgG with 0.58% acetic acid and 0.85% NaCl on protein A 
sepharose CL-4B column. Inset shows single band of IgG on 7.5% SDS-PAGE. 
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0.08 and 0.09 |ag/ml, respectively, of the protein inhibitors were sufficient to cause 
50% depletion in the TB-IgG activity (Table 3). 
Quantification of soluble TNF-a in sera of tuberculosis patients by ELISA: 
Since TNF-a is an autocrine cytokine known to have both deleterious as well 
as beneficial effects in tuberculosis, an attempt was made to detect and quantify the 
levels of soluble TNF-a present in sera of patients with active tuberculosis selected in 
this study, in comparison to sera from normal healthy individuals. ELISA results 
depicted in Fig. 6 clearly show an appreciable magnitude of soluble TNF-a present in 
sera of tuberculosis patients. As is evident from the data, a mean ± SEM concentration 
of soluble TNF-a was 207 ± 28 pg/ml (PO.001) in sera from tuberculosis patients 
(n=15), whereas no or negligible sTNF-a was detected in sera from normal healthy 
individuals (n=15). 
Quantification of circulating M. tuberculosis antigen 85 complex in sera of 
tuberculosis patients by ELISA: 
The presence of circulating M. tuberculosis 85B antigen (30 kDa) in sera of 
tuberculosis patients, either in the free form or complexed with fibronectin has been 
well established. Thus, in the present study, the selected tuberculosis sera were further 
characterized by subjecting them to evaluation of M. tuberculosis antigen 85 complex. 
The mean ± SEM concentration of M. tuberculosis 85 complex detected in sera of 
tuberculosis patients was 685 ± 55 pg/ml (n=15) (Fig. 7), whereas M. tuberculosis 85 
complex was not detected in sera from normal healthy individuals (n=15). 
Real-time RT-PCR of TNF-a and M. tuberculosis 85B mRNA expression in 
monocytes of tuberculosis patients: 
After characterizing sera from tuberculosis patients, we attempted the 
characterization of monocytes from tuberculosis patients, with respect to TNF-a and 
85B. PBMCs were isolated from the blood of tuberculosis patients to obtain adherent 
monocytes as described in the experimental section. Monocytes from tuberculosis 
patients were subjected to TNF-a mRNA evaluation by real-time RT-PCR. Monocytes 
from healthy individuals served as control. As evident from Fig. 8, in comparison to 
control monocytes, the monocytes of tuberculosis patients revealed the presence of 
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Figure 6. ELISA for TNF-a: Soluble TNF-a was determined in sera of tuberculosis patients and 
normal healthy individuals. Data represent mean ± SEM of 15 patients. 
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Figure 7. ELISA for antigen 85 complex: Secreted antigen 85 complex was determined in sera of 
tuberculosis patients and normal healthy individuals. Data represent mean ± SEM of 15 
patients. 
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Figure 8. Real-time RT-PCR for TNF-a mRNA expression: Monocytes of tuberculosis patients 
and normal healthy individuals were cultured in RPMI-1640 medium. Total RNA was 
extracted and assessed for TNF-a mRNA. Data represent mean ± SEM of 4 
experiments. 
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high basal levels of TNF-a mRNA copy number which was to the order of 5.47E+05 
(PO.001), i.e., basal levels of ~5 logs. Similarly, evaluation for M. tuberculosis 85B 
mRNA in the same monocytes by real-time RT-PCR showed appreciably high basal 
levels of 85B mRNA expression (-4.5 logs) in monocytes of tuberculosis patients as 
compared with control cells (Fig. 9). Thus, the data depicted in figures 8 and 9 
revealed appreciably high basal levels of TNF-a and 85B mRNA in monocytes of 
patients with active tuberculosis. 
Detection of soluble TNF-a and M. tuberculosis antigen 85 complex in 
supernatants of monocyte cultures of tuberculosis patients: 
Adherent monocytes from PBMCs of tuberculosis patients were cultured for 
24 hours and the supernatants obtained were subjected to ELISA for evaluation of 
soluble TNF-a as well as secreted M. tuberculosis 85 complex. 24 hours culture 
supernatants of tuberculosis monocytes exhibited soluble TNF-a to be present in the 
order of 235 ± 33 pg/ml (mean ± SEM; PO.001) (Fig. 10), whereas, negligible and 
insignificant amounts of soluble TNF-a were observed in supernatants of normal 
healthy monocyte cultures. 
The concentration of antigen 85 complex in 24 hours culture supernatants of 
tuberculosis monocytes was found to be 350 ± 41 pg/ml (mean ± SEM; PO.001) (Fig. 
11). Negligible amounts of antigen 85 complex were observed in supernatants of 
normal healthy monocyte cultures. As noted elsewhere (Wallis et al., 1998), M. 
tuberculosis 85B is a component of the M. tuberculosis antigen 85 complex, and 
changes in the antigen 85 complex immunoreactivity in supernatants of monocyte 
cultures or in sera likely reflect changes in 85B. 
(B) Preliminary Studies Probing the Identification of a Natural 
Antagonist of M. tuberculosis 85B: 
After ensuring that our laboratory protocols yield established results with 
minor variation, and prior to any further in-depth studies, we undertook preliminary 
studies to identify a natural antagonist of M. tuberculosis 85B. The objective of these 
experiments was to explore an economical and cost-friendly option towards combating 
tuberculosis. Taking into consideration the role of garlic in alternative medicine since 
ancient times, we opted to study its active component, allicin. 
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Figure 9. Real-time RT-PCR for M. tuberculosis 85B mRNA expression: Monocytes of 
tuberculosis patients and normal healthy individuals were cultured in RPMI-1640 
medium. Total RNA was extracted and assessed for M. tuberculosis 85B mRNA. Data 
represent mean ± SEM of 4 experiments. 
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Figure 10. ELISA for TNF-a: Soluble TNF-a was determined in supernatants of monocyte 
cultures of tuberculosis patients and normal healthy individuals. Data represent mean ± 
SEM of 10 patients. 
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individuals. Data represent mean ± SEM of 10 patients. 
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Dose-response effect of allicin on M. tuberculosis 85B mRNA expression in 
H37Rv cultures: 
M. tuberculosis (H37Rv) co-cultured with various concentrations of allicin (50, 
100, 250 and 500 ng/ml), as well as culture devoid of allicin which served as the 
corresponding control, were grown in Middlebrook 7H9 broth for 14 days at 37°C in 
5% CO2. After lysis of bacilli, RNA was extracted and assessed for 16S rRNA and 
85B mRNA. None of the concentrations of allicin had any significant effect on the 
expression of the housekeeping gene of M. tuberculosis, i.e., 16S rRNA (Fig. 12), 
thereby indicating that allicin did not non-specifically affect M. tuberculosis 
transcription. In contrast, the data showed appreciable effects of allicin on the 
expression of M. tuberculosis 85B mRNA. As is evident from Fig. 13, cultures of 
H37Rv, receiving 50 ng/ml allicin exhibited negligible changes in 85B mRNA level in 
comparison to control cultures devoid of allicin. A low magnitude decrease to the 
order of 0.5 logs (PO.05) in M. tuberculosis 85B mRNA expression was recorded 
with 100 ng/ml allicin. Further increase in allicin concentrations to 250 and 500 ng/ml 
in H37Rv cultures exhibited an appreciable suppression in M. tuberculosis 85B 
mRNA by ~2 and 2.5 logs (PO.001 for both), respectively, in comparison to control 
cultures (Fig. 13). The decrease in the 85B:16S ratio (Fig. 14) to the extent of 98% and 
99% observed for cultures challenged with 250 and 500 ng/ml of allicin, respectively, 
in comparison to control cultures devoid of allicin, supports the above data. It is to be 
pointed out here that previous reports have shown M. tuberculosis growth to be 
affected by allicin at relatively much higher concentrations and not at the lower 
concentrations that have been employed in this study. Although low concentrations of 
allicin do not affect the M. tuberculosis growth, it appreciably downregulates the M. 
tuberculosis 85B gene expression. 
Effect of allicin on the expression of antigen 85 complex in H37Rv cultures: 
M. tuberculosis (H37Rv) was cultured in Middlebrook 7H9 broth for 14 days 
with varying concentrations of allicin (0, 50, 100, 250 and 500 ng/ml). Thereafter, 
cultures were harvested and the bacilli were subjected to sonication to liberate 
intracellular proteins. Protein content was estimated in the untreated/treated sonic 
extracts as well as culture supernatants (MTCF). It is to be pointed out here that prior 
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Figure 12. Real-time RT-PCR for expression of mycobacterial 16S rRNA: M. tuberculosis 
(H37Rv) was grown in Middlebrook 7H9 broth with different doses (0-500 ng/ml) of 
allicin. Midlogarithmic mycobacterial cultures (14 days) were harvested and total 
RNA was extracted and assessed for mycobacterial 16S rRNA. Data represent mean ± 
SEM of 4 experiments and expressed as percent of control cultures. 
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Figure 13. Real-time RT-PCR for M. tuberculosis 85B mRNA expression: M. tuberculosis 
(H37Rv) was grown in Middlebrook 7H9 broth with different doses (0-500 ng/ml) of 
allicin. Midlogarithmic mycobacterial cultures (14 days) were harvested and total 
RNA was extracted and assessed for M. tuberculosis 85B mRNA. Data represent mean 
± SEM of 4 experiments. 
74 
l.OE-01 
- s -
1.0E-02 
i—i 
1.0E-03 -
1.0E-04 
0 50 100 250 500 
Concentration of allicin (ng/ml) 
Figure 14. Real-time RT-PCR for expression of M. tuberculosis 85B:16S ratio: M. tuberculosis 
(H37Rv) was grown in Middlebrook 7H9 broth with different doses (0-500 ng/ml) of 
allicin. Midlogarithmic mycobacterial cultures (14 days) were harvested and total 
RNA was extracted and assessed for M. tuberculosis 85B:16S ratio. Data represent 
mean ± SEM of 4 experiments. 
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to any further study, the presence of 30/31 kDa protein band in the electrophoresed gel 
was ascertained by ELISA using anti-antigen 85 complex antibody. As evident from 
Fig. 15, the effect of allicin on expression of M. tuberculosis antigen 85 complex 
(30/31 kDa) in M. tuberculosis sonic extract as revealed by gradient SDS-PAGE was 
found to be dose-dependent. Thus, in comparison to control cultures devoid of any 
allicin (Lane 6), 250 and 500 ng/ml of allicin proved to be a potent inhibitor of antigen 
85 complex (30/31 kDa) protein expression (Lanes 3 and 2, respectively). 
In addition, supernatants obtained from 14 days M. tuberculosis cultures, 
treated with various doses of allicin were subjected to ELISA to evaluate secreted M. 
tuberculosis antigen 85 complex. As evident from Fig. 16, the secretion of antigen 85 
complex was found to be dose-dependent and decreased by an appreciable amount 
with 250 and 500 ng/ml allicin. Hence, this decrease in antigen 85 complex secretion 
substantiates the above SDS-PAGE results. 
Immunoassays for MTSE and MTCF protein antigens of M. tuberculosis 
(H37Rv) co-cultured with allicin, against TB-IgG: 
Inhibition ELISA was performed to determine the tuberculosis antibody 
specificity on ELISA plates that were coated with sonic extract protein antigens of M. 
tuberculosis cultures. As evident from Fig. 17A, MTSE proteins obtained from 
cultures devoid of allicin exhibited a maximum of 89% inhibition in TB-IgG activity. 
50% inhibition was observed at a very low inhibitor concentration (0.08 |ig/ml). On 
the contrary, MTSE proteins of cultures receiving 50, 250, and 500 ng/ml allicin 
showed a maximum of 63%, 55%, and 49% inhibition in TB-IgG activity, 
respectively. MTSE proteins from cultures having 50 and 250 ng/ml allicin showed 
50% inhibition at 7.0 and 13.0 ug/ml inhibitor concentrations, respectively. However, 
MTSE proteins obtained from cultures having 500 ng/ml allicin failed to show 50% 
inhibition. 
Similarly, inhibition ELISA was performed to determine TB-IgG specificity 
using ELISA plates which were coated with MTCF protein antigens. As evident 
from Fig. 17B, MTCF proteins obtained from cultures devoid of allicin exhibited a 
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Figure 15. SDS-PAGE of mycobacterial proteins: Mycobacterium tuberculosis (H37Rv) was 
grown in Middlebrook 7H9 broth with different doses (0-500 ng/ml) of allicin. 
Midlogarithmic mycobacterial cultures (14 days) were harvested and intracellular 
proteins were liberated by sonication and 100 ug of each sample was resolved by 
10-20% gradient SDS-PAGE under reducing conditions and the gel was visualized 
by silver staining. Lane (1) molecular weight markers; Lanes 2-6 having 500, 250, 
100, 50 and 0 ng/ml allicin, respectively. 
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Figure 16. ELISA for antigen 85 complex: M. tuberculosis (H37Rv) was grown in Middlebrook 
7H9 broth with different doses (0-500 ng/ml) of allicin. Midlogarithmic mycobacterial 
cultures (14 days) were harvested and secreted antigen 85 complex was determined in 
supernatants of cultures. Data represent mean ± SEM of 4 experiments. 
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Figure 17. Inhibition ELISA of TB-IgG with mycobacterial proteins: M. tuberculosis (H37Rv) 
was grown in Middlebrook 7H9 broth with different doses (0-500 ng/ml) of allicin. 
Midlogarithmic mycobacterial cultures (14 days) were harvested and MTSE proteins 
as well as MTCF proteins were isolated. Inhibitors used were MTSE proteins (A) and 
MTCF proteins (B) having 0 ng/ml allicin (-o-), 50 ng/ml allicin (-•-), 250 ng/ml allicin 
(-A-) and 500 ng/ml allicin (-•-). Microtitre plates were coated with (A) MTSE 
proteins (30 ug/ml) and (B) MTCF proteins (30 ug/ml). Each data represents mean ± 
SD from three duplicate experiments. 
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maximum of 75% inhibition in TB-IgG activity at an inhibitor concentration of 20 
Hg/ml. It is noteworthy that even at the onset of reaction, appreciable binding was 
seen. The high degree of specificity was evident from 50% inhibition achieved at an 
extremely low inhibitor concentration. Here, 50% inhibition in the activity of TB-IgG 
was achieved at an inhibitor concentration of 0.09 u.g/ml. On the other hand, the 
degree of specificity of TB-IgG decreased tremendously in a somewhat linear manner 
when M. tuberculosis was co-cultured with varying doses of allicin. At a maximum 
inhibitor concentration of 20 ug/ml, a maximum of 68%, 61% and 55% inhibition in 
TB-IgG activity was achieved with MTCF proteins of cultures receiving 50, 250 and 
500 ng/ml of allicin, respectively. 50% inhibition in TB-IgG activity was seen at 
appreciably higher inhibitor concentrations, i.e., 1.0, 6.0 and 9.0 ug/ml inhibitors, for 
50, 250 and 500 ng/ml allicin-treated MTCF proteins, respectively (Fig. 17B). It is to 
be pointed out that the lower the amount of inhibitor required to achieve 50% 
inhibition in antibody activity, the more specific the immuno-interaction is. Thus, the 
results indicate that allicin decreases the specificity of TB-IgG for M. tuberculosis 
protein antigens. 
Gel retardation assay: 
The decrease in the specificity of IgG isolated from sera of patients with active 
tuberculosis against protein antigens of allicin-treated M. tuberculosis sonic extract 
and culture filtrate was further probed by gel retardation assay (Fig. 18). In 
comparison to control (Lane 1; 150 kDa IgG), a retarded mobility was observed for 
the mixture of IgG and protein antigens in total sonic extract (MTSE) (Lane 2, -180 
kDa), thereby indicating the formation of immune complex between IgG (150 kDa) 
and 30/31 kDa antigen 85 complex (Fig. 18A). To ascertain this, the above 180 kDa 
bands were spliced off and were used as coating antigen in ELISA against anti-antigen 
85 complex antibodies, where a binding of high magnitude was observed. On the 
contrary, MTSE prepared from 500 ng/ml allicin-treated H37Rv cultures failed to 
show any binding with IgG as is evident from the band observed in lane 3. Similar 
observations were recorded with MTCF proteins as is evident from Fig. 18B. 
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Figure 18. Gel retardation assay: Detection of retarded mobility of immune complex formed 
between TB-IgG and antigen 85 complex in MTSE and MTCF on 7% SDS-PAGE. The 
resolved samples for assessing retarded band shift were; (A): TB-IgG as control (Lane 1; 
150 kDa), immune complex of TB-IgG and antigen 85 complex in MTSE (Lane 2; -180 
kDa), immune complex of TB-IgG and 500 ng/ml allicin-treated MTSE (Lane 3); (B): 
TB-IgG as control (Lane 1; 150 kDa), immune complex of TB-IgG and antigen 85 
complex in MTCF (Lane 2; -180 kDa), immune complex of TB-IgG and 500 ng/ml 
allicin-treated MTCF (Lane 3). 
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(C) Studies on Healthy Monocytes Infected In Vitro with M. tuberculosis'. 
Time-dependent effect of M. tuberculosis infection on the expression of human 
housekeeping genes and on the expression of TNF-a mRNA and secreted 
TNF-a: 
An attempt was made to probe the effect of M. tuberculosis (H37Rv) infection, 
if any, on the human housekeeping genes. It was observed that M. tuberculosis infection 
had no effect at any time intervals (0-120 hours) of culturing of infected monocytes on 
the host housekeeping genes like R18 gene (18S rRNA) as revealed by quantitative real-
time RT-PCR (Fig. 19) or 0-actin gene as revealed by RT-PCR (Fig. 20). 
Thereafter, we investigated the kinetics (0-120 hours) of expression of TNF-a 
mRNA in M. tuberculosis-infected monocytes. TNF-a mRNA was corrected to host 
internal control, i.e., 18S rRNA, in the same sample. As evident from Fig. 21 A, the 
effect of M. tuberculosis infection on TNF-a mRNA was found to be time-dependent. 
The levels of TNF-a mRNA copy numbers in infected monocytes at various time 
intervals were recorded as 2.2 logs, 6.6 logs (PO.001), 11.5 logs (PO.001), 5.3 logs 
(PO.001) and 2.1 logs (PO.05), after 0, 4, 24, 72 and 120 hours of M. tuberculosis 
infection, respectively. Thus, the expression of TNF-a was maximal at 24 hours, 
which decreased considerably thereafter. A similar pattern of TNF-a mRNA 
expression was observed in RT-PCR results (Fig. 2IB). 
After this, we further probed the effect of M. tuberculosis infection on secreted 
TNF-a in culture supernatants that were harvested at various time intervals (0-120 
hours). As evident from Fig. 22, the effect of M. tuberculosis infection on secreted 
TNF-a was found to be time-dependent. The concentration of soluble TNF-a secreted 
in supernatants of infected monocyte cultures at various time intervals was observed 
as 30.2, 65.0 (PO.001), 93.2 (PO.001), 194.3 (PO.001), 112.2 (PO.001), 65.8 
(PO.001) and 13.8 (PO.001) pg/ml after 0, 4, 12, 24, 48, 72 and 120 hours of M. 
tuberculosis infection, respectively. Thus, the maximum secretion of TNF-a in culture 
supernatants was observed after 24 hours of M. tuberculosis infection, followed by a 
substantial decrease at the remaining time intervals of culture. 
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Figure 19. Real-time RT-PCR for kinetics of expression of host housekeeping gene: Human 
monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured 
for 0-120 hours in vitro. Total RNA was extracted and assessed for host R18 gene (18S 
rRNA). Data represent mean ± SEM of 6 experiments. 
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Figure 20. RT-PCR for kinetics of expression of p-actin gene: Human monocytes were infected 
with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured for 0-120 hours in vitro. 
Total RNA was extracted and assessed for human housekeeping gene p-actin mRN A. 
The amplification product for p-actin (514 bp) is shown. Lane (1) DNA ladder; Lanes 
2-8 for 0,4,12, 24,48, 72,120 hours of infection, respectively. 
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Figure 21A. Real-time RT-PCR for kinetics of TNF-a mRNA expression: Human monocytes 
were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured for 0-120 
hours in vitro. Total RNA was extracted and assessed for TNF-a mRNA. Expression 
of TNF-a was corrected to host 18S rRNA and expressed as copies of TNF-a in 1010 
copies of R18 (equivalent to 1 x 106 monocytes). Data represent mean ± SEM of 6 
experiments. 
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Figure 2IB. RT-PCR for kinetics of TNF-a mRNA expression: Human monocytes were infected 
with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured for 0-120 hours in vitro. 
Total RNA was extracted and assessed for TNF-a mRNA. The amplification product 
for TNF-a (342 bp) is shown. Lane (1) DNA ladder; Lanes 2-6 for 0, 4, 24, 72, 120 
hours of infection, respectively. 
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Figure 22. ELISA for kinetics of soluble TNF-a expression: Human monocytes were infected 
with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured for 0-120 hours in vitro. 
Soluble TNF-a was determined in supernatants of monocyte cultures. Data represent 
mean ± SEM of 6 experiments. 
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Time-dependent effect of M. tuberculosis (H37Rv) infection in healthy 
monocytes on M. tuberculosis 85B gene and on secreted antigen 85 complex: 
We also investigated the kinetics (0-120 hours) of expression of M. 
tuberculosis 16S rRNA and 85B mRNA in M. tuberculosis-infected monocytes. As 
evident from Fig. 23, 16S rRNA expression was observed to linearly increase with 
time. Also, the expression of 85B mRNA continued to increase up to 120 hours (Fig. 
24). The ratio of 85B:16S was found to increase with increasing time periods of 
infection. The 85B.T6S ratio recorded at various time intervals were 0.0011, 0.0019 
(PO.05), 0.0875 (PO.001), 0.3488 (P<0.001) and 0.7947 (PO.001), after 0, 4, 24, 
72 and 120 hours of infection, respectively (Fig. 25). Furthermore, between 4 and 24 
hours, M. tuberculosis 85B:16S increased significantly (PO.001). This increase in 
85BT6S ratio with time correlates with 85B mRNA levels at various time periods 
observed in Fig. 24. Thereafter, we probed the kinetics (0-120 hours) of expression of 
secreted M. tuberculosis antigen 85 complex in the supernatants of M. tuberculosis-
infected monocyte cultures. The expression of secreted antigen 85 complex was 
increased with increasing time intervals of infection (Fig. 26). 
Time-dependent effect of M. tuberculosis infection of monocytes on 
glutathione peroxidase activity: 
Time-course kinetics of GPx activity was determined in M. tuberculosis-
infected monocytes. Uninfected monocytes served as controls. At zero time, GPx 
activity in uninfected control and M. tuberculosis-infected monocytes was observed to 
be nearly the same. No significant change in GPx activity was observed at any of the 
time intervals of culturing (0-120 hours) of uninfected control monocytes. However, 
in comparison to control monocytes, the M. tuberculosis-infected monocytes exhibited 
a linear decrease in GPx activity with time. GPx activity in M. tuberculosis-infected 
monocytes was recorded as 67.1, 55.3 (PO.02), 40.1 (PO.01), 34.7 (PO.001) and 
26.8 (PO.001) U/mg protein, after 0, 4, 24, 72 and 120 hours of infection, 
respectively (Fig. 27). 
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Figure 23. Real-time RT-PCR for kinetics of expression of mycobacterial housekeeping gene: 
Human monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and 
cultured for 0-120 hours in vitro. Total RNA was extracted and assessed for 
mycobacterial 16S rRNA. Data represent mean ± SEM of 6 experiments. 
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Figure 24. Real-time RT-PCR for kinetics of M. tuberculosis 85B mRNA expression: Human 
monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured 
for 0-120 hours in vitro. Total RNA was extracted and assessed for M. tuberculosis 85B 
mRNA. Data represent mean ± SEM of 6 experiments. 
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Figure 25. Real-time RT-PCR for kinetics of expression ofM tuberculosis 85B:16S ratio: Human 
monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured 
for 0-120 hours in vitro. Total RNA was extracted and assessed for M. tuberculosis 
85B:16S ratio. Data represent mean ± SEM of 6 experiments. 
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Figure 26. ELISA for kinetics of secreted antigen 85 complex expression: Human monocytes 
were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured for 0-120 
hours in vitro. Secreted antigen 85 complex was determined in supernatants of 
monocyte cultures. Data represent mean ± SEM of 6 experiments. 
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Figure 27. Kinetics of glutathione peroxidase (GPx) activity: Human monocytes were infected 
with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured for 0-120 hours in vitro. 
Some cultures were not infected (white bars) and served as corresponding controls. 
GPx activity was determined in culture supernatants. Data represent mean ± SEM of 4 
experiments. 
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RESULTS 
(D) Modulation Studies of TNF-a and 85B gene expression in M. 
tuberculosis-infected monocytes: 
Dose-response effect of exogenous rhTNF-a on host TNF-a and M. tuberculosis 
85B gene expression in M. tuberculosis-infected monocytes: 
The above data suggested a role for endogenous TNF-a in auto-induction and 
in the induction of M. tuberculosis 85B gene expression. To further assess the role of 
TNF-a, in other experiments, exogenous rhTNF-a was added to M. tuberculosis-
infected monocytes, and then TNF-a and 85B mRNA were assessed. In these 
experiments, varying doses of rhTNF-a (0.1, 0.2, 2 and 10 ng/ml), or medium alone, 
were added to M. tuberculosis-infected monocytes. Thereafter, evaluation of cultures 
harvested after 24 hours of infection revealed high magnitude expression of 
endogenous TNF-a mRNA as a result of M. tuberculosis infection in monocytes 
devoid of exogenous rhTNF-a. In comparison to control infected monocytes, an 
increase in endogenous TNF-a mRNA by around 1.2 logs (PO.OOl), 1.5 logs 
(PO.001), 2.2 logs (PO.001) and 4.2 logs (PO.001) was recorded with treatments of 
0.1, 0.2, 2 and 10 ng/ml of rhTNF-a, respectively (Fig. 28). Interestingly, a significant 
change was seen in 85B:16S ratio after 24 hours of M. tuberculosis infection. As 
evident from Fig. 29, an increase in 85B:16S ratio was observed with the increase in 
dose of rhTNF-a. Thus, the 85B.T6S ratio observed were 0.089, 0.319 (PO.01), 0.375 
(PO.001), 0.444 (PO.001) and 0.920 (P<0.001), with 0, 0.1, 0.2, 2 and 10 ng/ml of 
rhTNF-a, respectively. Therefore, we conclude that cell activation by exogenous 
rhTNF-a induces expression of both TNF-a and M. tuberculosis 85B genes in M. 
tuberculosis-infected monocytes. 
Effect of sTNFR-I and sTNFR-II on TNF-a and M. tuberculosis 85B gene 
expression in M. tuberculosis-infected monocytes: 
The above data show that the expression of M. tuberculosis 85B is elevated 
after M. tuberculosis infection in monocytes, and correlates with TNF-a expression 
during the first 24 hours of infection. It showed that M. tuberculosis-indnced TNF-a in 
monocyte cultures modulated M. tuberculosis 85B gene expression during the first 24 
hours. To assess an effect of endogenous TNF-a on M. tuberculosis 85B expression, 
we inhibited TNF-a signalling by using its soluble receptors, TNFR-I and TNFR-II, 
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Figure 28. Real-time RT-PCR for effect of exogenous rhTNF-a on expression of TNF-a mRNA: 
Human monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and 
cultured with rhTNF-a (0-10 ng/ml) for 24 hours. Total RNA was extracted and 
assessed for TNF-a mRNA. Data represent mean ± SEM of 6 experiments. 
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Figure 29. Real-time RT-PCR for effect of exogenous rhTNF-a on expression of M. tuberculosis 
85B gene: Human monocytes were infected with M. tuberculosis H37Rv (1:1 
bacteria/cell) and cultured with rhTNF-a (0-10 ng/ml) for 24 hours. Total RNA was 
extracted and assessed for M. tuberculosis 85B:16S ratio. Data represent mean ± SEM 
of 6 experiments. 
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which bind and inactivate TNF-a. M. tuberculosis-infected monocytes were cultured 
either with sTNFR-I (10 ng/ml) or sTNFR-II (10 ng/ml), or medium alone, for 24 
hours. We found that both soluble receptors inhibited TNF-a as well as M. 
tuberculosis 85B mRNA expression in monocytes significantly. In comparison to M 
tuberculosis-infected monocytes, the infected cells co-cultured with sTNFR-I and 
sTNFR-II exhibited a suppression in TNF-a mRNA levels by around 5 logs (P<0.001) 
and 3.2 logs (PO.001), respectively (Fig. 30). Furthermore, inhibition of TNF-a by 
either sTNFR-I or sTNFR-II also decreased M. tuberculosis 85B mRNA expression 
significantly in M. tuberculosis-infected monocytes at 24 hours (PO.001 for both) 
(Fig. 31). Therefore, inhibition of endogenous TNF-a was associated with down-
modulation of both TNF-a and M. tuberculosis 85B gene expression. The results 
indicate sTNFR-I to be a stronger inhibitor of TNF-a and M. tuberculosis 85B gene 
expression in M. tuberculosis-infected monocytes than sTNFR-II. 
Role of NF-KB inM tuberculosis-infected monocytes: 
Cellular activation, and thereby induction of TNF-a, is mediated via NF-KB 
(Toossi et al., 1997; Fan et al., 2002). It has been well documented that TNF-a induced 
nuclear translocation of NF-KB was inhibited in SN50 peptide-treated human monocytic 
cell lines as demonstrated in EMSA (Lin et al., 1995). Thus, we employed SN50, an 
inhibitor of NF-KB, to assess the role of NF-KB in activation of gene expression in M. 
tuberculosis-infected monocytes. SN50 (100 p.g/ml) was added to monocytes 3 minutes 
prior to M. tuberculosis infection. Control cultures did not receive SN50. At 24 hours, 
SN50 suppressed endogenous TNF-a mRNA expression in M. tuberculosis-infected 
monocytes by around 6 logs (PO.001) in comparison to control cultures devoid of 
SN50 pre-treatment (Fig. 32A). To ensure that cellular inhibition was not non-specific, 
we compared the effect of SN50 with its inactive analogue, SN50/M at the same 
concentration. SN50/M did not affect TNF-a mRNA expression (P>0.05) (Fig. 32A). 
Similarly, SN50 was found to decrease the ratio of 85B:16S in M. tuberculosis-infected 
monocytes. This can be best viewed from the data depicted in Fig. 32B, where M 
tuberculosis 85BT6S ratio was found to be 0.088, 0.0003 (PO.001) and 0.090 (P>0.05) 
for control infected monocytes, infected monocytes challenged with SN50, and infected 
monocytes challenged with SN50/M, respectively (Fig. 32B). Therefore, it can be 
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Figure 30. Real-time RT-PCR for effect of soluble (s) TNF receptors (Rs) on expression of TNF-a 
mRNA: Human monocytes were infected with M. tuberculosis H37Rv (1:1 
bacteria/cell) and cultured with or without (-) 10 ng/ml sTNFR-I and 10 ng/ml 
sTNFR-II for 24 hours. Total RNA was extracted and assessed for TNF-a mRNA. 
Data represent mean ± SEM of 6 experiments. 
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Figure 31. Real-time RT-PCR for effect of soluble (s) TNF receptors (Rs) on expression of M. 
tuberculosis 85B gene: Human monocytes were infected with M. tuberculosis H37Rv 
(1:1 bacteria/cell) and cultured with or without (-) 10 ng/ml sTNFR-I and 10 ng/ml 
sTNFR-II for 24 hours. Total RNA was extracted and assessed for M. tuberculosis 
85B:16S ratio. Data represent mean ± SEM of 6 experiments. 
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Figure 32. Real-time RT-PCR for effect of inhibition of NFKB on expression of TNF-a and M. 
tuberculosis 85B mRNA: Human monocytes were infected with M. tuberculosis H37Rv 
(1:1 bacteria/cell) and cultured with or without (-) 100 ug/ml SN50 and 100 ug/ml 
SN50/M for 24 hours. Total RNA was extracted and assessed for expression of TNF-a 
mRNA (A) and M. tuberculosis 85B:16S ratio (B). Data represent mean ± SEM of 6 
experiments. 
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inferred that the increased expression of TNF-a and 85B mRNA in M. tuberculosis-
infected monocytes is mediated mainly via NF-KB. 
Role of ROI and RNI in M. tuberculosis-infected monocytes: 
NAC and NMMA, specific inhibitors of ROS and RNI pathways, and oATP, a 
known inhibitor of both ROI and RNI pathways, were employed in the present study 
to assess their effects on TNF-a and 85B mRNA expression in M. tuberculosis-
infected monocytes. After infection of monocytes with M. tuberculosis, NAC (10 
mM), NMMA (10 mM), or oATP (10 mM) were added to cultures. Control cultures 
received medium alone. Antioxidant effects of NAC, NMMA and oATP on TNF-a 
and 85B gene expression were probed, and it was found that NAC, NMMA and oATP 
downregulated TNF-a mRNA expression by around 6.2 logs (PO.001), 6.4 logs 
(PO.001) and 7.1 logs (PO.001), respectively, in cultures harvested after 24 hours of 
infection (Fig. 33A), as compared to control cultures. Furthermore, evaluation of M. 
tuberculosis 85B:16S ratio revealed similar results, with all three inhibitors decreasing 
the ratio of 85B:16S by an appreciable magnitude (PO.001 for all), when compared 
with infected monocytes devoid of any inhibitor (Fig. 33B). 
Furthermore, in view of the data obtained above with negative modulators, 
attempts were also made to probe the effects of positive modulators, namely, SNP, 
NADPH and NOC-9, on TNF-a and 85B gene expression in M. tuberculosis-infected 
monocytes. As evident from Fig. 34A, in comparison to control infected cultures 
devoid of any supplements and harvested after 24 hours of infection, M. tuberculosis-
infected monocytes that were co-cultured with SNP (0.5 uM), NADPH (5 uM) and 
NOC-9 (300 uM) exhibited an augmentation in TNF-a by around 1 log (PO.01), 3.1 
logs (PO.001) and 2.2 logs (PO.001), respectively. 
On determining the M. tuberculosis 85B:16S ratio for the above cells, an 
appreciable increase in 85B:16S ratio was observed with the above positive 
modulators. As illustrated in Fig. 34B, the 85B:16S ratio was 0.043 for control 
monocytes infected with M. tuberculosis that were devoid of any modulator, whereas 
the 85B-.16S ratio was 0.431 (PO.001), 0.737 (PO.001) and 1.072 (PO.001) for 
infected monocytes co-cultured with SNP, NOC-9 and NADPH, respectively. 
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Figure 33. Real-time RT-PCR for inhibition of expression of TNF-a and M. tuberculosis 85B 
mRNA by NAC, NMMA and oATP: Human monocytes were infected with M. 
tuberculosis H37Rv (1:1 bacteria/cell) and cultured with or without (-) 10 mM N-acetyl 
cysteine (NAC), NG-monomethyI-L-arginine monoacetate (NMMA), or oxidized ATP 
(oATP) for 24 hours. Total RNA was extracted and assessed for TNF-a mRNA (A) and 
M. tuberculosis 85B:16S ratio (B). Data represent mean ± SEM of 6 experiments. 
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Figure 34. Real-time RT-PCR for induction of expression of TNF-a and M. tuberculosis 85B 
mRNA by SNP, NADPH and NOC-9: Human monocytes were infected with M. 
tuberculosis H37Rv (1:1 bacteria/cell) and cultured with or without (-) sodium 
nitroprusside (SNP; 0.5 uM), NADPH (5 uM), or nonoate-9 (NOC-9; 300 uM) for 24 
hours. Total RNA was extracted and assessed for TNF-a mRNA (A) and M. 
tuberculosis 85B:16S ratio (B). Data represent mean ± SEM of 6 experiments. 
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(E) Modulation Studies of TNF-a and M. tuberculosis 85B Expression 
with the Natural Antioxidant Allicin: 
Toxicity assessment of allicin: 
Since higher doses of allicin from garlic have previously proven to be toxic by 
various investigators, the present study employed lower concentrations (0-500 ng/ml), 
which failed to show any toxic effect on monocytes as revealed by MTT (Fig. 35) or 
trypan blue exclusion assays. Cell viability is expressed as percent (mean ± SEM) 
viable cells compared to untreated cells (taken as 100% viable). Also, no effect was 
observed on housekeeping genes: R18 (18S rRNA) by quantitative real-time RT-PCR 
(Fig. 36A), or P-actin gene as revealed by RT-PCR (Fig. 36B), thereby indicating that 
allicin did not non-specifically affect human TNF-a transcription. Also, the effect of 
various doses of allicin employed in the present study failed to show any toxic or 
inhibitory effect (P>0.05 for all) on the mycobacterial housekeeping gene M. 
tuberculosis 16S rRNA by quantitative real-time RT-PCR in monocytes infected with 
M. tuberculosis and cultured for 24 hours (Fig. 37A). Furthermore, no effect was 
observed on amplification of M. tuberculosis 16S rRNA as revealed by RT-PCR 
results (Fig. 37B). 
Dose-response effect of allicin on TNF-a gene expression: 
M. tuberculosis-infected monocytes were co-cultured for 24 hours with 
varying doses of natural antioxidant allicin. Infected cultures devoid of allicin served 
as control. The dose-response effect of allicin on TNF-a gene expression was 
determined by real-time RT-PCR: in comparison to control, a linear downregulation of 
TNF-a mRNA copy numbers by -3.2 logs (PO.001), 4.1 logs (PO.001), 7.1 logs 
(PO.001) and 8.1 logs (PO.001) was recorded with 50, 100, 250 and 500 ng/ml of 
allicin, respectively (Fig. 3 8A). This was further substantiated by RT-PCR. The 
amplification of TNF-a gene in RT-PCR was dose-dependent, where concentrations of 
250 and 500 ng/ml allicin proved to be potent inhibitors as is evident from RT-PCR 
products (Fig. 38B). Thus, allicin potently inhibits the gene expression of pro-
inflammatory cytokine TNF-a. 
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Figure 35. MTT cell viability assay for dose-response effect of allicin (0-500 ng/ml) on M. 
tuberculosis-mftcted monocytes. Data represents the analysis of three independent 
experiments in duplicates, expressed as mean viable cells (±SEM) percentage of 
controls. 
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Figure 36A. Real-time RT-PCR for effect of allicin on expression of host housekeeping gene: 
Human monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and 
cultured with allicin (0-500 ng/ml) for 24 hours. Total RNA was extracted and 
assessed for host R18 gene (18S rRNA). Data represent mean ± SEM of 6 
experiments. 
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Figure 36B. RT-PCR for effect of allicin on amplification of p-actin gene: Human monocytes 
were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured with allicin 
(0-500 ng/ml) for 24 hours. The amplification product for p-actin (514 bp) is shown. 
Lane (1) DNA ladder; Lanes 2-6 having 0, 50, 100, 250 and 500 ng/ml allicin, 
respectively. 
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Figure 37A. Real-time RT-PCR for effect of allicin on expression of mycobacterial housekeeping 
gene: Human monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) 
and cultured with allicin (0-500 ng/ml) for 24 hours. Total RNA was extracted and 
assessed for mycobacterial 16S rRNA. Data represent mean ± SEM of 6 experiments. 
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Figure 37B. RT-PCR for effect of allicin on expression of mycobacterial housekeeping gene: 
Human monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and 
cultured with allicin (0-500 ng/ml) for 24 hours. The amplification product for 16S 
rRNA is shown. Lanes 1-4 having 0, 50, 250 and 500 ng/ml allicin, respectively and 
Lane (5) DNA ladder. 
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Figure 38A. Real-time RT-PCR for dose-response effect of allicin on expression of TNF-a 
mRNA: Human monocytes were infected with M. tuberculosis H37Rv (1:1 
bacteria/cell) and cultured with allicin (0-500 ng/ml) for 24 hours. Total RNA was 
extracted and assessed for TNF-a mRNA. Data represent mean ± SEM of 6 
experiments 
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Figure 38B. RT-PCR for dose-response effect of allicin on amplification of TNF-a mRNA: 
Human monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/ceil) and 
cultured with allicin (0-500 ng/ml) for 24 hours. The amplification product of TNF-a 
(342 bp) is shown as: Lane (1) DNA ladder; Lanes 2-6 having 0, 50, 100, 250 and 500 
ng/ml allicin, respectively. 
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RESULTS 
Dose-response effect of allicin on soluble TNF-a in M. tuberculosis-infected 
monocyte cultures: 
These experiments probed the effect of varying doses of allicin on the 
expression of soluble TNF-a in 24 hours culture supernatants by ELISA. The 
suppression in soluble TNF-a expression with varying doses of allicin in 24 hours 
culture supernatants of M. tuberculosis-infected monocytes was found to be dose-
dependent, which is evident from the data in Fig. 39, where the concentrations 
obtained for soluble TNF-a were 187.5, 185.5 (P>0.05), 181 (P>0.05), 50.5 (PO.001) 
and 38.7 (PO.001) pg/ml at 0, 50, 100, 250 and 500 ng/ml of allicin, respectively. 
These results show that at concentrations of 250 and 500 ng/ml, allicin potently 
inhibits the expression of soluble TNF-a in supernatants of M. tuberculosis-infected 
monocyte cultures. Thus, the doses of 250 and 500 ng/ml proved to be highly potent 
inhibitory concentrations of allicin. 
Dose-response effect of allicin on M. tuberculosis 85B gene expression: 
Next, we studied the dose-response effect of allicin on the M. tuberculosis 85B 
gene expression in M. tuberculosis-infected monocytes that were cultured with or 
without various doses of allicin for 24 hours. The expression of 85B mRNA was 
normalized with mycobacterial 16S rRNA and expressed as 85B:16S. Thereafter, the 
85B:16S ratio was computed to evaluate the effect of allicin. Fig. 40A clearly shows 
that the 85B:16S ratio decreased linearly with increase in allicin concentration. The 
85B:16S ratio recorded were 0.091, 0.087 (P>0.05), 0.012 (PO.001), 0.001 (PO.001) 
and 0.0002 (PO.001) in M. tuberculosis-infected monocytes treated with 0, 50, 100, 
250 and 500 ng/ml of allicin, respectively. Similar observations were found in RT-
PCR experiments where maximum downregulation in M. tuberculosis 85B mRNA 
expression was observed with 500 ng/ml of allicin (Fig. 40B). 
Dose-response effect of allicin on secreted antigen 85 complex in M. 
tuberculosis-infected monocyte cultures: 
Thereafter, we probed the dose-response effect of allicin on secreted antigen 
85 complex in culture supernatants of M. tuberculosis-infected monocytes harvested 
after 24 hours using ELISA. As illustrated in Fig. 41, the effect of allicin on secreted 
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Figure 39. ELISA for dose-response effect of allicin on soluble TNF-a expression: Human 
monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured 
with allicin (0-500 ng/ml) for 24 hours. Soluble TNF-a was determined in supernatants 
of monocyte cultures. Data represent mean ± SEM of 6 experiments. 
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Figure 40A. Real-time RT-PCR for dose-response effect of allicin on expression of M. 
tuberculosis 85B gene: Human monocytes were infected with M. tuberculosis H37Rv 
(1:1 bacteria/cell) and cultured with allicin (0-500 ng/ml) for 24 hours. Total RNA 
was extracted and assessed for M. tuberculosis 85B:16S ratio. Data represent mean ± 
SEM of 6 experiments. 
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Figure 40B. RT-PCR for dose-response effect of allicin on amplification of M. tuberculosis 85B 
mRNA: Human monocytes were infected with M. tuberculosis H37Rv (1:1 
bacteria/cell) and cultured with allicin (0-500 ng/ml) for 24 hours. The amplification 
product of 85B is shown as: Lanes 1-4 having 500, 250, 100 and 0 ng/ml allicin, 
respectively. 
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Figure 41. ELISA for dose-response effect of allicin on expression of antigen 85 complex: Human 
monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured 
with allicin (0-500 ng/ml) for 24 hours. Secreted antigen 85 complex was determined in 
supernatants of monocyte cultures. Data represent mean ± SEM of 6 experiments. 
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RESULTS 
antigen 85 complex was found to be dose-dependent. The concentrations of antigen 
85 complex secreted in supernatants of infected monocyte cultures at various doses of 
allicin treatment were recorded as 206.1, 203.2 (P>0.05), 162.3 (PO.01), 62.9 
(PO.001) and 49.3 (PO.001) pg/ml with 0, 50, 100, 250 and 500 ng/ml of allicin, 
respectively. Thus, the maximum inhibition in secretion of antigen 85 complex in 
culture supernatant was observed with 500 ng/ml of allicin. 
Dose-response effect of allicin on secreted TNFR-I and TNFR-H in M. 
tuberculosis-infected monocyte cultures: 
The effect of varying doses of allicin on the levels of secreted soluble TNF 
receptors, TNFR-I and TNFR-II, in supernatants of M. tuberculosis-infected monocyte 
cultures was determined by ELISA. As is evident from Fig. 42A, the effect of allicin 
on secreted TNFR-I in supernatants was found to be dose-dependent, where the 
concentrations of sTNFR-I observed were 106.8, 99.7 (PO.05), 91.7 (PO.01), 75 
(P<0.001) and 54 (PO.001) pg/ml with 0, 50, 100, 250 and 500 ng/ml of allicin, 
respectively. A similar trend was observed for sTNFR-II, which is clearly evident 
from Fig. 42B. The data obtained for sTNFR-II were 158, 154.8 (P>0.05), 132.3 
(PO.01), 65.7 (PO.001) and 35.7 (PO.001) pg/ml with 0, 50, 100, 250 and 500 
ng/ml of allicin, respectively. 
Dose-response effect of NAC on TNF-a and 85B gene expression in M. 
tuberculosis-infected monocytes: 
We next investigated the dose-response effect of NAC, an ROI inhibitor, on 
the expression of TNF-a and 85B mRNA. M. tuberculosis-infected monocytes were 
cultured with or without 1, 2, 4, 6, 8 and 10 mM of NAC for 24 hours. Thereafter, the 
cells were harvested and processed as per experimental design. The inhibitory effect of 
NAC doses on TNF-a expression is shown in Fig. 43 A, where no effect was observed 
with 1 and 2 mM of NAC. However, with the increase in NAC dose, its inhibitory 
effect became evident. In comparison to control monocytes, a downregulation of TNF-
a mRNA expression by around 0.7 logs (PO.01), 2.7 logs (PO.001), 5 logs 
(PO.001) and 6 logs (PO.001) was observed with 4, 6, 8 and 10 mM of NAC, 
respectively (Fig. 43 A). Computational analysis of the dose-response data revealed the 
IC50 value of NAC for TNF-a mRNA expression to be 8 mM. 
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Figure 42. ELISA for dose-response effect of allicin on soluble TNFR-I and TNFR-II expression: 
Human monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and 
cultured with allicin (0-500 ng/ml) for 24 hours. Soluble TNFR-I (A) and TNFR-II (B) 
were determined in supernatants of monocyte cultures. Data represent mean ± SEM of 
6 experiments. 
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Figure 43. Real-time RT-PCR for dose-response effect of NAC on expression of TNF-a and M. 
tuberculosis 85B mRNA: Human monocytes were infected with M. tuberculosis H37Rv 
(1:1 bacteria/cell) and cultured with NAC (0-10 mM) for 24 hours. Total RNA was 
extracted and assessed for TNF-a mRNA (A) and M. tuberculosis 85B:16S ratio (B). 
Data represent mean ± SEM of 6 experiments. 
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RESULTS 
Next, the inhibitory effect of varying doses of NAC on M. tuberculosis 85B 
mRNA expression was probed. As evidenced by data depicted in Fig. 43B, the 
85B:16S ratio was found to be dose-dependently modulated. M. tuberculosis 85B:16S 
ratio were recorded as 0.081, 0.053 (PO.05), 0.052 (PO.05), 0.046 (PO.01), 0.036 
(PO.001) and 0.009 (PO.001) with 0, 2, 4, 6, 8 and 10 mM of NAC, respectively 
(Fig. 43B). Therefore, 10 mM concentration of NAC was found to be most effective in 
suppressing TNF-a and M. tuberculosis 85B mRNA expression in M. tuberculosis-
infected monocytes at 24 hours of infection. 
Dose-response effect of SN50 on TNF-a and 85B gene expression in M. 
tuberculosis-infected monocytes: 
Furthermore, an attempt was made to study the dose-response effect of NF-KB 
inhibitor, SN50 on the expression of TNF-a and 85B mRNA. For this, M. 
tuberculosis-infected monocytes were cultured with or without 20, 40, 60, 80 and 100 
ug/ml of SN50. Thereafter, the cells were harvested and subjected to analysis for the 
determination of TNF-a and 85B mRNA. The inhibitory effect of SN50 doses on 
TNF-a expression is shown in Fig. 44A, where the downregulation of TNF-a mRNA 
expression by SN50 was found to be dose-dependent. There was negligible change 
with 20 |ig/ml of SN50, but TNF-a mRNA expression was found downregulated by 
~1 log (PO.01), 4 logs (PO.001), 5 logs (PO.001) and 6 logs (PO.001), with 40, 
60, 80 and 100 |a,g/ml of SN50, respectively (Fig. 44A). Computational analysis of the 
dose-response data revealed the IC50 value of SN50 for TNF-a mRNA expression to 
be 90 ug/ml. 
Thereafter, the inhibitory effect of varying doses of SN50 on M. tuberculosis 
85B mRNA expression was probed. Fig. 44B shows the 85B:16S ratio, which was 
found to be dose-dependent. M. tuberculosis 85BT6S ratio recorded were 0.081, 
0.046 (PO.02), 0.029 (PO.001), 0.003 (PO.001), 0.002 (PO.001) and 0.0004 
(PO.001) with 0, 20, 40, 60, 80 and 100 ug/ml of SN50, respectively (Fig. 44B). 
Therefore, 100 |xg/ml concentration of SN50 was found to be most effective in 
downregulating the expression of TNF-a and M. tuberculosis 85B mRNA in M. 
tuberculosis-infected monocytes at 24 hours of infection. 
120 
(A) 
i.vz+u -
.§ l.OE+lOn 
a 
u
 1.0E+08 -
< 
§ l.OE+06 -
S 
» 1.0E+04-
|5 l.OE+02 -
n 
0 20 40 60 80 100 
Concentration of SN50 (ug/ml) 
00 
1.0E-01 
1.0E-02 
1.0E-03 
1.0E-04 
- * -
-s-
[*1 
* 
0 20 40 60 80 100 
Concentration of SN50 (jig/ml) 
Figure 44. Real-time RT-PCR for dose-response effect of SN50 on expression of TNF-a and M. 
tuberculosis 85B mRNA: Human monocytes were infected with M. tuberculosis H37Rv 
(1:1 bacteria/cell) and cultured with SN50 (0-100 ug/ml) for 24 hours. Total RNA was 
extracted and assessed for TNF-a mRNA (A) and M. tuberculosis 85B:16S ratio (B). 
Data represent mean ± SEM of 6 experiments. 
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RESULTS 
Comparative study of modulatory effects induced by anti-TNF-a antibody 
versus allicin on TNF-a expression in M. tuberculosis-infected monocytes: 
In continuation with the above experiments, an attempt was also made to have 
an insight on the comparative inhibitory effect of anti-TNF-a antibody versus allicin, 
on endogenous TNF-a mRNA expression. As evident from Fig. 45A, in comparison to 
control uninfected monocytes, endogenous TNF-a mRNA in infected monocytes was 
found augmented to the order of-10.1 logs (PO.001), and was further enhanced by 
-4 logs (PO.05) with exogenous rhTNF-a. The effect of exogenous rhTNF-a was 
neutralized substantially by anti-TNF-a antibody or 500 ng/ml allicin, as evident from 
suppression in endogenous TNF-a mRNA expression, between 8.1 - 8.3 logs 
(PO.01). No effect was observed in uninfected monocytes that were either treated or 
untreated with 500 ng/ml of allicin for 24 hours. A suppression in endogenous TNF-a 
mRNA in M. tuberculosis-infected monocytes by -6.3 logs (PO.001) and -5.2 logs 
(PO.001) was observed with 500 ng/ml allicin and 10 ng/ml anti-TNF-a antibody, 
respectively (Fig. 45A). A similar pattern was observed with RT-PCR products (Fig. 
45B). Thus, the data is indicative of TNF-a involvement in positive auto-regulation, 
and also indicates that allicin proves to be a potent inhibitor of pro-inflammatory 
cytokine TNF-a, like anti-TNF-a antibody. 
After ascertaining the modulatory effects on TNF-a mRNA expression, an 
attempt was also made to probe the comparative effects of anti-TNF-a antibody and 
allicin on secreted soluble TNF-a in culture supernatants of M. tuberculosis-infected 
monocytes using ELISA. As evident from Fig. 46, supernatants of monocytes alone 
and of those co-cultured with 500 ng/ml allicin, but devoid of any M. tuberculosis 
infection, showed negligible or no expression of sTNF-a. On the other hand, 189 
pg/ml of sTNF-a was recorded in supernatants of monocytes infected with M. 
tuberculosis. Upon co-culturing M. tuberculosis-infected monocytes with 10 ng/ml 
exogenous rhTNF-a, the sTNF-a level increased to 232.5 pg/ml (PO.001). Addition 
of 10 ng/ml of anti-TNF-a antibody or 500 ng/ml of allicin to rhTNF-a (10 ng/ml)-
challenged M. tuberculosis-infected monocytes showed a decrease in sTNF-a levels to 
154 pg/ml (PO.001) and 113 pg/ml (PO.001), respectively. A further suppression in 
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Figure 45A. Real-time RT-PCR for modulation of TNF-a mRNA expression. Human monocytes 
were infected with M. tuberculosis H37Rv (1:1 bacteria/cell). Some cultures were not 
infected (MN only and MN+Allicin) and served as controls. Cultures then received 
either rhTNF-a (10 ng/ml) or rhTNF-a (10 ng/ml) + anti-TNF-a Abs (10 ng/ml) or 
rhTNF-a (10 ng/ml) + allicin (500 ng/ml) or anti-TNF-a Abs (10 ng/ml) or allicin (500 
ng/ml) or media alone (-) for 24 hours. Total RNA was extracted and assessed for 
TNF-a mRNA. Data represent mean ± SEM of 6 experiments. 
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Figure 45B. RT-PCR for modulation of TNF-a mRNA amplification: Human monocytes were 
infected with M. tuberculosis H37Rv (1:1 bacteria/cell) and cultured for 24 hours. The 
amplification product of TNF-a is shown as: Lanes (1) DNA ladder, (2) rhTNF-a (10 
ng/ml), (3) Infected monocytes, (4) anti-TNF-a Abs (10 ng/ml), (5) rhTNF-a (10 ng/ml) 
+ allicin (500 ng/ml), (6) rhTNF-a (10 ng/ml) + anti-TNF-a Abs (10 ng/ml) and (7) 
Allicin (500 ng/ml). 
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Figure 46. ELISA for modulation of soluble TNF-a expression: Human monocytes were infected 
with M. tuberculosis H37Rv (1:1 bacteria/cell). Some cultures were not infected (MN 
only and MN+Allicin) and served as controls. Cultures then received either rhTNF-a 
(10 ng/ml) or rhTNF-a (10 ng/ml) + anti-TNF-a Abs (10 ng/ml) or rhTNF-a (10 ng/ml) 
+ allicin (500 ng/ml) or anti-TNF-a Abs (10 ng/ml) or allicin (500 ng/ml) or media 
alone (-) for 24 hours. Soluble TNF-a was determined in supernatants of monocyte 
cultures. Data represent mean ± SEM of 6 experiments. 
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RESULTS 
sTNF-a levels was observed in supernatants of M. tuberculosis-infected monocytes by 
anti-TNF-a antibody and allicin, which was to the order of 85.5 pg/ml (PO.001) and 
40.7 pg/ml (PO.001), respectively (Fig. 46). Thus, the data obtained indicate that 500 
ng/ml of allicin has a potent inhibitory effect on soluble TNF-a in culture supernatants 
of M. tuberculosis-infected monocytes. 
Comparative modulatory effects of anti-TNF-a antibody versus allicin on M. 
tuberculosis 85B expression inM tuberculosis-infected monocytes: 
We also investigated the modulatory effects of anti-TNF-a antibody versus 
allicin on M. tuberculosis 85B mRNA expression as well as on secreted soluble M. 
tuberculosis antigen 85 complex. The data depicted in Fig. 47 illustrates the 
comparative effects on M. tuberculosis 85B mRNA expression. In comparison to M. 
tuberculosis-infected monocytes, 85B:16S ratio was significantly reduced by allicin. 
The 85B:16S ratio was recorded as 0.088 for M. tuberculosis-infected monocytes that 
were devoid of any inhibitor. On the contrary, in the presence of 10 ng/ml anti-TNF-a 
antibody and 500 ng/ml allicin, the 85B:16S ratio was reduced to the order of 0.002 
(PO.001) and 0.0002 (PO.001), respectively (Fig. 47). The results thus indicate the 
potent inhibitory effect of allicin on the 85B mRNA expression, similar to anti-TNF-a 
antibody. 
Next we probed the comparative inhibitory effects of anti-TNF-a antibody 
versus allicin on secreted soluble M. tuberculosis antigen 85 complex in culture 
supernatants of monocytes infected with M. tuberculosis by ELISA. The data clearly 
show a higher degree of suppression induced by 500 ng/ml of allicin, than by anti-
TNF-a antibody, in secreted antigen 85 complex levels in culture supernatants of M. 
tuberculosis-infected monocytes. The level of secreted antigen 85 complex in 
supernatants of M. tuberculosis-infected monocyte cultures was found to be 204.7 
pg/ml, whereas in the presence of 10 ng/ml anti-TNF-a antibody and 500 ng/ml 
allicin, it was reduced to 91.9 pg/ml (PO.001) and 48.7 pg/ml (PO.001), respectively 
(Fig. 48). 
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Figure 47. Real-time RT-PCR for modulation of M. tuberculosis 85B gene expression: Human 
monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell). Cultures then 
received either rhTNF-a (10 ng/ml) or rhTNF-a (10 ng/ml) + anti-TNF-a Abs (10 
ng/ml) or rhTNF-a (10 ng/ml) + allicin (500 ng/ml) or anti-TNF-a Abs (10 ng/ml) or 
allicin (500 ng/ml) or media alone (-) for 24 hours. Total RNA was extracted and 
assessed for M. tuberculosis 85B:16S ratio. Data represent mean ± SEM of 6 
experiments. 
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Figure 48. ELISA for modulation of expression of secreted antigen 85 complex: Human 
monocytes were infected with M. tuberculosis H37Rv (1:1 bacteria/cell). Cultures then 
received either rhTNF-a (10 ng/ml) or rhTNF-a (10 ng/ml) + anti-TNF-a Abs (10 
ng/ml) or rhTNF-a (10 ng/ml) + allicin (500 ng/ml) or anti-TNF-a Abs (10 ng/ml) or 
allicin (500 ng/ml) or media alone (-). Antigen 85 complex was determined in culture 
supernatants at 24 hours. Data represent mean ± SEM of 6 experiments. 
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RESULTS 
Comparative modulatory effects of anti-TNF-a antibody versus allicin on 
secreted soluble TNFR-I and TNFR-II in M. tuberculosis-infected monocyte 
cultures: 
We also probed the comparative modulatory effects of anti-TNF-a antibody 
verses allicin on expression of secreted soluble TNFR-I and TNFR-II using ELISA. 
As illustrated in Fig. 49, the level of secreted TNFR-I in supernatants of M. 
tuberculosis-infected monocyte cultures was found to be 105 pg/ml, whereas on 
addition of 10 ng/ml rhTNF-a, it was augmented to 161 pg/ml (PO.001). On the other 
hand, in the presence of 10 ng/ml anti-TNF-a antibody and 500 ng/ml allicin, sTNFR-
I was reduced to 69 pg/ml (PO.001) and 54.7 pg/ml (PO.001), respectively, in M. 
tuberculosis-infected monocyte cultures. Similarly, as evident from Fig. 50, level of 
secreted TNFR-II in supernatants of M. tuberculosis-infected monocyte cultures at 24 
hours was recorded as 154 pg/ml. On addition of 10 ng/ml rhTNF-a, it was increased 
to the order of 208 pg/ml (PO.001). On the contrary, when M. tuberculosis-infected 
monocytes were cultured for 24 hours with 10 ng/ml anti-TNF-a antibody and 500 
ng/ml allicin, the level of secreted TNFR-II in supernatants was reduced to 75.5 pg/ml 
(PO.001) and 30 pg/ml (PO.001), respectively. Thus, the results obtained indicate 
that allicin is a potent suppressor of secreted TNFR-I and TNFR-II expression, like 
anti-TNF-a antibody. 
Comparative modulatory effects of various inhibitors versus allicin on TNF-a 
and M. tuberculosis 85B mRNA expression in M. tuberculosis-infected 
monocytes: 
Here, we investigated the comparative antioxidant effects of NAC versus 
allicin on TNF-a and M. tuberculosis 85B mRNA expression in M. tuberculosis-
infected monocytes at 24 hours of infection. Comparative antioxidant effect of NAC 
versus allicin on TNF-a gene expression is shown in Fig. 51, where 10 mM NAC and 
500 ng/ml allicin downregulated TNF-a mRNA expression by around 5.5 logs 
(PO.001) and 6.3 logs (PO.001), respectively, as compared to control M. 
tuberculosis-infected monocytes. Thus, allicin proved to be around 0.8 logs more 
effective than NAC. The IC50 values for TNF-a inhibition in our system, by allicin and 
NAC were calculated to be 170 ng/ml and 1.3 mg/ml, respectively. 
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Figure 49. ELISA for modulation of soluble TNFR-I expression: Human monocytes were 
infected with M. tuberculosis H37Rv (1:1 bacteria/cell). Cultures then received either 
rhTNF-a (10 ng/ml) or rhTNF-a (10 ng/ml) + anti-TNF-a Abs (10 ng/ml) or rhTNF-a 
(10 ng/ml) + allicin (500 ng/ml) or anti-TNF-a Abs (10 ng/ml) or allicin (500 ng/ml) or 
media alone (-) for 24 hours. Soluble TNFR-I was determined in supernatants of 
monocyte cultures. Data represent mean ± SEM of 6 experiments. 
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Figure 50. ELISA for modulation of soluble TNFR-II expression: Human monocytes were 
infected with M. tuberculosis H37Rv (1:1 bacteria/cell). Cultures then received either 
rhTNF-a (10 ng/ml) or rhTNF-a (10 ng/ml) + anti-TNF-a Abs (10 ng/ml) or rhTNF-a 
(10 ng/ml) + allicin (500 ng/ml) or anti-TNF-a Abs (10 ng/ml) or allicin (500 ng/ml) or 
media alone (-) for 24 hours. Soluble TNFR-II was determined in supernatants of 
monocyte cultures. Data represent mean ± SEM of 6 experiments. 
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Figure 51. Real-time RT-PCR for comparative effects of NAC, SN50 and allicin on expression of 
TNF-ct mRNA: Human monocytes were infected with M. tuberculosis H37Rv (1:1 
bacteria/cell) in the presence or absence (-) of NAC (10 mM), SN50 (100 ug/ml), 
SN50/M (100 jig/ml) or allicin (500 ng/ml). Total RNA was extracted at 24 hours and 
was assessed for expression of TNF-a mRNA. Data represent mean ± SEM of 6 
experiments. 
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We also probed the comparative effects of SN50 versus allicin on TNF-a and 
M. tuberculosis 85B mRNA expression in M. tuberculosis-infected monocytes at 24 
hours of infection. SN50 (100 ug/ml) was added to monocytes 3 minutes prior to M. 
tuberculosis infection. Control cultures did not receive SN50. At 24 hours, SN50 
suppressed endogenous TNF-a mRNA expression in M. tuberculosis-infected 
monocytes by around 6 logs (PO.001), in comparison to control cultures devoid of 
SN50 pre-treatment (Fig. 51). Thus, allicin proved to be around 0.3 logs more 
effective than SN50. The IC50 value calculated for TNF-a inhibition in M. 
tuberculosis-infected monocytes by SN50 was 90 ug/ml. To ensure that cellular 
inhibition was not non-specific, we compared the effect of SN50 with its inactive 
analogue, SN50/M at the same concentration. SN50/M did not affect TNF-a mRNA 
expression (P>0.05) (Fig. 51). 
Addition of H2O2 to M. tuberculosis-infected monocytes resulted in a further 
augmentation of ~1.2 logs in TNF-a mRNA expression (Fig. 52), compared to control 
infected monocytes devoid of H2O2 treatment. Conversely, addition of NAC, SN50 or 
allicin in F^C^-challenged M. tuberculosis-infected monocytes revealed a suppression 
by ~5 logs (PO.001), 7.7 logs (PO.001) and ~8 logs (PO.001), respectively, in 
comparison to corresponding control cultures. SN50/M failed to show any effect on 
TNF-a mRNA expression (Fig. 52). 
Thereafter, an attempt was made to evaluate the comparative modulatory effects 
of NAC and SN50 versus allicin on M. tuberculosis 85B gene expression in M 
tuberculosis-infected monocytes at 24 hours of infection. As evident from Fig. 53, the 
M. tuberculosis 85B.T6S ratio recorded was 0.088 in M. tuberculosis-infected 
monocytes at 24 hours, whereas on addition of either 10 mM NAC, 100 ug/ml SN50, or 
500 ng/ml of allicin, the 85BT6S ratio was downregulated to 0.001 (PO.001), 0.0003 
(PO.001), and 0.0002 (PO.001), respectively, in M. tuberculosis-infected monocytes. 
No effect on 85B mRNA expression was found with SN50/M. Furthermore, the data 
depicted in Fig. 54 revealed a significant effect of NAC, SN50 and allicin in the 
presence of H2O2 on 85B.T6S ratio inM tuberculosis-infected monocytes. The 85BT6S 
ratio was found to be 0.088 in M. tuberculosis-infected monocytes. On addition of 10 
nM H202, the 85B:16S ratio was augmented to 0.348 (PO.001). On the other hand, the 
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Figure 52. Real-time RT-PCR for comparative effects of NAC, SN50 and allicin in the presence 
of H202 on expression of TNF-a mRNA: Human monocytes were infected with M. 
tuberculosis H37Rv (1:1 bacteria/cell) in the presence or absence (-) of H202 (10 nM), 
NAC (10 mM) + H202 (10 nM), SN50 (100 fig/ml) + H202 (10 nM), SN50/M (100 ng/ml) 
+ H202 (10 nM) or allicin (500 ng/ml) + H202 (10 nM). Total RNA was extracted at 24 
hours and was assessed for expression of TNF-a mRNA. Data represent mean ± SEM 
of 6 experiments. 
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Figure 53. Real-time RT-PCR for comparative effects of NAC, SN50 and allicin on M. 
tuberculosis 85B mRNA expression: Human monocytes were infected with M. 
tuberculosis H37Rv (1:1 bacteria/cell) in the presence or absence (-) of NAC (10 mM), 
SN50 (100 ug/ml), SN50/M (100 ug/ml) or allicin (500 ng/ml). Total RNA was extracted 
at 24 hours and was assessed for expression of M. tuberculosis 85B:16S ratio. Data 
represent mean ± SEM of 6 experiments. 
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Figure 54. Real-time RT-PCR for comparative effects of NAC, SN50 and allicin in the presence 
of H202 on M. tuberculosis 85B gene expression: Human monocytes were infected with 
M. tuberculosis H37Rv (1:1 bacteria/cell) in the presence or absence (-) of H202 (10 
nM), with NAC (10 mM), SN50 (100 ug/ml), SN50/M (100 ug/ml) or allicin (500 ng/ml). 
Total RNA was extracted at 24 hours and was assessed for expression of M. 
tuberculosis 85B:16S ratio. Data represent mean ± SEM of 6 experiments. 
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85B:16S ratio was reduced to 0.005 (P<0.001), 0.003 (PO.001), and 0.002 (PO.001) 
with NAC, SN50 and allicin, respectively, in M. tuberculosis-infected monocytes co-
cultured with H2O2 for 24 hours (Fig. 54). The results obtained here are again suggestive 
of allicin to be the most potent inhibitor of host TNF-a and M. tuberculosis 85B gene 
expression in M. tuberculosis-infected monocytes in 24 hours cultures. 
Modulation of GPx activity in M. tuberculosis-infected monocytes: 
GPx activity was determined in M. tuberculosis-infected monocytes co-
cultured for 24 hours with or without NAC, SN50, SN50/M and allicin. Uninfected 
and M. tuberculosis-infected, but non-treated, monocytes served as controls. GPx 
activity was suppressed by -41% (PO.001) in M. tuberculosis-infected monocytes 
relative to uninfected monocytes. Moreover, in comparison to M. tuberculosis-infected 
monocytes, addition of allicin (500 ng/ml), NAC (10 mM) and SN50 (100 u.g/ml) 
enhanced GPx activity by -43%, 40% and 37% (PO.001 for all), respectively (Fig. 
55). A nearly similar trend in GPx activity was also observed when M. tuberculosis-
infected monocytes were cultured in the presence of 10 nM H2O2 with allicin, NAC 
and SN50, respectively (Fig. 55). Thus, the results obtained show that allicin proved to 
be a potent enhancer of GPx activity in M. tuberculosis-infected monocytes, both in 
the presence or absence of H2O2. 
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Figure 55. Modulation of glutathione peroxidase (GPx) activity. Human monocytes were infected 
with M. tuberculosis H37Rv (1:1 bacteria/cell). Some cultures were not infected (MN 
only) and served as controls. Cultures then received either NAC (10 mM), SN50 (100 
ug/ml), SN50/M (100 ug/ml), allicin (500 ng/ml), H202 (10 nM), NAC (10 mM) + H202 
(10 nM), SN50 (100 ug/ml) + H202 (10 nM), SN50/M (100 ug/ml) + H202 (10 nM) or 
allicin (500 ng/ml) + H202 (10 nM). GPx activity was determined in culture 
supernatants at 24 hours. Data represent mean ± SEM of 4 experiments. 
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Tuberculosis remains a major global concern, with a staggering two million 
fatalities annually due to infection by the exclusively human pathogen, 
Mycobacterium tuberculosis. Declared a global health emergency more than a decade 
ago (WHO, 2002), tuberculosis resurgence is assuming threatening proportions. 
Among the important reasons for the causative killer parasite spiralling out of control 
at an alarming rate is attributed to the emergence of multidrug-resistant (MDR) strains 
and the AIDS epidemic (Toossi et al., 2004b). Despite current treatment regimens, 
tuberculosis continues to confound attempts at control, fuelling an urgent need for 
developing novel therapeutic strategies. 
The initial interaction (both, phagocytic and non-phagocytic) of M. 
tuberculosis with mononuclear phagocytes gives rise to a cytokine profile that is 
dominated by TNF-a, a pro-inflammatory cytokine (Hirsch et al., 1994; Means et al., 
2001). TNF-a is present at the site of active M. tuberculosis infection in humans, 
regardless of the stage of mycobacterial infection (Schwander et al., 2000; Hirsch et 
al., 2001). TNF-a is a pleiotropic cytokine, and its role in harmful or beneficial 
inflammatory processes is complex (Keane, 2005). Although this cytokine is involved 
in multiple cell regulatory and differentiation processes leading to immunity in 
tuberculous infection, however, TNF-a also mediates effects deleterious to the host 
contributing to the pathophysiology of tuberculosis. High levels of the cytokine at the 
site of infection induce an excessive damaging inflammatory response that 
overwhelms its beneficial effects (Bekker et al., 2000). 
Of the various M. tuberculosis genes shown to be upregulated after M. 
tuberculosis infection of human mononuclear cells, the 85B gene was expressed most 
frequently (Graham and Clark-Curtiss, 1999). M. tuberculosis 85B is a predominant 
protein produced during human M. tuberculosis infection (Salata et al., 1991); however 
its role in tuberculosis pathogenesis is not clear and warrants further investigation. At 
least with regard to mycolyl transferase activity, which underlies cell-wall biosynthesis, 
it appears that both M. tuberculosis 85A and 85B are redundant (Puech et al., 2002). In 
sputum from patients with tuberculosis, levels of M. tuberculosis 85B protein and 
mRNA correlate with M. tuberculosis growth, and maintenance of 85B levels correlates 
with a lack of response to therapy (Wallis et al., 1998; Desjardin et al., 1999). The 
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expression of antigen 85B in M. tuberculosis-infected monocytes correlates positively 
with both the amount of secreted TNF-a and subsequent intracellular mycobacterial 
growth (Wilkinson et al., 2001). Interestingly, although many mycobacterial 
components induce TNF-a in mononuclear phagocytes (Barnes et al., 1992; Wallis et 
al., 1993; Toossi, 2000), only the members of 85 complex interact with host fibronectin 
(Abou-Zeid et al., 1988). Moreover, binding of 85B to fibronectin enhances the 
expression of TNF-a in monocytes (Aung et al., 1996). Therefore, the role of M. 
tuberculosis 85B in intracellular infection may be the maintenance of an inflammatory 
response. In addition, M. tuberculosis 85 complex may act as an intermediary to 
synthesis of trehalose dimycolate, which enhances the host inflammatory response 
(Lima etal., 2001). 
It has been previously shown that infection of human alveolar macrophages 
with M. tuberculosis induces M. tuberculosis 85B and, TNF-a, both at mRNA and 
protein levels, which may be important to the immunopathogensis of disease (Islam et 
al., 2004). The rationale for the use of monocytes in this study is based on the fact that 
in vivo, the initial interaction of M. tuberculosis is with residential alveolar 
macrophages. If initial pulmonary defenses are overcome, successful control of the 
infection depends upon recruitment of blood monocytes, which are activated by 
cytokines, and form a granuloma restricting the growth and spread of this pathogen. 
Whereas the interaction of M. tuberculosis with more mature alveolar macrophages 
occurs at the very initiation and all through M. tuberculosis infection, the continuous 
recruitment of monocytes (Peters et al., 2001) to sites of M. tuberculosis infection 
ascertains that this less mature cell type interacts with M. tuberculosis intensely also. 
Thus, the cytokines and activation profile of both cell types need to be considered to 
develop a better understanding of host-M tuberculosis interactions in situ. As 
mononuclear cells are recruited to sites of M. tuberculosis infection, their in vitro 
functional capacities may reflect in situ immune responsiveness (Toossi et al., 2004a). 
Although attenuation of the biological activity of TNF-a has lately become an 
important therapeutic intervention in the management of a wide variety of chronic 
inflammatory diseases (Shanahan and St Clair, 2002), a growing body of clinical 
evidence indicates that neutralization of TNF-a is associated with an increased risk of 
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opportunistic infections, including mycobacterial diseases (Dinarello, 2003). In view 
of this, modulation of TNF-a release is being proposed as the basis for novel 
therapeutic approaches (Warwick-Davies et al., 2001). Focus has now shifted to 
development of compounds from natural sources that have antimycobacterial activity. 
By boosting host immunologic responsiveness, these compounds may be particularly 
useful in the treatment of drug-resistant tuberculosis. Our study involves the 
incorporation of such a compound, namely, allicin in garlic, as the natural herbal 
component for tuberculosis management. 
Allicin (diallyl thiosulfmate) is the major biologically active component and 
thiosulfinate compound of freshly crushed garlic. It has been reported to enhance the 
actions of antibiotics such as chloramphenicol and streptomycin against M. 
tuberculosis. Also, it has been shown to have a broader range of bactericidal powers 
than penicillin: 1 mg allicin has been reported to have the equivalent antibacterial 
power of 15 standard units of penicillin (Koch and Lawson, 1996). The antimicrobial 
activity of allicin is considered to depend on its inhibitory effects on certain thiol-
containing enzymes via strong SH-modifying properties, as reflected by the 
production of S-allylmercaptocysteine (Ankri and Mirelman, 1999; Rabinkov et al, 
2000). ESR and spin trapping technique demonstrated that allicin and its precursor, 
alliin (+S-allyl-L-cysteine sulfoxide), possess significant antioxidant activity. In 
addition, it has been reported that allicin scavenges OH' and inhibits lipid peroxidation 
(Prasad et al , 1995). Furthermore, it has been reported that experiments with human 
umbilical vein endothelial cells (HUVEC) showed that garlic extract and S-
allylcysteine reduce hydrogen peroxide or tumor necrosis factor-induced NF-KB 
activation (Geng et al., 1997; Ide and Lau, 2001). Allicin has also been reported to 
exhibit its antimicrobial activity by a rapid inhibition of RNA synthesis (Feldberg et 
al., 1988). 
In the present study, first we probed the reactivity of sera from tuberculosis 
patients against both, sonic extracts as well as MTCF protein antigens of cultured 
H37Rv and found a remarkably high magnitude of immuno-binding of both, 
intracellular protein antigens as well as secretory MTCF protein antigens, with 
tuberculosis sera. In addition, specificity of TB-IgG against M. tuberculosis protein 
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antigens was of an appreciably high degree, as evidenced by 50% inhibition being 
achieved at extremely low inhibitor concentrations. Further characterization of 
tuberculosis sera used in our study revealed elevated basal levels of TNF-a and 
circulating M. tuberculosis antigen 85 complex, which was consistent with earlier 
studies. Monocytes from patients with active tuberculosis were also characterized 
similarly. Real-time RT-PCR was employed to evaluate TNF-a and M. tuberculosis 
85B mRNA expression, and both were found to be elevated appreciably. Furthermore, 
supernatants of monocyte cultures from tuberculosis patients also exhibited 
appreciable levels of soluble TNF-a and secreted antigen 85 complex proteins. 
After establishing the virulence of the pathogenic M. tuberculosis strain used 
in our laboratory, we examined the effectiveness of allicin as a natural 
antimycobacterial compound, focussing on its role as an antagonist of M. tuberculosis 
85B, in H37Rv cultures. Previous reports employing concentrations higher than those 
used in our study, have shown a suppression in M. tuberculosis growth. For this 
reason, we selected a lower allicin concentration that was both non-toxic and also did 
not affect M. tuberculosis growth, as evidenced by an insignificant effect on the 
expression of M. tuberculosis housekeeping gene (16S rRNA). The dose-response 
studies clearly demonstrated downregulation of M. tuberculosis 85B mRNA 
expression in H37Rv cultures. 
Electrophoresed gel results clearly indicate the decreased expression of antigen 
85 complex (30/31 kDa) in M. tuberculosis cultures treated with varying doses of 
allicin. ELISA results for secreted antigen 85 complex in M. tuberculosis culture 
supernatants also indicate the decreased secretion of antigen 85 complex when co-
cultured with varying doses of allicin. To have further insight, we further designed 
immunoassays to study the effect of allicin on the immuno-interaction of antibodies 
present in sera of patients with tuberculosis against protein antigens in M. tuberculosis 
sonic extract as well as in MTCF. It was determined that allicin appreciably decreased 
the specificity of TB-IgG for M. tuberculosis protein antigens in both, sonic extracts as 
well as MTCF, lending support to the inhibitory effect of allicin. A concentration of 
250 and 500 ng/ml of allicin proved to be a potent inhibitor of M. tuberculosis 85B 
mRNA as well as antigen 85B protein expression in M. tuberculosis cultures. 
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Next, we examined the interaction of M. tuberculosis with human monocytes, 
focussing on the relationship between expression of TNF-a and M. tuberculosis 85B 
mRNA, with or without modulators. M. tuberculosis induces high amounts of TNF-a 
(Hirsch et al., 1994; Silver et al., 1998), and the success of intracellular growth of 
virulent M. tuberculosis has been in part attributed to the capacity to induce TNF-a. In 
agreement with previous findings, our study also shows a time-dependent increase in 
TNF-a mRNA expression and protein production, reaching a maximum 24 hours post-
infection. Interestingly, M. tuberculosis 85B mRNA expression and protein production 
were increased well beyond 24 hours of infection. Our results demonstrate that the 
induction of TNF-a and M. tuberculosis 85B mRNA expression mutually 
corresponded at t0 and 24 hours. Thus, stronger cell activation, as has been reflected by 
induction of TNF-a, seems to be associated with increased expression of 85B gene. In 
support of this finding, exogenous TNF-a was also found to significantly induce the 
expression of both TNF-a and M. tuberculosis 85B, in parallel. These results are 
suggestive of a modulatory role being exerted by M. tuberculosis-induced TNF-a, in 
monocyte cultures, over the expression of M. tuberculosis 85B during the initial 24 
hours of infection. This seems to be further reinforced by a significant down-
modulation in the expression of either gene following neutralization of TNF-a by 
sTNFR-I and sTNFR-II. 
It is to be pointed out that TNF-a may not be involved in sustaining the 
continued expression of M. tuberculosis 85B with time. The maintenance of 85B 
expression at time points beyond 24 hours, when TNF-a activity is reduced, suggests 
the involvement of alternative mechanisms as has been previously observed in 
macrophages (Islam et al, 2004). It has to be noted that expression of the TNF-a gene 
and production of its protein are under strong intracellular control mechanisms. The 
TNF-a mRNA expression at 24 hours showed a positive linear correlation with the 
secretion of antigen 85B into parallel cultures. An effect of cytokines released by M. 
tuberculosis-infected monocytes on intracellular expression of M. tuberculosis gene 
throughout infection of mononuclear phagocytes needs to be considered. The 85B:16S 
ratio at 24 hours showed a positive linear correlation with the secretion of TNF-a into 
parallel cultures. 
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Cellular signalling by TNF-a is mediated mainly through activation of NF-KB 
(Baeuerle and Baltimore, 1996). In turn, activation of NF-KB and other pathways 
sustain TNF-a activity (Ropert et al., 2001). To assess the role of NF-KB in the 
expression of TNF-a in M. tuberculosis-infected monocytes, we employed SN50, an 
inhibitor of NF-KB. From our results, it was apparent that the induction of TNF-a and 
M. tuberculosis 85B expression in M. tuberculosis-infected monocytes was mediated 
through activation of NF-KB, because both mRNAs were suppressed when SN50 was 
present in cultures. The inactive analogue of SN50 did not have any effect. Thus, as 
previously reported in macrophages (Islam et al, 2004), this study also shows that 
cellular activation is associated with augmentation of expression of both TNF-a and 
M. tuberculosis 85B in M. tuberculosis-infected monocytes 
Putative and effective host defense mechanisms by innate immune cells to M. 
tuberculosis within the phagolysosomes of activated macrophages include the 
production of reactive oxygen (ROY) and reactive nitrogen intermediates (RNI). 
Phagocytosis of microbes as well as cellular activation activates ROIs (Takao et al, 
1996), and H2O2, a product of the ROI pathway activates the expression of iNOS and 
production of NO (Han et al., 2001). Both ROI and RNI are downstream mediators of 
macrophage-activating cytokines and are thought to be microbicidal. Activation of 
iNOS and production of NO may be important in the final containment of M. 
tuberculosis by macrophages (MacMicking et al, 1997). However, M. tuberculosis 
has evolved resistance mechanisms against both, ROI (Hillas et al., 2000) and RNI (St 
John etal., 2001). 
Regarding antioxidant studies, here, when the activation of RNI and ROI was 
inhibited by NMMA, NAC, or oATP, the expression of both TNF-a and M. 
tuberculosis 85B was significantly downregulated in monocytes infected with M. 
tuberculosis. Our results have substantiated these observations by using agents that 
release oxygen radicals (NADPH and H202) or NO (SNP or NOC-9). In M 
tuberculosis-infected monocytes, these reagents increased expression of both TNF-a 
and M. tuberculosis 85B. Thus, both RNI and ROI, induced early after M. tuberculosis 
infection of monocytes, activate expression of M. tuberculosis gene. 
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Thus, our study demonstrates that M. tuberculosis-infection of monocytes 
leads to a concomitant induction of TNF-a, and expression of the M. tuberculosis 85B 
gene. Based on these findings, we probed here the regulation of TNF-a and 85B 
activation in M. tuberculosis-infected human monocytes, by allicin. 
Since higher doses of allicin (>100 uM) have previously proven toxic by 
various investigators (Ankri et al., 1997), cell viability and potential cytotoxicity were 
determined for the lower concentrations employed in this study using trypan blue and 
MTT assays, where viability of -98-99% was observed. Interestingly, no effect of 
allicin was observed on human housekeeping genes like R18 and (3-actin, thereby 
demonstrating that the effect of allicin was not mediated by cellular death, but rather 
by specific inhibition of expression as well as secretion of TNF-a and M. tuberculosis 
85B. It is to be pointed out here that allicin had no inhibitory effect on the intracellular 
growth of M. tuberculosis as revealed by the insignificant effect of allicin on 16S 
rRNA expression. 
Allicin has earlier been reported to inhibit spontaneous and TNF-a induced 
secretion of pro-inflammatory cytokines and chemokines from intestinal epithelial 
cells (Lang et al., 2004). To the best of our understanding, we show for the first time 
that allicin exerts potent anti-inflammatory effects on host mononuclear cells infected 
with M. tuberculosis as evidenced by a strong inhibition of the pro-inflammatory 
cytokine TNF-a and in turn, of M. tuberculosis 85B. The results indicate an 
appreciable suppression in soluble TNF-a secretion as well as endogenous TNF-a 
mRNA expression by -7.1 logs and 8.1 logs with 250 and 500 ng/ml of allicin, 
respectively in M. tuberculosis-infected monocytes. A parallel dose-response effect of 
allicin was found on M. tuberculosis 85B protein secretion as well as on 85B mRNA 
expression in M. tuberculosis-infected monocytes. 
TNF-a production in monocytes is regulated at multiple intracellular levels, 
beginning with transcription (Raabe et al, 1998). Augmented expression of TNF-a 
mRNA (Friedland et al., 1992) and activation of a relevant transcription factor, NF-KB 
(Toossi et al., 1997) have been reported in monocytic cells infected with M. 
tuberculosis. Induction of TNF-a expression was mediated through activation of NF-
KB, as evidenced by the suppression of TNF-a mRNA in the presence of SN50, an 
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inhibitor of NF-KB. On the contrary, SN50/M, an inactive analogue of SN50, failed to 
show any such effect. It has been well established that TNF-a induced nuclear 
translocation of NF-KB is inhibited by SN50 peptide as demonstrated in EMS A (Lin et 
al., 1995). In view of it, our data demonstrated that this effect involved inhibition of 
the NF-KB pathway induced by allicin, probably by inhibiting the degradation of 
IKBCC. The NF-KB heterodimer is retained in the cytoplasm in an inactive form through 
association with one of the IKBS inhibitory proteins. As a consequence of stimulation 
by TNF-a, IKBCX is phosphorylated by a specific kinase complex (IKK) leading to its 
ubiquitination and subsequent proteolysis by the 28S proteosome (Lang et al., 2004; 
Li and Verma, 2002). The degradation of IKB releases active NF-KB, which 
translocates to the nucleus and regulates gene expression by binding to KB binding 
sites or by interacting with other transcriptional factors (Brown et al., 1995). Since a 
number of genes involved in inflammatory responses are regulated by NF-KB 
pathway, thus a high magnitude downregulation of the NF-KB pathway by allicin 
would predictably reduce the elaboration of NF-KB-mediated TNF-a mRNA 
expression and thereby, 85B mRNA expression. In addition, allicin exerted a higher 
degree of neutralizing effects than NAC and anti-TNF-a antibodies on TNF-a-induced 
actions in M. tuberculosis-infected human monocytes. 
The exact mechanism underlying the antioxidant activity of allicin still remains 
poorly understood. Allicin-induced enhancement of glutathione peroxidase activity 
has been reported (Perchellet et al., 1986; Bryk et al, 2002). In continuation to the 
above, a role for the antioxidant enzyme glutathione peroxidase (GPx) in infected 
mononuclear cells was investigated with respect to various modulators employed in 
this study. Glutathione directly reacts with ROS, and GPx catalyzes the removal of 
hydrogen peroxide (Mesiter and Anderson, 1983). Decrease in GPx activity indicates 
impairment of hydrogen peroxide-neutralizing mechanisms (Rukmini et al., 2004). 
Here, we observed a decline in GPx activity in M. tuberculosis-infected monocytes 
that were untreated or treated either with H202, SN50/M or H2O2+SN50/M, thereby 
concurring with earlier reports that substantial amounts of ROS are being generated in 
cells infected with M. tuberculosis due to cellular activation (Islam et al., 2004). 
Enhancement of GPx activity in M. tuberculosis-infected monocyte cultures after 
addition of NAC, a precursor of the in vivo antioxidant glutathione, indicates reversal 
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of impaired neutralizing mechanisms. Surprisingly, GPx activity was observed to be 
further augmented when allicin was co-cultured instead of NAC, indicating allicin to 
be an effective natural antioxidant combating ROS, generated as a consequence of 
cellular activation in M. tuberculosis-infected mononuclear phagocytes. 
Thus, in summary, the present study shows that in human monocytes early 
after infection with M. tuberculosis, a vicious circle may exist in which expression 
of host inflammation and mycobacterial products amplify one another. Our study 
also shows enhancement of GPx activity by allicin, which correlated inversely with 
the downregulation of TNF-a and M. tuberculosis 85B mRNA expression as well as 
TNF-a and M. tuberculosis 85B protein expression in monocytes infected with M. 
tuberculosis. 
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In conclusion, it can be inferred from the present study that: 
• There exist high basal levels of TNF-a and M. tuberculosis 85B proteins in 
sera as well as in monocyte cultures of tuberculosis patients. Furthermore, 
monocyte cultures of tuberculosis patients also show high basal levels of TNF-a 
and M. tuberculosis 85B mRNA. 
• Allicin suppresses the expression of M. tuberculosis 85B mRNA and the 
secretion of M. tuberculosis 85B protein in M. tuberculosis (H37Rv) cultures. 
• Activation of monocytes by M. tuberculosis induces the expression of both 
TNF-a and M. tuberculosis 85B mRNA. 
• Both RNI and ROI, induced early after M. tuberculosis infection of monocytes, 
increase expression of both TNF-a and M. tuberculosis 85B mRNA. 
• Activation of monocytes by M. tuberculosis initiates a cascade of events 
whereby a vicious circle may exist in which expression of host inflammation 
and mycobacterial products amplify one another. 
• 500 ng/ml allicin exhibited no toxic effect on the viability of human 
monocytes. Moreover, this concentration of allicin has no inhibitory effect on 
growth of M. tuberculosis. 
• Allicin inhibits the expression of TNF-a mRNA and its protein production in a 
dose-dependent manner in M. tuberculosis infected monocyte cultures after 24 
hours of infection. 
• After 24 hours of M. tuberculosis infection, allicin downregulates the 
expression of M. tuberculosis 85B mRNA as well as its protein secretion in 
monocyte cultures. 
• Suppression of TNF-a and M. tuberculosis 85B by allicin in M. tuberculosis-
infected monocytes is mediated mainly via NF-KB. 
• Allicin enhances the glutathione peroxidase activity in M. tuberculosis-infected 
monocytes. 
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